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Abstract
One of the biggest challenges for personalized medicine is to link genetic information of dis-
ease-causative genes to disease mechanisms. This requires functional characterization of the 
respective gene products. Since proteins are the key players in most biological processes, elu-
cidation of protein-protein interactions (PPI) of disease-associated proteins can provide impor-
tant insights into disease mechanisms. The first part of the present thesis describes the devel-
opment of a quantitative protein-protein interaction screen with a focus on proteins involved 
in four common neurodegenerative diseases (NDDs): Alzheimer’s disease (AD), Parkinson’s 
disease (PD), Huntington’s disease (HD) and spinocerebellar ataxia type 1 (SCA1). The inter-
action screen combines stable-isotope labeling by amino acids in cell culture (SILAC) with af-
finity purification and high-resolution mass spectrometry. This approach aims to systematical-
ly identify and quantify interaction partners of normal and known disease-associated variants 
of proteins involved in NDDs. Moreover, the quantitative interaction screen was employed to 
study how PPIs are affected by disease-associated mutations, which lead to the identification 
of so-called differential interactors with potential direct implications in disease pathogenesis 
or progression. Along with validation of possible off-target effects and comparison of the data 
with literature-reported PPIs, a subset of identified interactors was validated by additional co-
immunoprecipitation experiments in two different cell lines. Utilizing NDD Drosophila models 
for SCA1 in combination with RNAi-mediated silencing of identified interactors, a large frac-
tion of candidates was observed to also affect neurodegeneration in vivo. In addition, AD-spe-
cific PPI data was mapped to large-scale patient cohort data obtained from genome-wide as-
sociations studies. Notably, single-nucleotide polymorphisms in the genes of interactors of the 
disease-associated protein variants were more likely associated with susceptibility to AD than 
randomly selected genes. Finally, functional follow-ups for two selected interaction partners 
provided evidence for a yet unreported role of N-linked glycosylation in AD, and a novel link 
to mitochondrial dysfunction in AD by means of the RNA-binding protein LRPPRC. In summa-
ry, the findings of the present thesis show that quantitative interaction proteomics provides 
novel insights into mechanisms of neurodegenerative diseases, particularly for early-onset Al-
zheimer’s disease. The present dataset also represents a valuable resource for the neurode-
generative disease community. 
- V -
Zusammenfassung
Eine der größten Herausforderungen der individualisierten Medizin ist die Verknüpfung genetisch-
er Information ursächlicher Gene mit Erkrankungsmechanismen, welche eine eine funktionelle 
Charakterisierung der jeweiligen Genprodukte voraussetzt. Da Proteine in der Prozessierung zel-
lulärer Informationen eine Schlüsselrolle einnehmen, bietet die Aufklärung von Protein-Protein-
Interaktionen (PPI) krankheitsassoziierter Proteine eingehende Erkenntnisse in Erkrankungsmech-
anismen. Der erste Teil dieser Arbeit beschreibt die Durchführung eines quantitativen Ansatzes 
zur Detektion von Protein-Protein-Interaktionen mit einem Schwerpunkt für Proteine, welche in 
vier häufigen neurodegenerativen Erkrankungen eine Rolle spielen: die Alzheimer-, Parkinson- 
und Huntington-Krankheit, sowie die spinozerebelläre Ataxie Typ 1 (SCA1). Die Interaktionsstudie 
kombiniert die stabile Isotopen-Markierung von Aminosäuren in der Zellkultur mit der Affinität-
saufreinigung von Proteinen und hochauflösender Massenspektrometrie. Dieser Ansatz zielt 
darauf ab, systematisch die Interaktionspartner von gesunden und krankheitsassoziierten Pro-
teinvarianten zu identifizieren und zu quantifizieren. Darüber hinaus wurde das quantitative 
Interaktionsverfahren genutzt, um zu prüfen ob PPI durch krankheitsassoziierte Mutationen 
beeinträchtigt werden. Dies führte zur Identifizierung sogenannter differenzieller Interakto-
ren, welche potenziell einen direkten Einfluss auf die Entstehung oder das Fortschreiten der 
Erkrankung haben. Neben der Validierung möglicher Nebeneffekte sowie dem Vergleich der 
Daten mit Informationen über PPI aus der Literatur, wurde ein Teil der identifizierten Interak-
toren durch zusätzliche Koimmunopräzipitations-Experimente in zwei verschiedenen Zelllinien 
bestätigt. Mit Hilfe von SCA1-Erkrankungsmodellen in der Fruchtfliege Drosophila und in Kom-
bination mit RNA-Interferenz-basierter Stummschaltung identifizierter Interaktoren wurde 
festgestellt, dass ein großer Teil der Kandidaten neurodegenerative Prozesse in vivo beein-
flusst. Um zu bestimmen, ob ein weiterer Teil der identifizierten Interaktoren möglicherweise 
an der ursächlichen Entstehung der Alzheimer-Erkrankung beteiligt ist, wurden die PPI-Daten 
auf umfassende genomweite Assoziationsstudien übertragen. Bemerkenswerterweise waren 
Polymorphismen in einzelnen Nukleotiden in den Genen zugehöriger Interaktoren wahrschein-
licher mit solchen Genen assoziiert, die eine Prädisposition für die Alzheimer-Krankheit ha-
ben, als mit zufällig ausgewählten Genen. Schlussendlich konnten Folgeexperimente für 
zwei ausgewählte Interaktionspartner den Nachweis für eine bislang unbekannte Rolle der 
N-Glykosylierung in der Alzheimer-Krankheit vorlegen, sowie einen neuen Zusammenhang 
zwischen dem RNA-bindenden Protein LRPPRC und mitochondrialer Dysfunktion in der Al-
zheimer-Krankheit. Die Erkenntnisse der vorliegenden Doktorarbeit zeigen zusammenfassend 
auf, dass quantitative Interaktionsproteomik neue Einblicke in die Wirkungsweise neurodegen-
erativer Erkrankungen ermöglicht, insbesondere für Alzheimer-Erkrankungen mit frühzeitigem 
Ausbruch. Der bestehende Datensatz repräsentiert außerdem eine wertvolle Bezugsquelle für 
die neurodegenerative Forschungsgemeinschaft.
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Abbreviations
A ampere
ABC ammonium bicarbonate
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cfu colony formig units
CID collision induced dissociation
ConA Concanavalin A
dFCS dialyzed fetal calf serum
DMEM Dulbecco’s Modified Eagle Medium
DNA deoxyribonucleic acid
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hrs hours
HCD higher-energy collisional dissociation
HPLC high performance liquid chromatography
IP immunoprecipitation
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LC-MS/MS liquid chromatography-tandem mass spectrometry
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min minutes
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m/z mass-to-charge ratio
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MS mass spectrometry
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PTM post-translational modification
q-AP-MS quantitative affinity purification followed by mass spectrometry
qRT-PCR quantitative reverse transcription polymerase chain reaction
RP-HPLC reversed-phase high performance liquid chromatography
RIPA radioimmunoprecipitation assay
RNAi ribonucleic acid interference
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RT room temperature
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SILAC stable isotope labeling by amino acids in cell culture
shRNA short hairpin ribonucleic acid
siRNA small interfering ribonucleic acid
STAGE tips stop-and-go extraction tips
TFA trifluoroacetic acid
Tris tris(hydroxymethyl)aminomethane
UAS upstream activating sequence
V volt
XIC extracted ion chromatogram
Important gene products and diseases
Aβ peptide amyloid-beta peptide
AD Alzheimer’s disease
APP amyloid precursor protein (amyloid beta A4 protein)
ATXN1 ataxin-1
COX1 cytochrome c oxidase subunit 1
FTD frontotemporal dementia
HD Huntington’s disease
Hsp heat shock protein
HTT huntingtin
LRPPRC leucine-rich pentatricopeptide repeat motif-containing protein
LSFC Leigh syndrome French-Canadian type
MAPT microtubule-associated protein Tau
NDD neurodegenerative disease
OST complex oligosaccharyltransferase complex
PARK2 parkin
PD Parkinson’s disease
PSEN1 presenilin-1
SCA1 spinocerebellar ataxia type 1
SNCA alpha-synuclein
Ub ubiquitin
UPS ubiquitin proteasome system
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I Introduction
I.1   Neurodegenerative diseases (NDDs)
Decoding disease concepts is central to an effective cure of human patients. Technological de-
velopments and innovations have profoundly driven our understanding of many diseases over 
the last centuries. While improved antibiotics, vaccines and drugs have helped to successful-
ly treat or even eradicate plenty of infectious diseases, disorders with a hereditary component 
or a genetic disposition are, with some few exceptions, mostly remediless and can be treat-
ed only symptomatically, if at all. Within the last decades, the genomic revolution has dramat-
ically improved our ability to reveal the genetic basis of hereditary diseases. Given the enor-
mous increase in sequencing speed at dramatically reduced costs, next generation sequencing 
approaches and large-scale genome-wide association studies (GWAS) are now able to identify 
disease-associated alleles at an unprecedented pace. Yet, compared to the speed of their dis-
covery, functional characterization of disease-causative genes is still lagging behind. One pos-
sible explanation for this is the current lack of straightforward methods to study gene func-
tion with a sufficiently high throughput. Besides, the hereditary component of many complex 
diseases is often distributed over many genes, thus known associations might explain only a 
small fraction of the disease burden within the population (Gandhi and Wood, 2010). Transla-
tion of genetic information into functional mechanisms most relevant to disease pathogenesis 
remains one of the largest challenges for personalized medicine.
This challenge is in particular important for neurodegenerative diseases (NDDs), a heteroge-
neous group of disorders characterized by a progressive loss of neuronal cells. While disease-
causing mutations have been identified for most NDDs, the mechanistic details of pathogen-
esis for almost all of them remain largely elusive. It is assumed that progression of NDDs is 
largely mediated at the protein level, thus investigating NDD-related proteins and their behav-
ior seems to be a promising approach to decipher disease mechanisms. An important aspect 
of protein function is characterization of protein-protein interactions (PPIs). PPIs are an imme-
diate lead to biological function and can provide valuable insights into cell signaling (Scott and 
Pawson, 2009; Walhout and Vidal, 2001). Mass spectrometry, especially combined with quan-
titative information, has become an attractive approach to elucidate PPI formation and even 
more importantly, dynamic changes in protein complex composition (Gingras et al., 2007; 
Kocher and Superti-Furga, 2007; Vermeulen et al., 2008). 
In this thesis, quantitative mass-spectrometry was used to systematically identify and quan-
tify protein-protein interactions across several different NDDs. Subsequent validation experi-
ments have been carried out to assess the quality of the PPI dataset and to establish links to 
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disease phenotypes in vivo. Finally, functional characterization of selected PPI targets was per-
formed, thereby identifying novel mechanistic details for an early-onset forms of Alzheimer’s 
disease. The following introduction will first focus on the commonalities of several different 
NDDs and the cause-effect principle of imbalanced protein aggregation with a special empha-
sis on Alzheimer’s disease. Second, the introduction will describe quantitative mass spectrom-
etry as the major technology used in this study.
 
I.1.1  Commonalities of NDDs and the role of protein aggregation
Neurodegenerative diseases such as Alzheimer’s disease (AD), Huntington’s disease (HD), Par-
kinson’s disease (PD) or different types of spinocerebellar ataxias (SCAs) are devastating multi-
factorial disorders with a clear genetic background (Martin, 1999). However, while for some 
diseases the genetic causality is now fully disclosed, other diseases seem to be caused by 
many disease causing genes and additional risk factors. On one hand, expansion of CAG re-
peats in the ataxin-1 or huntingtin gene over a certain threshold leads to pathogenic proteins 
with abnormally long polyglutamine (polyQ) tracts that irrevocably cause SCA1 or HD with full 
penetrance (Chung et al., 1993; Orr et al., 1993; Rubinsztein et al., 1996). On the other hand, 
AD and PD are genetically complex and more heterogeneous diseases with no single mode of 
inheritance. Rare early-onset forms are caused by a handful of genes while frequent late-on-
set forms show less obvious or no apparent familial inheritance at all. These so-called ‘sporad-
ic’ forms of disease are likely to be affected by a cohort of risk alleles across a number of differ-
ent genes (Bertram and Tanzi, 2008). In spite of the diverging genetic causalities, NDDs show 
a considerable overlap of clinical phenotypes characterized by a selective loss of neurons in 
cognitive and motor systems, suggesting common pathogenic features at the molecular lev-
el. One such feature is protein misfolding and formation of insoluble protein aggregates – a 
key event during molecular pathogenesis of NDDs (Ross and Poirier, 2004, 2005; Taylor et al., 
2002). As the name implies, NDDs most severely affect neuronal cells. Neurons, being post-mi-
totic cells, are in particular vulnerable to the deleterious effects of misfolded proteins, since 
they cannot dilute toxic protein species through normal cell division. To understand the im-
pact of protein misfolding events during initiation of neurodegenerative diseases, it is crucial 
to realize why especially NDD-related proteins are prone to aggregation and how they bypass 
the numerous mechanisms which cells have evolved to protect themselves from detrimental 
misfolding effects.
Proteins are synthesized as linear chains of amino acids in a specific order. In order to func-
tion properly, it is necessary for the nascent chains to fold into the native three-dimensional 
structure that is unique for each protein. Hence, polypeptide chains undergo a highly compli-
cated and energy-consuming assembly process which is referred to as protein folding (Dobson 
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et al., 1998). All the information that is necessary to achieve a functional three-dimensional 
structure of a given protein is contained in the amino acid sequence of the polypeptide chain, 
a premise that is known as the Anfinsen postulate (Anfinsen, 1973). However, already in 1968 
the famous Levinthal paradox (Levinthal, 1968) proclaimed the inconsistency that an unfolded 
polypeptide chain would have an astronomical number of possible conformation states, thus 
will never find its native structure. In an attempt to solve this paradox, Levinthal himself pro-
posed ‘folding pathways’ that would speed up the folding process significantly. Indeed, par-
tially folded transition states and folding intermediates were experimentally detected later on, 
suggesting a concept of funnel-like energy landscapes, where the native structure of protein is 
the thermodynamically most stable and thus most desirable structure to achieve in terms of 
thermodynamic properties (Dill et al., 2008; Dobson et al., 1998).
In addition, some proteins do also need the help of specific assistance molecules termed mo-
lecular chaperones to fold properly. Chaperones recognize and bind to nascent polypeptide 
chains and folded intermediate states, assisting proper protein folding assembly. There are nu-
merous classes of chaperones with distinct functions: for instance, the HSP70/HSP40 families 
and others seem to be primarily involved in remodeling already misfolded polypeptide chains 
and minimizing further aggregation. In contrast, the HSP60 family and others rather actively 
support and facilitate the intrinsic folding process (Fink, 1999). The ability of cellular proteins 
to assemble with high precision and high fidelity is therefore strongly facilitated by chaper-
ones, making them the first line of defense to prevent aggregation of protein molecules before 
their actual folding process is finished. Even though a multitude of chaperone species is con-
stantly expressed and active, the folding process is not always accurate and misfolding of na-
scent proteins is a common event within a healthy cell. It is estimated that roughly 30 % of all 
newly synthesized proteins are not folded correctly and thus are either subjected to refolding 
or undergo degradation via the ubiquitin-proteasome system (UPS) for recycling of amino ac-
ids (Schubert et al., 2000). As the failure of proper protein folding is a major threat to cell func-
tion and overall viability, additional elaborate quality control mechanisms have evolved over 
time to constantly monitor protein folding within the cell and to countermeasure deleterious 
effects of misfolded proteins (Berke and Paulson, 2003; Taylor et al., 2002). 
The cellular quality control is composed of different mechanistic pathways, including (i) the al-
ready introduced molecular chaperones, (ii) the ubiquitin-proteasome system (UPS), (iii) un-
folded protein response in the ER (UPR), (iv) endoplasmatic reticulum-associated protein deg-
radation (ERAD) and finally (v) autophagy clearance of protein aggregates. 
The proteasome is large multi-protein complex of about 2.5 MDa, which is responsible for deg-
radation of mainly nuclear and cytoplasmic proteins, as well as secretory and membrane pro-
teins that have been retrotranslocated from the ER to the cytoplasm via the ERAD pathway 
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(Coux et al., 1996; Glickman and Ciechanover, 2002). Briefly, recognition of proteasome tar-
gets is achieved through covalent modification of proteins with small protein modifiers, most 
commonly by ubiquitin. The ubiquitin-substrate conjugation system is highly complex, giving 
rise to an ubiquitination code with a wide variety of downstream signaling and processing ef-
fects (Glickman and Ciechanover, 2002; Hershko and Ciechanover, 1998). Besides the cyto-
plasm, the ER represents the second major environment for protein folding. Proteins entering 
the secretory pathway are specifically folded in the ER and rise of unfolded proteins in the ER 
is coped by the UPR and ERAD in both overlapping and compensatory means in order to elim-
inate misfolded proteins under normal conditions (Buchberger et al., 2010; Friedlander et al., 
2000; Travers et al., 2000). However, under stress conditions, such as constant expression of 
an aggregation-prone gene product, the continuous flux of misfolded protein species usual-
ly overcomes the capabilities of the cellular protein quality control (Morimoto, 2008). In ad-
dition, substrates of the 26S proteasome need to be unfolded prior to their degradation, an 
assignment that usually precludes insoluble protein aggregate species. Thus, when aggrega-
tion-prone protein substrates cannot be sufficiently cleared by the proteasome system, sub-
sequent resistance seems to be mediated via autophagy clearance of aggregates (Rubinsz-
tein, 2006; Williams et al., 2006). Though, as the drastic increase in aggregation-propensity of 
NDDs-associated proteins presumably overcharges the cellular capacity of handling protein 
misfolding stress, definite aggregate species can then mediate their neurotoxic effects. Collat-
eral stress, for instance mitochondrial dysfunction, likely contributes to failure of aggregation 
clearance as well (Martinez-Vicente and Cuervo, 2007).
Similar to native protein folding, progressive protein aggregation is also a complex process, in-
cluding several transition steps which give rise to a multiplicity of soluble oligomers or interme-
diate aggregate species (FIG. I.1). Structural properties and pathogenic impact of these inter-
mediates differ quite substantially within the range of NDD-related proteins (Chiti and Dobson, 
2006; Ross and Poirier, 2004). Ultimately, the final stage of protein aggregation is the seques-
tration of intermediate aggregates into so-called aggresomes or inclusion bodies by microtu-
bule-mediated transport. Aggresomes are then translocated near the nucleus where the cell 
attempts to clear them by macroautophagy (Johnston et al., 1998; Ross and Poirier, 2005).
One of the major unsolved questions in the neurodegeneration field deals with the identifica-
tion of the genuine intermediate aggregate species that is mainly responsible for neurotoxic 
effects within the cell. Whether monomers, soluble oligomers or even larger aggregate struc-
tures are the most neurotoxic species is still the subject of debate (Ross and Poirier, 2005). His-
torically, final aggregate deposits have been the prime suspect for a long time as they were 
identified as pathological hallmarks of the corresponding diseases in autopsy material from af-
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fected patient brains. However, this view changed over the last decades towards the more sol-
uble oligomers being the toxic species (Ross and Poirier, 2004). There is some evidence that 
this proposition might hold true at least for Aβ oligomers (Gandy et al., 2010; Walsh et al., 
2002), although others propose a more complex view of Aβ-mediated neurotoxicity (Benilova 
et al., 2012). For further disease-associated proteins involved in different NDDs, however, the 
nature of the toxic species remains largely elusive to date. 
Although it has not yet been possible to pinpoint 
the essence of the true toxic species, the even 
more important question is how the toxic aggre-
gates actually induce neurotoxicity. Within the last 
ten years, the scientific community focused most 
extensively on the interference with protein qual-
ity control (Bence et al., 2001; Cuervo et al., 2004; 
Tanaka et al., 2001), albeit many other direct toxic-
ity-effects have been observed as well (Song et al., 
2011; Zhu et al., 2003); this has been extensively 
studied for Aβ-mediated neurotoxicity (described 
later, cf. I.1.2). Most notably, many proteins that 
are natively not prone to aggregate are seques-
tered to already formed intermediate stages or 
final aggregates and are thus deposited in these 
inclusion bodies as well. These differential pro-
tein interactions also contribute to neurotoxicity 
as uninvolved proteins are intercepted and hence 
not available any more to fulfill their normal tasks 
within the cell (described later in more detail, cf. 
I.1.3). The final inclusion bodies, full of misfolded 
and sequestrated proteins, are nowadays suspect-
ed to have a more protective than toxic function 
– a last-ditch attempt of the cell to corral irrevo-
cably damaged proteins in order to prevent them 
from sequestering additional proteins and getting 
more detrimental.
FIG I.1 | Hypothetical several-step pathway of protein 
aggregation. An initiative event converts a native dis-
ease protein into an abnormal form. Globular (oligo-
meric) intermediates may subsequently form, and then 
protofibrilliar structures are assembled. Fibers form 
possibly through association of protofibrils, resulting in 
aggresome or inclusion formation visible in the light mi-
croscope. The intermediate species are considered to 
be the more toxic ones, rather than precursors or final 
aggregates (Illustration adapted from Ross and Poirier, 
2004).
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While it now has become clear that accumulation of misfolded proteins is a common feature 
of many neurodegenerative diseases, less is known about the actual initiation of aggregation 
in vivo. Initiation of protein misfolding may be a stochastic event, with a constant risk over 
the lifetime of the individual (Clarke et al., 2000). Aggregate formation may then proceed and 
accelerate via a ‘seeded polymerization’ effect (Dobson, 2003; Lansbury, 1997; Soto, 2003). 
More tangible effects that increase the likelihood of aggregation are: (i) increased protein con-
centration, (ii) protein-coding mutations or (iii) covalent modifications of proteins. Evidence 
for increased protein concentrations as cause for aggregation initiation has come from genet-
ic dosage alterations in familial PD patients with triplication of the alpha-synuclein gene locus 
(Singleton et al., 2003) or early Aβ plaque load in individuals with Down’s syndrome, who carry 
an extra copy of the Alzheimer-causing gene APP on chromosome 21 (Schupf and Sergievsky, 
2002; Tanzi et al., 1988). Protein-coding mutations are a common cause for protein aggrega-
tion and exert their effects in two ways: either the mutation directly alters the primary struc-
ture of the affected protein and thus makes it more prone to aggregation, e.g. polyglutamine 
expansion in the huntingtin gene (Scherzinger et al., 1997; The Huntington’s Disease Collabor-
ative Research Group, 1993),  or the mutation affects the processing of other disease proteins, 
e.g. the PSEN1-A431E mutation modulates γ-secretase activity hence altering the Aβ isoform 
pattern (Portelius et al., 2010). Finally, covalent modification of proteins can also initiate the 
aggregation of several protein species, most importantly via phosphorylation, e.g. hyperphos-
phorylation of Tau protein (Grundke-Iqbal et al., 1986) or the disease-critical phosphorylation 
of Ataxin-1 on position Serine776 (Emamian et al., 2003). Additionally, misfolding and aggre-
gation can also proceed via transmission of infectious protein species. However, this has so 
far only been experimentally validated for prion particles that are not within the focus of this 
work. Earlier indications, whether or not Aβ isoforms can be transmitted in a prion-like fashion 
in vivo, are still inconclusive. Although inoculation of postmortem AD brain extracts can accel-
erate deposition of Aβ fibrils when directly injected to either the brain or the peritoneal cavity 
of transgenic AD mice (Eisele et al., 2010; Kane et al., 2000; Meyer-Luehmann et al., 2006), all 
host animals utilized so far were predisposed to develop AD pathology as they overexpressed 
mutant amyloid precursor protein already. The extra inoculation with AD brain extracts thus 
might be an additional amyloid enhancer only.
In a nutshell, disease-associated mutations provoke erroneous protein folding, commuting na-
tive gene products into aggregation-prone protein species responsible for the formation of 
NDDs. Despite the evolution of numerous cellular countermeasures to prevent toxic effects of 
those pathogenic protein species, the disease-causing mutation and thus the primordial cau-
sality of the disorder is not restored. As a result, the cell is not able to cope with the continuous 
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flux of mutated gene products and the protein homeostasis is imbalanced over time. This pro-
cess is, however, rather slow and can take decades until full penetration of clear clinical symp-
toms, hence the vast majority of all NDD cases are late-onset forms with an age of onset great-
er than 65 years. Given the fact that population ageing has emerged as a major demographic 
trend in most countries worldwide, the frequency of NDD cases is considered to increase dra-
matically over the next decades. For example, prevalence for dementia patients only is esti-
mated to triple worldwide from around 36 million nowadays to 115 million by 2050 (World Al-
zheimer Report, 2011). 
Conclusively, substantial progress has been made over the last 30 years in discovering the dis-
ease-causing mutations for several different NDDs, however, functional characterization is still 
lagging behind. The drastic increase in NDD-affected patients and the lack of therapeutic strat-
egies will therefore have an enormously high socio-economic impact on the health care sys-
tems and affiliated societies, reflecting the urgent need for further substantial research on 
NDDs to elucidate disease mechanisms in more detail.
 
I.1.2  Alzheimer’s disease: competing hypotheses and causative agents
Alzheimer’s disease (AD) is the most common neurodegenerative disease, currently affect-
ing approximately 30 million people worldwide. It is named after the German psychiatrist and 
neuropathologist Alois Alzheimer who defined the ‘first’ Alzheimer’s disease case (Alzheimer, 
1907), even though there is evidence that at least six other physicians have described the dis-
ease prior to Alois Alzheimer (Berrios, 1990), going along with Stiegler’s law of eponymy. 
Clinically, Alzheimer’s disease is characterized by a progressive impairment of short-term mem-
ory, judgment, orientation and language toward a state of profound dementia. Pathological 
hallmarks of the disease are neuronal loss, particularly in the frontotemporal cortex and the 
hippocampus, and aggregation of two proteinaceous species, Aβ and tau. Protein aggregates 
are found as intracellular neurofibrillary tangles (NFTs), mainly composed of hyperphosphory-
lated forms of the microtubule-associated protein tau (MAPT), and extracellular senile plaques 
containing mainly different isoforms of the beta-amyloid peptide Aβ. The Aβ peptide is derived 
from the amyloid precursor protein (APP) through sequential cleavage by two transmembrane 
proteases: the β-secretase and the γ-secretase (Bertram and Tanzi, 2008; Selkoe, 2001). 
AD can be classified into early-onset cases with familial inheritance (onset of disease before 60 
years) and late-onset cases (onset after 60 years). So far, all mutations that are known to cause 
early-onset AD are located either in the APP gene itself or in genes of presenilin-1 (PSEN1) or 
presenilin-2 (PSEN2), both catalytic subunits of the γ-secretase complex (Bertram and Tanzi, 
2008). However, the vast majority of all Alzheimer’s disease cases (>90-98%) presents as late-
onset forms with no single mode of inheritance, thus often called sporadic AD. As mentioned 
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earlier, sporadic forms of AD are probably modulated by a several risk alleles with relatively 
low penetrance but high prevalence (Bertram et al., 2007). So far, hundreds of gene polymor-
phisms have been claimed to be implicated in the origin of AD. The AlzGene database (www.
alzgene.org) currently lists ~3,000 polymorphisms in ~700 different genes as risk factors for 
AD, although, with the exception of the ε4 allele of the apolipoprotein E gene (APOE), none of 
these purported candidates has been proven to consistently influence disease risk or onset in 
more than a handful of samples or restricted populations of patients (Bertram et al., 2007; Bu, 
2009). Consequently, as the genetic basis for most AD cases remains largely elusive, it is not 
surprising that no unifying mechanism has been posted to date that would explain all variet-
ies of causal AD formation. Nonetheless, many different hypotheses have been proposed over 
the last 20 years, trying to better understand general disease concepts and pathogenic path-
ways of AD. In the following, I will focus on the two most prominent hypotheses: the amyloid 
cascade hypothesis and the mitochondrial cascade hypothesis. 
The amyloid cascade hypothesis has dominated AD research over the last two decades (Hardy 
and Selkoe, 2002; Hardy and Higgins, 1992; Selkoe, 1991), as the evidence for a central role of 
Aβ in AD pathogenesis is indisputable. The main proposition of the amyloid cascade hypothe-
sis is that sufficient accumulation of toxic Aβ species induces all biochemical and histological 
changes in AD-affected neurons. Aβ is a proteolytic fragment of the APP protein and is gen-
erated mainly in neurons by sequential scission of APP by β- and γ-secretase enzymes (Sel-
koe, 2001). An alternative processing of APP via α-secretase followed by γ-secretase generates 
shorter hydrophobic peptide species, termed p3, whose role in AD are yet unclear. The pro-
cessing of APP via the α-secretase prevents formation of Aβ, as the α-cleaving site is located 
within the Aβ sequence domain. Hence, p3 was initially claimed to have a non-amyloidogenic 
function, although it has later been found as constituent of both Aβ plaques in AD patients and 
cerebellar preamyloids in Down’s syndrome (Higgins et al., 1996; Lalowski et al., 1996). 
It is important to realize that Aβ is actually present in several isoforms, thus representing a het-
erogeneous mixture of several Aβ species of different lengths and modifications. Due to varia-
tions in γ-secretase sequence specificity, the C-terminal part of APP is cleaved at different po-
sitions giving rise to Aβ
37-43
 (digits indicate the number of amino acids comprising the peptide, 
with residue 1 being the amino acid residue aspartyl-1 of the Aβ sequence in APP, FIG. I.2). So 
far, only Aβ
37
, Aβ
38
, Aβ
40
, Aβ
42
 and Aβ
43
 have been detected in cell culture and body fluids. Ad-
ditional heterogeneity is produced by aminopeptidases, glutaminyl-isomerases and kinases, 
which can modify Aβ peptides even further (Benilova et al., 2012; Selkoe, 2004). This mélange 
of Aβ species contributes to different extents to putative Aβ functions in both healthy and AD-
afflicted neurons. While earlier publications focused mainly on the role of selected Aβ isoforms 
only, the view has now shifted to a more holistic perception of the whole Aβ family. It now 
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becomes evident that the 
different Aβ isoforms influ-
ence each other in a com-
plex process. Accordingly, 
equilibrium alterations with-
in the scope of different Aβ 
peptides are more likely to 
change biophysical proper-
ties of Aβ with regard to tox-
icity and aggregation propen-
sity, rather than quantitative 
increases of individual Aβ 
peptide species alone (Be-
nilova et al., 2012). Owing to 
their inherent cross-β-sheet 
structure, Aβ monomers can 
arrange into soluble Aβ oligomers giving rise to many different Aβ assemblies (up to 36-mers) 
with a wide biological effector spectrum (Benilova et al., 2012). For instance, known toxic ef-
fects of Aβ oligomers are direct inhibition of several receptors (Giuffrida et al., 2010; Thathiah 
and De Strooper, 2009; Yamin, 2009), microtubule loss (King et al., 2006) or membrane bilay-
er permeabilization, either indirect or through amyloid pore formation, thus strongly affect-
ing mitochondrial function through Ca2+ overload and direct interference with the respiratory 
chain (Manczak et al., 2006; Smith et al., 2000). Additionally, Aβ assemblies seem to derogate 
synaptic functionality of neurons, leading to restraints in long-term potentiation (Cleary et al., 
2005; Walsh et al., 2002). Most importantly, Aβ oligomerization is associated with tau pathol-
ogy, probably by ultimately triggering the hyperphosphorylation and other post-translational 
modifications of tau (Cohen et al., 2011; Iqbal et al., 2010), hence allowing NFT formation. Ge-
netics of AD suggest that Aβ acts upstream of tau, as mutations in APP lead to AD with amyloid 
plaques and NFTs (Bertram et al., 2010), whereas MAPT mutations alone cause NFTs but nev-
er lead to amyloid plaque formation or development of AD. MAPT gene polymorphisms cause 
frontotemporal lobar degeneration (FTLD), a neurodegenerative disease closely connected to 
AD (Ballatore et al., 2007). Adverse effects of Aβ are, at least partly, dependent on tau but not 
vice versa, making Aβ the primary causative agent of familial AD cases according to the amy-
loid cascade hypothesis (Huang and Mucke, 2012). In summary, it is most likely that neurotox-
icity in early-onset AD-afflicted neurons is primary due to the accumulation of Aβ oligomers, 
triggering a fatal cascade of downstream effectors and copathogens, which contribute to or 
potentiate pathological conditions even further.
FIG I.2 | Generation of Aβ from amyloid precursor protein APP. The transmembrane 
region of APP is displayed in grey, red arrows indicate the sites of β- and γ-secretase-
mediated cleavage sites (upper panel). Familial Alzheimer’s disease-associated mu-
tations (illustrated in the lower panel) either increase the total net production of Aβ 
(blue), alter biophysical properties of Aβ  (black) or affect  the Aβ peptide spectrum 
in both quantitative and qualitative ways (green) (llustration adapted from Benilova 
et al., 2012).
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Although the amyloid cascade hypothesis is of help to understand familial AD cases in more 
detail, numerous open questions are still remaining in order to completely decode AD mech-
anisms. For instance, the amyloid cascade hypothesis has been extrapolated to sporadic cas-
es of AD, albeit these patients do not have mutations in APP or the PSEN genes but still show 
elevated levels of Aβ species. The cause for this phenomenon is still unclear, although, pre-
sumably other AD-associated gene polymorphisms may alter the processing of APP and thus 
the generation of Aβ isoforms as well. Another frequently voiced concern has been the poor 
correlation of insoluble Aβ levels with the progression of the disease or amyloid plaque load 
(McLean et al., 1999; Terry et al., 1991). Even many non-demented elderly individuals have 
amyloid plaques and NFTs (Savva et al., 2009). Conversely, significant correlation has been 
observed between soluble Aβ levels and cognitive decline (Hsiao et al., 1996; Naslund et al., 
2000). These and many other observations suggest that plaque amyloids per se are a weak in-
dicator to describe cognitive status in AD.
In order to account for AD cases which do not seem to meet the amyloid cascade hypothesis, 
Swerdlow and Khan formulated the mitochondrial cascade hypothesis (Swerdlow and Khan, 
2004). It posits that defects in mitochondrial activity within AD-afflicted neurons are the pri-
mary cause of AD, actually driving Aβ production and subsequent neurodegeneration (Khan et 
al., 2000; Markesbery, 1997; Yao et al., 2009).
One of the major strengths of the mitochondrial cascade hypothesis is the implementation of 
ageing phenomena. It proclaims that both, inherited and age-driven acquired mtDNA muta-
tions predispose the pathological features toward late-onset sporadic AD. It is commonly ac-
cepted that mitochondrial function is declining with age and one of the greatest risk factors 
for NDDs is increased age. Mitochondria are thought to contribute to ageing, mainly through 
accumulation of mutations within the mitochondrial DNA (mtDNA). This has been experimen-
tally shown utilizing mtDNA-mutator mice with proofreading-deficient mitochondrial DNA-
Polymerase, which exhibited an almost twofold decrease in average lifespan (Trifunovic et al., 
2004). Another important contributing factor to ageing is the net production of reactive ox-
ygen species (ROS). Gene expression studies of human postmortem cortex samples have re-
vealed that oxidative damage contributes to ageing-accompanied cognitive decline (Lu et al., 
2004). Extensive support from the literature emphasizes the role of mitochondrial dysfunction 
and oxidative damage in AD, even before onset of significant plaque pathology (Lin and Beal, 
2006; Nunomura et al., 2001; Pratico et al., 2001). Among the earliest detectable defects in 
AD are altered cytochrome C (COX) activity (Parker, 1991) and a general decrease in the cellu-
lar energy metabolism levels. For instance, these manifestations include loss of body weight, 
peak oxygen consumption or altered insulin levels (Burns et al., 2008; Craft et al., 1998; John-
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son et al., 2006). Evidence supporting inherited mtDNA polymorphisms as drivers of sporadic 
AD has come from findings on amplified mtDNA deletion mutations found in several late-on-
set AD patients when compared to healthy controls (Bosetti et al., 2002; Castellani et al., 2002; 
Corral-Debrinski et al., 1994; Coskun et al., 2004). Caught in a vicious circle, somatic mtDNA 
mutations would cause increased ROS production, which in turn inhibit mitochondrial activi-
ty and can, through accumulation, cause more mutations in the mtDNA and ultimately lead to 
mitochondrial dysfunction.
However, the mitochondrial cascade hypothesis, similar to the amyloid cascade hypothesis, 
cannot account for all AD variations observed so far. Especially, it only focuses on late-onset, 
sporadic AD cases, whereas early-onset AD cases are regarded as primary amyloidoses only. In 
addition, the mitochondrial cascade hypothesis claims that Aβ production and plaque deposi-
tion is a secondary event in sporadic AD, actually mediated by primary defects in mitochondri-
al function. However, early APP processing events and accumulation of soluble or insoluble Aβ 
species might fall below the current limit of detection, thus defining mitochondrial dysfunc-
tion as cause or consequence of Aβ-mediated toxicity becomes extremely challenging.
The amyloid and the mitochondrial 
cascade hypothesis have both pro-
vided unique perspectives on AD, 
contributing to our understanding 
of AD-based neurodegeneration 
(FIG. I.3). Nonetheless, many more 
factors are likely to be involved in 
AD awaiting further elucidation. By 
way of example, the most impor-
tant risk factor for late-onset AD to 
date is APOE (Corder et al., 1993; 
Strittmatter et al., 1993), it is the 
only risk allele that has been vali-
dated in numerous genome wide 
association studies across different 
populations around the world (it 
ranks number one in the AlzGene 
database). The APOE ε4 allele fre-
quency is about 15% in general pop-
ulations but about 40% in patients 
with AD (Bu, 2009). The mechanis-
FIG I.3 | Multifactorial basis of Alzheimer’s disease pathogenesis. Aggregation and 
accumulation of amyloid-β (Aβ) in the brain may result from increased neuronal 
production of Aβ, decreased activity of Aβ-degrading enzymes, or alterations in 
transport processes that shuttle Aβ across the blood–brain barrier. Aβ oligomers 
impair synaptic functions, whereas fibrillar amyloid plaques displace and distort 
neuronal processes. Aβ oligomers interact with cell-surface membranes and recep-
tors, altering signal-transduction cascades, changing neuronal activities and trig-
gering the release of neurotoxic mediators by microglia (resident immune cells). 
Vascular abnormalities impair the supply of nutrients and removal of metabolic by-
products, cause microinfarcts and promote the activation of astrocytes (not shown) 
and microglia. The lipid-carrier protein apoE4 increases Aβ production and impairs 
Aβ clearance. When produced within stressed neurons, apoE4 is cleaved into neu-
rotoxic fragments that destabilize the cytoskeleton and, like intracellular Aβ, impair 
mitochondrial functions. The proteins tau and α-synuclein can also self-assemble 
into pathogenic oligomers and can form larger intra-neuronal aggregates, displac-
ing vital intracellular organelles.
Reprinted by permission from Macmillan Publishers Ltd: [Nature] Mucke, 2009 
(doi:10.1038/461895a)©.
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tic details of ApoE4 in AD are not yet completely understood but ApoE4 probably acts in both 
Aβ-dependent and Aβ-independent pathways. On the one hand, ApoE4 impairs Aβ clearance 
and elevates Aβ deposition thus promoting Aβ-related effects in AD patients. On the other 
hand, proteolysis of ApoE4 under stress or injury conditions can mediate downstream Tau pa-
thology and mitochondrial energy impairment, hence promoting mitochondrial neurotoxicity 
(Bu, 2009; Huang and Mucke, 2012). 
Figure I.4 summarizes the heterogeneity of different effectors that have been proposed so far 
to contribute to AD. As evident from the multiplicity of involved factors, it becomes clear that 
there is probably no single linear chain of disease-driving events but initiation and progres-
sion of late-onset AD may be a complicated conglomerate of pathways with mutual interplay 
(Querfurth and LaFerla, 2010). It is likely that future findings enable a more detailed view on 
AD mechanisms allowing classification of AD subtypes with heterogeneous origins – thus po-
tentially unifying diverging hypotheses.
FIG I.4 | Heterogeneity of Alzheimer’s disease-associated risk factors. Early-onset AD cases are caused by mutations in either 
PSEN1/2 or APP genes. Late-onset AD cases are most likely modulated by a several risk alleles, for instance ApoE4 or other 
minor genetic risk factors. Important co-pathogens are considered to influence both early- and late-onset variants of AD and 
can act synergistically with each other and/or with Aβ. Further mechanistic effects which can influence onset and progression 
of AD include mitochondrial pertubations, epigentic events or further nongenetic risk factors. Mutual interplay between most 
effectors additionally increases the complexity of AD-causing pathways.
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I.1.3  Protein-protein interactions and their impact on neurodegeneration
Biomolecular interactions are central to all biological processes. A key aim in the postgenomic 
era is to systematically understand the roles of protein-protein interactions (PPIs) on a global 
scale, as signal information cascades are transmitted and processed throughout the cell main-
ly via protein interaction networks (Scott and Pawson, 2009). Proteins very rarely act isolat-
ed, in fact, the cellular environment is densely packed and rich in interfaces of a plethora of 
biomolecules, which are mostly dynamic and move around to fulfill their biological function. 
Thus, already the precise definition of a PPI becomes challenging since some PPIs are stable 
across almost the whole lifetime of a cell, while others are more transient and happen with-
in a nanosecond timescale. For instance, the assembly of the histone octamer arises from ex-
tremely stable PPIs, whereas the binding of most kinases towards their substrates is rather 
temporary. 
Given the importance of PPIs in biological systems, numerous techniques have been devel-
oped over the last decades to systematically map PPIs, nonetheless, most of them are limit-
ed in either throughput or reproducibility. For instance, low-throughput methods such as iso-
thermal titration calorimetry, ITC, (Pierce et al., 1999), Förster resonance energy transfer, FRET, 
(Kenworthy, 2001) or classical co-immunoprecipitation are accompanied by high-throughput 
methods such as yeast-two-hybrid, Y2H, (Fields and Song, 1989) or protein fragment comple-
mentation assays (Tarassov et al., 2008). Most of the aforementioned assays focus on bina-
ry interactions and have specific advantages and disadvantages. An alternative approach is 
mass spectrometry (MS)-based identification of PPIs, which relies on affinity purification of a 
bait molecule followed by mass spectrometry, AP-MS (Rigaut et al., 1999). AP-MS can be per-
formed in high-throughput and is currently the most powerful and unbiased experimental tool 
to identify the constituents of whole protein complexes (Ewing et al., 2007; Malovannaya et 
al., 2011). In addition, AP-MS retains posttranslational modifications (PTMs) of target proteins 
and is therefore able to detect PTM-dependent PPIs as well, which are often crucial for com-
plex formation (Seet et al., 2006). Also, AP-MS can be performed under near physiological con-
ditions and in the relevant organism and subcellular compartment (Gingras et al., 2007). Over 
the years, several advances have been made, which now allow researchers to choose between 
plenty of different experimental variations of the original AP-MS approach. Technical develop-
ments primarily focused on either (i) optimizing the expression level of the bait protein, (ii) im-
provements of the tag system, (iii) advances in mass spectrometry-based identification of pro-
teins and (iv) assessment of data quality via bioinformatic filtering (Gavin et al., 2011; Gingras 
et al., 2007). 
Almost all biochemical approaches for identification of PPI suffer from the trade-off between 
sensitivity and specificity. Affinity matrices used in AP-MS are composed of an antibody target-
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ed against the bait protein (or directed against a fused purification tag) coupled to a matrix. 
Both components, matrix and antibodies, are subject to extensive interaction with non-spe-
cific binders, which will give rise to false-positive identifications. On the one hand, stringent 
washing procedures are required to eliminate these non-specific binders. On the other hand, 
transient interactors of the bait protein can be lost due to excessive washing steps (false-nega-
tives). In order to circumvent this problem, sophisticated bioinformatic tools have been devel-
oped, which try to extract background noise from AP-MS experiments. This can be addressed 
either through accentuation of potential genuine interactors or by exclusion of potential spuri-
ous interactors. The latter approach has been systematically assessed by comparing the ‘bead 
proteome’ of routinely used affinity matrices such as Sepharose, agarose and magnetic beads 
(Trinkle-Mulcahy et al., 2008). The reported bead proteome filters provide a useful resource, 
however, they are restricted to certain baits and cell lines so far and indicated contaminants 
might readily have a genuine function under different experimental conditions or in different 
cell extracts. Highlighting true interactors from biochemical purifications is much more chal-
lenging. More elaborate software approaches have been designed, trying to implement scor-
ing systems utilizing socio-affinity scores (Gavin et al., 2006), semi-quantitative information 
(Sardiu et al., 2008; Sowa et al., 2009) or probability distributions (Choi et al., 2010). However, 
software tools do not get to the root of the true problem and face the background discrimina-
tion dilemma after the actual experiment has been carried out. Thus, implementation of quan-
titative information prior to the data analysis provides an attractive alternative to minimize 
false-positive interactions arisen from unspecific protein binding. Quantitative proteomics is a 
smart tool, which allows distinguishing true interaction partners from background binders by 
differentially labeling the specific and the control pull-down (Paul et al., 2011; Vermeulen et 
al., 2008). In addition to background discrimination, quantitative proteomic approaches can 
also uncover dynamic changes in the composition of PPIs. This becomes of particular interest 
when focusing on signaling networks upon activation with a certain effector (Blagoev et al., 
2003), dynamic changes of PTM-mediated PPIs (Olsen et al., 2006), cellular differentiation pro-
cesses (Brand et al., 2004), and many more biological questions (Mousson et al., 2008; Pflieg-
er et al., 2008; Vermeulen et al., 2008). 
Progression of many human diseases commonly involves abnormal protein-protein interac-
tions, thus knowledge of PPIs is crucial to understand disease mechanisms in general (Schus-
ter-Bockler and Bateman, 2008; Vidal et al., 2011). It has been observed that proteins caus-
ative for several disease phenotypes frequently interact with each other (Ideker and Sharan, 
2008). Loss of binding partners can abolish the ‘normal’ function of the protein, depriving the 
cell of certain vital capacities. Contrary, gain of protein binding partners can trigger toxic sec-
ondary actions, as for instance activation of additional pathways or sequestration of other un-
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related proteins. Thus, not surprisingly, several reports have linked differential PPIs to patho-
genic effects strongly mediating NDD progression. For instance, wild-type ataxin-1 associates 
with at least two distinct protein complexes: one containing the transcriptional repressor Capi-
cua (CIC) and another one containing the splicing factor RBM17. Disease-associated polyglu-
tamine expansion of ataxin-1 now strongly enhances the formation of the ataxin-1/RBM17 
complex, whereas the formation of the ataxin-1/CIC complex is reduced, resulting in a partial 
loss of ataxin-1 function and worsening of SCA1 neuropathology (Lim et al., 2008). Another ob-
servation is the interaction of polyglutamine expanded huntingtin with a wide range of tran-
scription factors, such as CBP, TAFII130, SF1, TBP, N-CoR, Sin3A and many other factors of the 
basal transcription machinery (Harjes and Wanker, 2003). Hence, transcriptional dysfunction 
is an early event observed in Huntington’s disease (Cha, 2000; Sugars and Rubinsztein, 2003). 
Prospective studies on deciphering protein interactions in NDDs should enable a more de-
tailed view on disease-related dysfunction of cellular information processing and overall fideli-
ty. Applying quantitative AP-MS to resolve both dynamic and differential PPIs in the context of 
NDDs presumably seems to be the most promising approach to address this issue.
 
I.2 Mass spectrometry-based quantitative proteomics
The term “proteomics” expresses the ambition to obtain a systematic survey of all proteins 
in a sample such as a single cell or an individual organism, ultimately in a tempo-spatial man-
ner (Wilkins et al., 1996). Proteomics encompasses many different techniques including yeast-
two-hybrid assays, protein microarrays or high-throughput protein production and crystalliza-
tion. Among the various proteomic approaches, mass-spectrometry (MS)-based proteomics is 
particular popular. A major breakthrough in MS-based proteomic research was accomplished 
by the development of soft ionization methods such as matrix-assisted laser desorption/ion-
ization (MALDI) and electrospray ionization (ESI), which made large biological molecules ame-
nable to mass spectrometry – an advance recognized by the 2002 Nobel prize in Chemistry. 
Over the last ten years many technological improvements, both on the hardware and the soft-
ware side, made MS-based proteomics the dominant technique for most proteomic purpos-
es. Ongoing developments on novel types of mass spectrometers, fragmentation techniques, 
more sophisticated data analysis tools but also improved pre-fractionation approaches for 
sample preparation have pushed the limits of MS-based applications even further. Currently, 
MS-based proteomics is routinely applied to study global protein composition of complete cell 
lines or whole organisms, changes in protein characteristics upon perturbation, biomarker dis-
covery, for detection of a magnitude of post-translational modifications (PTMs) and protein-
protein interactions (Aebersold and Mann, 2003; Cox and Mann, 2011; Cravatt et al., 2007; 
Domon and Aebersold, 2006; Mallick and Kuster, 2010).
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I.2.1  Instrumentation and workflow of mass spectrometry
Mass spectrometers determine the mass-to-charge (m/z) ratio of chemical and biological enti-
ties, such as peptides and proteins. Thus, they can either be used to measure simply the plain 
molecular mass of a polypeptide species or to infer the exact amino acid sequence and other 
more structural features such as PTMs and their respective positional site on the polypeptide 
chain. Identification of proteins can be performed in two ways, either “top-down” by measur-
ing the mass of intact proteins or “bottom-up” through peptide analysis of digested proteins. 
While the first approach is attractive and valuable for certain kinds of biological questions, it 
is technically more feasible to analyze peptides and not whole proteins by MS. Separation and 
solubility issues can be solved easier at the peptide level, furthermore, combinatorial effects 
of ubiquitous protein modifications complicate the exact m/z determination of intact proteins 
(Steen and Mann, 2004). 
A typical bottom-up experimental design for MS-based proteomics is depicted in FIG. I.5. As 
this workflow is central to all MS-related experiments in the present thesis, it will be described 
in more detail. Following the isolation of a protein sample from any biological source, proteins 
are subjected to proteolytic digestion by sequence-specific proteases. Depending on the com-
plexity, samples can be further fractionated at the peptide or the protein level. Most com-
monly, this is achieved by SDS-PAGE, electrostatic exchange procedures (strong anion/cation 
exchange) or isoelectric focusing of peptides or proteins. The generated peptide mixture usu-
ally comprises thousands of peptides of various length and sequence composition. Mass spec-
trometers yet cannot handle the massive sample complexity, since the peptide stoichiometry 
spans additionally several orders of magnitude in abundance. In order to resolve the complex-
ity issue, it is necessary to interpose amendatory separation techniques within the proteomic 
workflow. Most commonly, various combinations of sequential electrophoretic or chromato-
graphic separation methods are used to gain satisfying separation efficiency. One of the high-
est resolving powers can be achieved via reversed-phased liquid chromatography (rpLC). Pep-
tides are injected onto microscale capillary columns filled with reversed-phase material, which 
are directly coupled to the mass spectrometer thus allowing “on-line” examination of ana-
lytes. Eventual, solvent gradients with an increasing fraction of organic content are applied to 
elute peptides from the column in order of their hydrophobicity. As mass spectrometric mea-
surements are carried out in the gas phase, LC-separated peptides are directly ionized by elec-
trostatic dispersion. While the peptide-solvent mixture is nebulized to highly charged droplets 
at the needle tip by the action of high voltage applied to the column, peptides subsequently 
ionize and the solvent vaporizes completely (Steen and Mann, 2004). This electrospray ioniza-
tion allows peptide ions to enter the orifice of the MS, whereas uncharged background mole-
cules do not reach the instrument’s transfer capillary. ESI-generated peptides within the vacu-
um system of the MS are then guided and further manipulated by electrostatic fields. 
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By definition, mass spectrometers consist of three components: an ion source, a mass ana-
lyzer which determines the m/z ratio of ionized analytes and a detector that records the ion 
count at each m/z value (Aebersold and Mann, 2003). There are many different types of mass 
spectrometers available, however, as all described experiments in the present thesis were ex-
clusively analyzed using either LTQ-Orbitrap or Q-Exactive systems, all further remarks refer to 
these types of instruments. The LTQ-Orbitrap is a hybrid mass spectrometer, which combines 
the unique advantages of a linear trap quadrupole (LTQ) system and an Orbitrap mass ana-
lyzer. It became the first fundamentally new mass analyzer for more than 20 years and since 
its introduction in 2005, the LTQ-Orbitrap is the instrument of choice for many applications in 
the proteomic field. The major breakthrough feature of the Orbitrap is its name-giving orbital-
shaped ion trap, where ions move around a central electrode trapped by an electrostatic field. 
Although already theoretically anticipated in the 1920s (Kingdon, 1923), technical limitations 
hindered a successful adaption for mass spectrometry until 2000 (Makarov, 2000). The Q-Ex-
active system is the state-of-the art MS device for large-scale identification of proteins derived 
from complex samples. It combines the Orbitrap mass analyzer with an upstream, high-preci-
sion quadrupole mass filter (Michalski et al., 2011). Though conceptually distinct, both types 
of instruments follow the general principle of mass spectra acquisition in a similar way.
Ionized peptides trapped in the Orbitrap circle around the central electrode with distinct fre-
quencies, which are inversely proportional to the m/z value of each individual peptide. The 
frequency oscillation induces a current which can be constituted in a frequency spectrum and, 
by help of Fourier transformation, can be mathematically converted into a mass spectrum. Os-
cillations frequencies from individual peptides with different masses are used to compute the 
respective m/z value of a given peptide, whereas the amplitude of the oscillation is utilized to 
infer the signal intensity of the analyzed peptide. Recording all peptide masses present in the 
Orbitrap mass analyzer at a specific point in time results in the so called precursor scan.
Having determined the initial mass and intensity information, the MS then proceeds to acquire 
structural information on the peptide sequence by selecting specific peptide ions and subject-
ing them to fragmentation through collision (Steen and Mann, 2004). This approach is called 
tandem MS (MS/MS). While in the LTQ-Orbitrap system inert gas molecules such as helium 
are used to fragment the precursor peptide (referred to as collision-induced dissociation, CID), 
- 29 -
I INTRODUCTION: QUANTITATIVE MASS SPECTROMETRY
the Q-Exactive uses higher-energy collisional dissociation (HCD) to break the selected ion into 
smaller structural pieces. Similar to CID, HCD also uses collision gas such as nitrogen for frag-
mentation, but the radiofrequency voltage in the collision cell is increased by 60% to generate 
high-energy collisions of precursor ions (Olsen et al., 2007). During the precursor scan in the 
Orbitrap, the top N most abundant precursor ions are selected for fragmentation in either the 
LTQ or the quadrupole filter, depending on the system. As a result, the precursor ion produc-
es fragment ions of specific m/z values, from which the amino acid sequence of the selected 
precursor can be deduced. The mass spectrometer will cycle between a sequence of generat-
ed MS and MS/MS spectra, resulting in a specific cycle time for data acquisition.
As described earlier, hybrid mass spectrometers combine the strengths of different mass an-
alyzers. Each system has unique performance parameters, which can be outlined in generic 
terms such as resolution, speed, sensitivity and dynamic range. The resolution of a MS resem-
bles its ability to sufficiently resolve peptide peaks with minimal variations in m/z value. For 
instance, high resolution instruments can itemize distinct isotopes of a specific peptide. This 
is an important consideration as peptide peaks are not displayed as single peak lines but as 
isotope clusters reflecting their natural isotopic distribution. Speed constitutes the number of 
spectra that can be acquired per unit of time, thus is mainly dependent on the instrument’s 
cycle time. The sensitivity represents the ability of an MS instrument to detect the smallest 
possible quantity of an analyte, which is currently in the lower attomolar range. Finally, the 
dynamic range describes the range between the most intense and the least intense analyte 
signal observed in a survey. At present, MS-based identification of proteins is mainly limited 
by the dynamic range of protein expression within a cell. The dynamic range of proteins spans 
seven orders of magnitude in most human cell types (Geiger et al., 2012), human plasma is 
even estimated to have a concentration range that exceeds ten orders of magnitude (Ander-
son and Anderson, 2002). State-of-the art mass spectrometers can nowadays cover a dynamic 
range of 103-105 in single shot experiments (Makarov et al., 2006a,b), still, complete proteome 
FIG I.5 | Common workflow for mass spectrometry-based proteomics. Proteins derived from a biological source are fraction-
ated by various techniques in order to reduce sample complexity, and are subsequently subjected to enzymatic digestion. The 
generated peptide mixture is then further separated by reversed phase high performance liquid chromatography (rpHPLC) di-
rectly coupled to electrospray ionization (ESI). Alternatively, peptides can also be ionized via matrix-assisted laser desorption/
ionization (MALDI). Thereupon, ionized peptides are subjected to the orifice of a mass spectrometer and further manipulated 
by electrostatic fields within various types of mass spectrometers in order to determine the accurate mass of ionized peptides 
(MS spectra) or to obtain sequence information from the fragmented peptides (MS/MS spectra). Finally, the peptide-sequenc-
ing data deduced from the acquired mass spectra are searched against protein databases using different analysis software 
tools, e.g. the MaxQuant platform. (Illustration adapted from Steen and Mann, 2004).
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coverage can be achieved through more extensive pre-fractionation and oversampling, i.e. re-
peated mass spectrometric measurements of the very same sample, at least for most standard 
cell lines (Geiger et al., 2012). Conclusively, the temporal and spatial separated acquisition of 
MS and MS/MS spectra enable hybrid MS instruments to develop their full potential through 
exploitation of their distinct analytical systems. 
In a final step of the proteomic workflow, the acquired mass spectra information needs to 
be converted into peptide and subsequent protein identification events. A probability-based 
matching algorithm is applied which compares the acquired spectra to theoretical spectra ob-
tained from in silico digestion and fragmentation with the very same parametric prerequisites 
as given from the experimental analysis. The algorithm selects the best matching MS/MS spec-
tra and subjects them to a database search of the particular organism under investigation. Giv-
en the tremendous amount of high-resolution mass spectra that are acquired on state-of-the-
art mass spectrometers nowadays, it is no surprise that all the data analysis regarding peptide 
and protein assignment are performed automatically using sophisticated bioinformatic tools. 
As a concluding remark, it is important to mention that all proteomic experiments in the pres-
ent thesis have been performed conducting “shotgun” or “discovery” proteomics. This meth-
od attempts to sequence all proteins present in a particular sample, thus always means de 
novo discovery of a given protein set. The main strength of the shotgun approach is its experi-
mental simplicity and the high proteomic coverage. However, it suffers from the yet limited dy-
namic range of modern mass spectrometers and bioinformatic challenges related to inferring 
protein information from peptide information (Domon and Aebersold, 2006). Hence, if only a 
subset of proteins is under investigation, for instance a particular signaling pathway, “target-
ed” proteomics might be preferable. Such an approach exclusively targets a well defined set of 
proteins; nonetheless, it inherently requires a priori information on the peptide sequence for 
the target selection, which has to be compiled by previous discovery proteomic experiments.
 
I.2.2  Stable isotope labeling by amino acids in cell culture (SILAC)
Recent progress in MS-based proteomics has enabled the routine and robust identification of 
peptides. However, maybe the even more interesting biological questions remain unaddressed 
without adding a quantitative dimension, thus quantification of proteins is of central impor-
tance. Mass spectrometry is not inherently quantitative, therefore, several quantitative tech-
niques have been developed by the MS community to enable accurate assessments of quanti-
tative differences between cellular conditions. 
Relative quantification allows comparing proteins derived from different cell populations rela-
tive to each other. Several methods have been employed in recent years but a thorough review 
of all quantification strategies is beyond the scope of the present thesis, thus they will be de-
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scribed only very briefly. The easiest way to quantify proteins from distinct conditions is the so-
called label-free approach. High abundant proteins are more likely to be detected within the 
mass spectrometer. Therefore, most label-free approaches apply either counting of fragment 
spectra (termed spectral counting) or raw MS signal intensities of peptides derived from the 
very same protein (termed extracted ion current, XIC). Label-free approaches are easy to im-
plement within the proteomic workflow and do not cause extra costs as quantification of pep-
tides and proteins is done bioinformatically. However, label-free approaches inherently com-
pare peptide abundances across independent LC-MS runs, thus several limitations accompany 
label-free strategies. Mainly, differences in sample preparation, ionization efficiency, flyability 
of ionized peptides and minimal shifts in chromatographic retention times may affect the pre-
cision of label-free quantification approaches. 
More accurate quantification can be achieved by stable isotopes. The isotopes can be intro-
duced into biological systems either via chemical modification of proteins or peptides or via 
metabolic labeling of living cells. Frequently used chemical modification approaches are, for 
instance, the transfer of heavy oxygen (18O) during the enzymatic protein digestion (Yao et al., 
2001), chemical tagging of peptides (called isotope-coded affinity tag, ICAT) (Gygi et al., 1999) 
or proteins (termed isobaric tags for relative and absolute quantification, iTRAQ) (Ross et al., 
2004). Like chemical modification strategies, metabolic labeling approaches also require the 
incorporation of heavy stable isotopes, which is based on supplementing growth media of liv-
ing cells with stable isotopes. The basic concept of stable isotope labeling to elucidate cellu-
lar functions has been pioneered by the work of Rudolf Schoenheimer already in the 1930s 
essentially to study intermediary metabolism (Schoenheimer and Rittenberg, 1938). Applica-
tion of metabolic labeling to quantitative proteomics was adapted by 15N labeling and has 
been applied to a wide range of biological questions (Gouw et al., 2011). However, it is only 
since 2002 that another metabolic labeling approach, called SILAC, has received a lot of atten-
tion and has now become the most widely used metabolic labeling approach in quantitative 
MS. SILAC stands for stable isotope labeling by amino acids in cell culture and has been devel-
oped by Shao-En Ong in the lab of Matthias Mann (Ong et al., 2002). As all quantitative MS ex-
periments in this present thesis were accomplished using SILAC, the SILAC strategy will be dis-
cussed in more detail.
SILAC entails the cultivation of cells in different growth media, supplemented with either nor-
mal light or heavy stable isotope versions of essential amino acids containing a distinct num-
ber of 13C, 15N or 2H atoms (Ong et al., 2002). Hence, heavy amino acids are incorporated into 
all newly synthesized proteins. For particular reasons, arginine and lysine are most commonly 
employed as heavy amino acid carriers: lysine is an essential amino acid, which cannot be syn-
thesized by cells and thus has to be taken up from exogenous sources to maintain cell viabil-
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ity. Arginine is an conditionally essential amino acid and is mostly gained through the normal 
diet of cells. In addition, both arginine and lysine have a rather uniform distribution through-
out the proteome of most organisms, ensuring a high labeling saturation of most peptides. Fi-
nally, in most cases trypsin is used as proteolytic enzyme to digest proteins to peptides with-
in the proteomic workflow. As trypsin usually cleaves carboxyl-terminally after each arginine 
and lysine, its sequence specificity generates tryptic peptides carrying only one labeled ami-
no acid, which facilitates the bioinformatic data analysis. Furthermore, labeling by SILAC is 
very fast: after at least five cell doublings the incorporation rate of the heavy isotopes is about 
~97% (1- (0.5)5) (Ong and Mann, 2006) and given the fast cell division rates of most immortal-
ized cell lines, a proper labeling is usually achieved within less than 10 days. The biggest advan-
tage of SILAC, however, is the sample combination at a very early stage right after the actual 
experiment, which minimizes potential errors introduced by sample handling and processing 
compared to label-free and other common chemical labeling strategies. Although stable iso-
tope labeling affects chromatographic characteristics of peptides, co-eluting pairs of chemical-
ly equivalent peptides (referred to as “SILAC pairs”) can still be distinguished from each other 
due to the constant mass differential introduced by the heavy isotopes. Noteworthy, 13C and 
15N-labeled peptides disclose less retention time shifts compared to 2H-labeled peptides, thus 
most researchers use amino acids carrying 13C and 15N atoms in SILAC-based quantitative mass 
spectrometry. As a result, signal intensities derived from the either the light or the heavy pep-
tide peak can be compared reliably and allow an accurate quantification of several thousands 
of proteins in a single experiment, relative to their distinct abundance in the conditions under 
investigation.
In addition, SILAC is not restricted to cultivated cell lines. Over the last years, the scientific 
community has successfully adapted the once in vitro-technique to living organisms such as 
yeast (Gruhler et al., 2005), flies (Sury et al., 2010), nematodes (Larance et al., 2011), newts 
(Looso et al., 2010), mice (Kruger et al., 2008) and others. Even proteins derived from human 
tissue, which is not applicable to metabolic labeling itself, can be quantified via a so called Su-
per-SILAC approach: here, unlabeled human tissue is compared against a Super-SILAC mixture 
of several stable isotope labeled human cell lines, which most closely resembles the tissue’s 
protein expression profile (Geiger et al., 2010). In principle, SILAC is amenable to every living 
organism if a sufficient heavy stable isotope containing diet can be assured and if the organ-
ism does not dilute the introduced stable isotopes via conversion to other than the desired 
amino acids. Interestingly, SILAC can also be utilized to distinguish non-cell autonomous pro-
teins in human cells derived from infectious pathogens, referred to as trans-SILAC (Rechavi et 
al., 2010).
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The overall simplicity has made the SILAC strategy one of the most commonly used quantita-
tive labeling approaches; however, SILAC does have some drawbacks and limitations. First of 
all, SILAC is not easily applicable to primary cell lines, which are potentially the most interest-
ing in vitro system being closest to in vivo conditions in a Petri dish. Secondly, SILAC requires 
proper labeling which can be time-consuming when working with cells exhibiting extremely 
slow cell division rates, such as many neuronal cell lines. Thirdly, SILAC can only be used to dis-
tinguish up to five different conditions at once (Molina et al., 2009), thus other labeling strat-
egies have to be employed if even more conditions are under investigation. Fourthly, extreme 
care is required when handling the growth medium: fetal calf serum (FCS) is required as sup-
plemental for most cell lines but it is a potential source of light amino acids. Consequently, di-
alyzed FCS (dFCS) has to be used that is, however, not compatible with all cell lines, as some 
rare ones do need certain growth factors lost by dialysis. In addition, trypsin can be a com-
mon source of light amino acids as it is necessary to dissociate adherent cells during passag-
ing. Therefore, cells have to be centrifuged after each trypsinization step in order to remove 
remaining trypsin. Fifthly, certain cell lines convert excessive arginine towards proline. Though, 
this problem can be circumvented by either titrating the amount of arginine in the media (Ong 
and Mann, 2006) or by computationally setting off the heavy proline peaks against the heavy 
arginine peak leftovers (Park et al., 2009). Finally, the utilized heavy stable isotopes are expen-
sive, making in vitro SILAC and especially in vivo SILAC-based quantitative proteomics rather 
expensive compared to other labeling strategies.
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I.3 Outline and objectives of the thesis
Neurodegenerative diseases are devastating disorders with a clear proteopathic impact, caus-
ing millions of deaths worldwide each year. Currently, no therapeutic treatment option is avail-
able for any of the described NDDs that substantially cures the disease. 
Given the shared pathogenic commonalities of many NDDs at the protein level, a comprehen-
sive PPI screening approach across several NDD-causative bait proteins might have a great po-
tential to pinpoint disease-critical proteins. Although several studies have been performed to 
elucidate PPI networks for one particular NDD alone (Bai et al., 2008; Goehler et al., 2004; Jin 
et al., 2007; Soler-Lopez et al., 2011), there is only very limited data available for a compar-
ative PPI analysis of several different NDDs altogether (Lim et al., 2006; Limviphuvadh et al., 
2007) clearly pointing out the need for systematic and in-depth PPI analysis across distinct 
NDDs. The aim of the present thesis was thus to systematically identify and quantify PPIs of 
the major disease proteins involved in the most common NDDs, utilizing SILAC-based quanti-
tative mass spectrometry. 
The q-AP-MS approach is ideally suited for studying quantitative PPIs. On one hand, it allows 
unambiguous discrimination of unspecific binders and thus excludes many spurious interac-
tors from the dataset. On the other hand, it enables the detection of preferential binders, 
hence shows how PPIs might be affected by NDD-associated mutations.
To this end, the q-AP-MS strategy is applied to highlight both total and differential interac-
tors of wild-type and disease-associated variants implicated in neurodegeneration, resulting 
in a global PPI network for NDDs. The generated quantitative PPI data should provide a highly 
valuable resource for the neurodegenerative disease community. Functional follow-up exper-
iments of either wild-type or mutant bait variants will most likely gain novel insights into mo-
lecular mechanisms involved in progression and potential crosstalk of distinct neurological dis-
eases.
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II.1 General suppliers
All chemicals were purchased from the laboratory suppliers Merck (Darmstadt, Germany), 
Roth (Karlsruhe, Germany) or Sigma-Aldrich (Steinheim, Germany), if not stated otherwise.
II.2  General buffers and solutions
Solutions and buffers for bacterial handling
LB (lysogeny broth) medium
10 g Bacto tryptone (BD, Franklin Lakes, NJ, USA), 5 g Bacto yeast extract (BD), 5 g NaCl, ad 1 L 
with dH2O adjusted to pH 7.4; for plates 1.5% (w/v) agar was added.
Ampicillin
100 mg/µl stock solution in dH2O, sterilized by filtration, aliquots were stored at -20°C. Work-
ing concentration was 100 µg/µl.
IPTG (Isopropyl β-D-1-thiogalactopyranoside)
1 M stock solution in dH2O, sterilized by filtration, aliquots were stored at -20°C. Working con-
centration was 1 mM. 
Solutions and buffers for DNA manipulation and electrophoresis
PEI (polyethylenimine) transfection reagent 
10 mg of linear PEI Max (nominally MW 40,000; PolySciences, Eppelheim, Germany) was dis-
solved in 10 ml dH2O, neutralized to pH 7.5 with approximately 100 µl 1 M NaOH and sterilized 
by filtration. Aliquots were stored at -20°C.
1x TE buffer
10 mM Tris-HCl pH 7.4, 1 mM EDTA 
1x TAE running buffer
40 mM Tris-HCl (pH 8.5), 40 mM acetic acid, 1 mM EDTA
5x DNA loading buffer
63 mM Tris-HCl (pH 6.8), 2% [w/v] SDS, 10% [v/v] glycerol, 0.01% [w/v] bromphenol blue
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Solutions and buffers for protein electrophoresis and protein purification 
Radioimmunoprecipitation assay (RIPA) buffer for cell lysis
50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% [v/v] Triton-X 100, 1% [w/v] Na-Deoxy-
cholate,  0.1% [w/v] SDS. Complete Protease Inhibitor Cocktail (Roche) (1:25) and Phosphatase 
Inhibitor Mix 1 (Sigma) (1:100) were added right before use.
SDS running buffer MES
40 ml 20x NuPAGE MES SDS running buffer for Bis/Tris gels (Invitrogen, Karlsruhe, Germany) 
in 760 ml dH2O.
Transfer buffer
25 mM Tris-HCl pH 8.5, 190 mM glycine, 10% [v/v] methanol, 0.1% [w/v] SDS
Stripping buffer
68 mM Tris-HCl pH 7.5, 2% [w/v] SDS, 0.8% [v/v] β-mercaptoethanol
10x TBS
200 mM Tris base, 1.4 M NaCl, adjusted to pH 7.4
1x TBST
0.1 % [v/v] Tween-20 in 1x TBS
Blocking solution
1x TBST supplemented with 5% [w/v] non-fat dry milk powder
ConA buffer
100 mM sodium acetate pH 7.0, 0.1 M NaCl, 5 mM MgCl2, 5 mM MnCl2, 5 mM CaCl2
Solutions and buffers for LC-MS sample preparation and instrumentation
ABC buffer
50 mM ammonium bicarbonate (NH
4
HCO3) in water (pH 8.0)
Destaining buffer
25 mM ammonium bicarbonate / 50% [v/v] ethanol (EtOH). Equal volumes of 50 mM ABC buf-
fer and 100% [v/v] EtOH were combined.
Reduction buffer 
10 mM dithiothreitol (DTT) in 50 mM ABC buffer. Stored in small aliquots at -20°C. 
Alkylation buffer
55 mM iodoacetamide in 50 mM ABC buffer. Stored in small aliquots at -20°C and kept in the 
dark.
Extraction buffer
3% [v/v] trifluoroacetic acid (TFA) / 30% [v/v] acetonitrile (ACN). Stored at RT.
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Denaturation buffer
6 M urea / 2 M thiourea in 10 mM HEPES (pH 8.0). Stored in small aliquots at  -80°C.
Buffer A
5% [v/v] acetonitrile, 0.1% [v/v] formic acid in water. Stored at RT.
Buffer A*
5% [v/v] acetonitrile, 0.1% [v/v] formic acid in water, 3% [v/v] trifluoroacetic acid. Stored at 
RT.
Buffer B
0.1% formic acid, 80% acetonitrile in water. Stored at RT.
All solutions with direct application for LC-MS/MS analysis were made with LiChrosolv grade 
water or acetonitrile. Further fine chemicals were conform to the standard laboratory equip-
ment.
II.3  Consumables
DNA cloning and purification
- LR Clonase II Enzyme Mix, including LR Clonase II and Proteinase K (Invitrogen)
- Plasmid purification Mini and Midi kits (Qiagen, Hilden, Germany)
SDS-PAGE & Western blotting
- NuPAGE Novex Bis-Tris gels 4-12% (Invitrogen)
- NuPAGE MES SDS running buffer (Invitrogen)
- 4x LDS sample buffer (Invitrogen)
- PVDF blotting membrane Millipore Immobilon-P, 0.45µm pore size (Roth)
- Western Lightning Chemilumincescence Reagent Plus Enhanced Luminol 
 (PerkinElmer, Rodgau, Germany)
- Amersham Hyperfilm ECL (GE Healthcare, München, Germany)
Immunoprecipitation
- µMACS c-myc isolation kit, MACS MultiStand, OctoMACS separation unit, µ and M 
 columns (Miltenyi Biotec, Bergisch Gladbach, Germany)
- NHS-activated Sepharose 4 FastFlow (GE Healthcare) 
- ConcanavalinA Sepharose 4B beads (Sigma-Aldrich)
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Mitochondria isolation and Aconitase activity test
- Mitochondria isolation kit (human), QuadroMACS separation unit, LC columns 
 (Miltenyi Biotec, Bergisch Gladbach, Germany)
- Aconitase activity assay kit (Novagen, Merck)
II.4  Biologicals
Escherichia coli strains
-  OneShot Mach1 T1R for chemocompetent transformation of bacteria, genotype:                         
 F- φ80(lacZ)ΔM15 ΔlacX74 hsdR(rK-mK+) ΔrecA1398 endA1 tonA (Invitrogen)
-   OneShot TOP10 for chemocompetent transformation of bacteria, genotype: F- mcrA  
 Δ(mrr-hsdRMS-mcrBC) φ80(lacZ)ΔM15 ΔlacX74 recA1 araD139 Δ(ara-leu) 7697 galU  
 galK rpsL StrR endA1 nupG λ- (Invitrogen)
Drosophila melanogaster strains
Transgenic flies and housing conditions
All fly-related work was accomplished by Hannes Vossfeldt (University Clinics, RWTH Aachen, 
Aaron Voigt lab). Fly stocks were maintained on standard cornmeal-agar-yeast-molasses-based 
food at 18 °C. Standard crossbreeding of adult Drosophila were conducted at 25 °C. RNAi fly 
strains comprising the human homolog sublibrary were purchased from the Vienna Drosophi-
la RNAi Center (VDRC) where they have been generated by random integration of shRNA-tran-
scribing inverted repeats under UAS-GAL4 control into the Drosophila genome (UAS-shRNA). 
Screening for eye changes by shRNA expression itself was conducted using the GMR-GAL4 
line as a control (TAB.II.1). GMR-GAL4 and UAS-ATXN1-Q30/82 strains were recombined in or-
der to generate the screening stock for the polyQ modifier screen (GMR_ATXN1-Q30/Q82). 
For the screening of polyQ specificity of RNAi candidates, flies overexpressing the mutant tau 
transgene in the eye were utilized (UAS_Tau[R406W] > GMR_Tau[R406W]). For screening pur-
poses, GMR driver stocks were crossbred with UAS-shRNA lines from the VDRC. Screening for 
eye changes by shRNA expression itself was conducted using the GMR-GAL4 line as a con-
trol. GMR-ATXN1-Q82 virgins were crossed to males carrying UAS-RNAi constructs. F1 females 
(GMR-ATXN1 in combination with the respective UAS-RNAi expression) were selected for REP 
evaluation 1-5 days post eclosion. The 29 RNAi lines for the human homologue sublibrary used 
in this study were selected by the VDRC considering known or predicted human homologues 
to the fly genes (Supplementary TAB. VII.1).
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Table II.1 | Utilized Drosophila melanogaster strains
Transgenic line Genotype1 Source
Oregon-R-C wild-type Bloomington #5
GMR-GAL4 w[*];P{w[+mC]=GAL4-ninaE.GMR}12 Bloomington #1104
UAS-lacZ P{w[+mC]=UAS-lacZ.Exel}2 Bloomington #8529
UAS-ATXN1-Q30 y[1]w[118] P{[+]=UAS-SCA1.30Q}[F7] gift of Juan Botas
UAS-ATXN1-Q82 y[1]w[118] P{[+]=UAS-SCA1.82Q}[F7] gift of Juan Botas
GMR_ATXN1-Q30 y[1]w[118]P{[+]=UAS-SCA1.30Q}[F7]/
FM7c; w[*]; P{w[+mC]=long GMR-
GAL4}/CyO
created by Hannes Voss-
feldt
GMR_ATXN1-Q82 y[1]w[118]P{[+]=UAS-SCA1.82Q}[F7]/
FM7c; w[*]; P{w[+mC]=long GMR-
GAL4}/CyO
created by Hannes Voss-
feldt
UAS-Tau[R406W] w[*];;P{w[+mC]=UAS-hTau[R406W]} gift of Mel Feany
GMR_Tau[R406W] w[*];P{w[+mC]=GAL4-ninaE.GMR}12/
CyO;P{w[+]=UAS-Tau[R406W]}/TM3,S
created in the Aaron 
Voigt lab
1 genotype as suggested by Flybase
Evaluation of rough eye phenotype (REP) modification
For assessment of REP modulation, at least five female flies were analysed for changes in the 
severity of eye degeneration. Modifications by the induction of RNAi in polyQ and tau mod-
els were categorized as follows: wild type-like phenotype (---), obvious REP suppression (--), 
subtle REP suppression (-), no change of REP (0), subtle enhancement of REP (+), obvious en-
hancement of REP (++) and lethal (+++). For the GMR-GAL4 screening only the “no change” 
and enhancement terms apply. RNAi lines exhibiting such effects in the GMR-GAL4 control 
flies were excluded from subsequent experiments due to impact unconnected to expression of 
elongated polyQ. Designation of an RNAi line as polyQ modifier candidate required no change 
in control flies and an at least obvious enhancement/suppression of the REP in three inde-
pendent experiments. Candidate lines were tested for polyQ specificity by rescreening with 
Tau[R406W] screening stock. RNAi lines exhibiting similar effects in both models were exclud-
ed from the polyQ candidate set and remainder strains were subjected to more detailed anal-
ysis. Drosophila compound eyes were pictured using an Olympus zoom stereo microscope at 
6.3x magnification and Cell A software.
Homo sapiens cell lines
- HEK293TN: adherent human embryonic kidney cells, carrying a plasmid containing  
 the temperature sensitive mutant of SV-40 large T-antigen and a neomycin resistance  
 cassette. Obtained from System Biosciences, Mountain View, CA, USA
- SH-SY5Y: adherent human neuroblastoma cells. Obtained from the Erich Wanker lab  
 (MDC, Berlin)
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Mus musculus brain samples
Freshly prepared mice brains (female BL/6 mice, 12 weeks old) were obtained from the Ibanez-
Tallon lab (MDC, Berlin). Mice brains were dissected by making a sagittal cut and each cere-
bral hemisphere was lysed completely with 500 µl brain lysis buffer (50 mM Tris pH 7.4, 150 
mM NaCl, 1% [v/v] Triton X-100, 1 mM EDTA, 1 mM EGTA, Complete Protease Inhibitor Cocktail 
1:25) in a glass dounce tissue grinder with approximately 50 strokes on ice. Fully grinded brain 
lysate was immediately snap frozen in liquid nitrogen and stored at -80°C until further usage.
Table II.2 | Antibodies
Name (clone) Host species working dilution 
1st antibody
working dilution 
2nd antibody
Supplier
αAPP (B-4) mouse monoclonal 1:500 1:20,000 Santa Cruz
αATXN1 (L-19) goat polyclonal 1:500 1:30,000 Santa Cruz
αc-Myc (9E10) mouse monoclonal 1:500 1:20,000 Santa Cruz
αCOX1 (1D6E1A8) mouse monoclonal 1:1,000 1:20,000 MitoSciences
αDHCR24 (H-300) rabbit polyclonal 1:500 1:20,000 Santa Cruz
αLRPPRC (H-300) rabbit polyclonal 1:500 1:20,000 Santa Cruz
αPSEN1 (N-19) goat polyclonal 1:500 1:30,000 Santa Cruz
αRPN1 (E-7) mouse monoclonal 1:500 1:20,000 Santa Cruz
αSKP1 (H-6) mouse monoclonal 1:500 1:20,000 Santa Cruz
αSNCA (211) mouse monoclonal 1:500 1:20,000 Santa Cruz
αTBL1XR1 (L-08) mouse monoclonal 1:500 1:20,000 Santa Cruz
αBeta-actin mouse monoclonal 1:50,000 1:20,000 Sigma
HRP conjugated 
anti-mouse
sheep - as indicated 
above
GE 
Healthcare
HRP conjugated 
anti-rabbit
donkey - as indicated 
above
GE 
Healthcare
HRP conjugated 
anti-goat
donkey - as indicated 
above
Santa Cruz
Working dilutions used for Western blotting experiments.
II.5 Cell culture and medium preparation
II.5.1 Cell culture
All cells were cultivated at 37°C with 5% CO2 and split every second or third day. To generate 
cell stocks ~106 confluent cells were briefly washed with 1x PBS, trypsinized (Invitrogen) and 
centrifuged at RT and 1,200 rpm for 5 min, the supernatant was discarded. Next, the cells were 
resuspended in cell freezing medium (Gibco) and gradually frozen using a 5100 cryo 1°C freez-
ing container (VWR, Darmstadt, Germany) filled with isoproanol at -80°C. After two days the 
cell stocks were transferred to the liquid nitrogen storage and kept at -160°C.
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II.5.2 Standard media for cell culture
Dulbecco’s Modified Eagle’s Medium GlutaMAX (DMEM GlutaMAX, High Glucose 4.5 g/l, 
Gibco) was supplemented with fetal calf serum (FCS, Invitrogen). Media were filtered ster-
ile through 0.22 µM vacuum filtration systems (TPP, Trasadingen, Switzerland). For metabolic 
pulse labeling experiments the glucose concentration was lowered to 2.5 g/l.
II.5.3 SILAC media for cell culture
For the preparation of SILAC media for mammalian cells, Dulbecco’s Modified Eagle’s Medi-
um (DMEM, High Glucose 4.5 g/l) lacking arginine and lysine (a custom preparation from In-
vitrogen) was supplemented with dialyzed fetal calf serum (dFCS, Invitrogen) and 4 mM glu-
tamine (Invitrogen). “Heavy” and “medium-heavy” SILAC media were prepared by adding 28 
mg/l 13C
6
15N
4
 L-arginine plus 49 mg/l 13C
6
15N2 L-lysine or by adding 28 mg/l 
13C
6
-L-arginine plus 
49 mg/l D
4
-L-lysine, respectively. Labeled amino acids were obtained from Sigma Isotec (13C
6
-
L-arginine, 13C
6
15N
4
 L-arginine and 13C
6
15N2 L-lysine) and Cambridge Isotope Laboratories (D4-L-
lysine). To prepare “light” SILAC medium, the corresponding non-labeled amino acids (Sigma) 
were added. All SILAC media were filtered sterile through 0.22 µM vacuum filtration systems 
(TPP, Trasadingen, Switzerland).
Table II.3 | Media composition (standard and SILAC media)
Cell line Medium Serum Glutamine source Antibiotics
HEK293TN DMEM 10 % [v/v] FCS GlutaMAX 100 U/ml penicillin, 
100 µg/ml streptavidin
HEK293TN SILAC-DMEM 10 % [v/v] dFCS 4 mM glutamine 100 U/ml penicillin, 
100 µg/ml streptavidin
SH-SY5Y DMEM 15 % [v/v] FCS GlutaMAX 100 U/ml penicillin, 
100 µg/ml streptavidin
SH-SY5Y SILAC-DMEM 15 % [v/v] dFCS 4 mM glutamine 100 U/ml penicillin, 
100 µg/ml streptavidin
 
II.6  Nucleic Acid Work
II.6.1 Cloning utilizing the GATEWAY system
Genes of interest for the protein-protein interaction assay were provided in pDONR201, 
pDONR221 or pDONR223 entry clone plasmids by Katja Muehlenberg (PostDoc in the group of 
Erich Wanker, MDC, Berlin). To shuttle the inserts into the pcDNA5/FRT/TO::1xc-myc destina-
tion vector used for immunoprecipitation, a LR reaction via the GATEWAY system (Invitrogen)
was performed. 50 ng of entry clone was mixed with 150 ng of destination vector and filled up 
to 8 µl with TE buffer (pH 8.0). After adding of 2 µl LR Clonase II the reaction was incubated at 
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25°C for one hour before the shuttling was terminated using 1 µl Proteinase K to degrade the 
LR Clonase II at 37°C for 10 minutes. Destination vectors carrying the shuttled gene of interest 
were subsequently transformed into E.coli Mach1 cells.
II.6.2 Preparation of plasmid DNA
For isolation of plasmid DNA from bacteria a Mini or Midi prep kit (Qiagen) was used accord-
ing to the manufacturer’s instructions. The DNA concentration was measured spectrometrical-
ly using a NanoDrop ND-1000 device (Peqlab, Erlangen, Germany).
II.6.3 Agarose gel electrophoresis
Preparative analysis of shuttled plasmid vectors was achieved by DNA restriction reaction and 
subsequent agarose gel electrophoresis. 1 µg plasmid DNA was incubated with 1 µl (10 U) Bsr-
GI (NEB, Frankfurt a.M., Germany) restriction enzyme, 3 µl Buffer 2 (NEB), 0.3 µl 100x BSA 
(NEB) and 23.7 µl dH2O. The restriction reaction was incubated for 1 hour at 37°C and stopped 
by incubation at 80°C for 20 minutes. Restricted probes were mixed with DNA loading buffer. 
Separation and detection of DNA fragments in the gel was performed with 0.6-1.0% [w/v] of 
agarose in 0.5x TAE buffer supplemented with 1 µg/ml ethidiumbromide and applying 80-120 
V for the aspired time. Visualization of DNA was achieved using an Gel iX imager (Intas, Göt-
tingen) thereby detecting the fluorescence of the DNA-intercalating dye ethidiumbromide. To 
identify the size of nucleic acids, a standard marker (DNA ladder 1kb, NEB) was used. 
II.6.4 Sequencing of plasmid DNA
To guaranty sequence quality of isolated plasmid DNA, all DNA samples were send to an ex-
ternal DNA sequencing facility (SMB Services in Molecular Biology, Berlin). Obtained DNA se-
quence chromatograph data were carefully checked for quality and mutations using DNA Chro-
matogram Explorer (HeracleSoftware).
II.6.5 qRT-PCR
Expression changes at the transcript level were analyzed by qRT-PCR (quantitative reverse 
transcription polymerase chain reaction) performed by Emanuel Wyler (Markus Landthaler 
lab, MDC Berlin). Total RNA from cells were isolated using the miRNeasy kit (Qiagen) according 
to the manufacturer’s protocol. RNA concentration was measured using a NanoDrop system 
(Thermo Scientific, Wilmington, DE, USA). Reverse transcription was performed using 2.2 µg 
total RNA, except for RIP (cf. II.6.6) precipitates where isolated RNA was used completely. After 
DNaseI (Invitrogen) digestion for 15 minutes at 25 °C, the sample was split in 2x20 µl reactions 
and one of them was reversed transcribed using SuperScript III (Invitrogen) and an oligo-dT18 
primer for 1 hour at 50 °C. For quantitative PCR, the 2x SYBR green PCR Mastermix (Applied 
Biosciences, Carlsbad, CA, USA) was used in a 20 µl reaction with 400 nM of each primer and 
0.4 µl of the RT reaction. The amplification was measured and quantified using the StepOne 
system from applied biosciences using relative quantification for all primer pairs. 
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Table II.4 | Primer sequences
Gene Sequence
COX1 (forward) CAGCAGTCCTACTTCTCCTATCTCT 
COX1 (reverse) GGGTCGAAGAAGGTGGTGTT
LRPPRC (forward) GAAGATGCCTTGAACTTGAAAGA
LRPPRC (reverse) GCCTACATACTTGCCGGTGT
Vinculin (forward) CTCGTCCGGGTTGGAAAAGAG
Vinculin (reverse) AGTAAGGGTCTGACTGAAGCAT
Primers are taken from PrimerBank (http://pga.mgh.harvard.edu/primerbank/citation.html) 
(Vinculin) and from the Roche Universal ProbeLibrary (COX1 and LRPPRC).
II.6.6 RIP (RNA-immunoprecipitation)
In order to test whether a distinct protein binds to certain RNA molecules, the protein of in-
terest was immunoprecipiated (cf. II.9.3). Total RNA from lysates used for RIP experiments 
was extracted using Trizol (Invitrogen) followed by ethanol precipitation. RIP precipitates were 
treated with Proteinase K, extracted using Phenol/Chloroform and RNA was isolated using eth-
anol precipitation. Isolated RNA was then subjected to qRT-PCR analysis (cf. II.6.5).
II.7 Bacterial work
II.7.1 Transformation of chemocompetent bacteria
For the transformation of DNA into bacterial cells the heat shock transformation technique 
was used. Chemocompetent E.coli cells were thawed on ice, 200 ng plasmid DNA was added 
to the cells and incubated for 30 min on ice to guarantee an efficient attachment of the plas-
mid DNA to the bacterial membrane. The bacteria/DNA mixture was heat shocked for 30 sec 
at 42°C in a waterbath and immediately put on ice afterwards for 1 min. Next, 250 µl SOC me-
dium (Invitrogen; warmed to 37°C) was added to the cells, followed by a 1 hour incubation at 
37°C and 220 rpm. An adequate dilution of transformed cells was plated on LB agar plates. Ob-
tained efficiency was 108-109 cfu/µg plasmid DNA.
II.8 Working with mammalian cells
II.8.1 Transient transfection of mammalian cells
Plasmid DNA and polyethylenimine (PEI) transfection reagent were mixed together (ratio 
DNA:PEI 1:2) with serum-free cell culture medium (DMEM) and incubated for 15 min at RT to 
ensure an efficient binding of the negatively charged DNA to the polycation PEI. The transfec-
tion setup was then applied directly to the adherent cells and harvested 24-72 hrs after trans-
fection. Cells were transfected at 60% confluency.
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Table II.5 | Setup for PEI-mediated transient transfection of mammalian cells
dish size DNA PEI serum-free medium final medium volume on plate
6well 2 µg 4 µg 0.2 ml 2 ml
10cm 10 µg 20 µg 1.0 ml 10 ml
15cm 15 µg 30 µg 1.5 ml 15 ml
II.8.2 Transfection of siRNAs for RNAi-mediated knockdown
For the transfection of 6well plates 2.5 µg siRNA was mixed with 5 µl Dharmafect transfection 
reagent (Thermo Scientific) and 285 µl serum-free cell culture medium (DMEM). The transfec-
tion setup was incubated for 20 min at RT and then applied directly to the adherent cells and 
harvested 72-96 hrs after transfection. Cells were transfected at 60% confluency.
II.8.3 Harvesting of mammalian cells
Adherent mammalian cells were washed with ice-cold PBS buffer. Next, ice-cold RIPA lysis buf-
fer was added (300 µl RIPA buffer/15 cm cell culture dish) and the cells were scraped off the 
plate using cell scrapers (Corning Inc., Amsterdam, The Netherlands). Depending on the cell 
line, 2-10 U of Benzonase endonuclease (Merck) were added and incubated on ice for 30 min 
to degrade DNA. Cell debris was cleared by centrifugation at 4°C and 13,000 rpm for 15 min.
II.9 Protein analytics
II.9.1   SDS-PAGE
Molecular weight separation of proteins according to their electrophoretic mobility was 
achieved by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis). To ensure 
equal loading of all lanes on the gel the protein concentration was determined spectrometri-
cally upfront using a NanoDrop ND-1000. Protein probes were mixed with SDS loading buffer 
and heated up to 95°C for 5 min. Separation was achieved using discontinous 4-12% Bis-Tris 
gels (NuPAGE, Invitrogen) and applying 200 V (100 mA, 30 Watt) for the desired time. Visual-
ization of proteins was achieved by Coomassie blue staining. Therefore, the gel was incubated 
for 10 min in fixing solution (40% [v/v] methanol, 10% [v/v] acetic acid and 40% [v/v] dH2O), 
another 10 min in pre-staining solution (30% [v/v] methanol, 30% [v/v] NuPAGE Stainer A and 
40% [v/v] dH2O) and 1 hour in colloidal Coomassie blue. After 1 hour, the staining solution was 
replaced with water.
 
II.9.2   Western blotting
One-dimensional separation of protein samples was performed by SDS-PAGE (cf. II.9.1). Gels 
were then blotted onto PVDF membranes via wet (tank) blotting using the XCell II Blot Mod-
ule (Invitrogen) according to the manufacturer’s instructions, applying 1 mA of current per 
cm2 of membrane for 2 h. The membrane was activated prior to use with 100% [v/v] metha-
nol and washed once in transfer buffer. Unspecific binding sites were blocked with 5% [w/v] 
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dry milk powder in 1x TBST at 4°C for 60 min. In order to visualize specific protein bands, the 
membrane was incubated with the respective primary antibody (TAB. II.2) in blocking solution 
at 4°C overnight with shaking. Blots were washed three times in TBST and incubated either 
with the appropriate secondary antibody (TAB. II.2) conjugated to horseradish peroxidase for 
1 h at RT. After three more washing steps in TBST for 10 min the signals of the bound second-
ary antibodies were detected by applying Western Blot Chemiluminescence Reagent Plus for 
ECL immunostaining (PerkinElmer) to the membrane followed by exposition to X-ray films (GE 
Healthcare). For sequential detection of different proteins on the same membrane, the PVDF 
membrane was stripped in stripping buffer (37°C, 20 min, 200 rpm shaking) and washed thor-
oughly with distilled water. Subsequently, the membrane was blocked again and treated as de-
scribed above.
 
II.9.3   Immunoprecipitation
Immunoprecipitations of c-myc-tagged bait proteins were performed using the µMACS c-myc 
Isolation Kit (Miltenyi Biotec) according to the manufacturer’s instructions. Cell lysates with 
overexpressed c-myc::bait fusion proteins (from 2x107 cells) were lysed (cf. II.8.3.) and incu-
bated with 75 µl of anti-c-myc µMACS beads for 30 min on ice. Next, the beads were trans-
ferred to a µMACS M column placed in the magnetic field of the OctoMACS separator. Before, 
M columns were equilibrated with 100 μl RIPA lysis buffer. The on-column beads were washed 
three times with wash buffer 1 and once with wash buffer 2 that are both part of the Miltenyi 
µMACS kit. Proteins bound to the beads were eluted by applying three times 100 µl elution 
buffer (100 mM glycine pH 2.5). The collected eluates were combined in a fresh 2 ml Eppen-
dorf tube and set to protein precipitation (cf. II.9.7).
II.9.4   Co-immunoprecipitation
For one pull-down experiment 50 µl of NHS-Sepharose (N-Hydroxysuccinimide-Sepharose) 
slurry was transferred into a 1.5 ml Eppendorf tube and centrifuged (1,000 g for 2 min) to re-
move the isopropanol conservation covering. Subsequently, the beads were washed once with 
500 µl 1 mM hydrochloric acid and centrifuged again (1,000 g for 2 min), the supernatant was 
discarded. The beads were now washed twice with 200 µl coupling buffer (0.2 M sodium bo-
rate pH 9.0) by centrifugation (1,000 g for 2 min) and removing of the supernatant. Next, 5 -10 
µg of the anti-bait antibody was crosslinked to the NHS-activated beads by incubating for 2 hrs 
at RT on a spinning wheel. Afterwards the beads were centrifuged (1,000 g for 2 min), super-
natant was discarded, and free binding sites on the beads were quenched with 150 µl quench-
ing buffer (0.2 M ethanolamine pH 8.0) for 30 min at RT on a spinning wheel. After quenching, 
the beads were centrifuged (1,000 g for 2 min), supernatant was removed, and the beads were 
washed three times each with 200 µl alternating washing buffers (wash buffer 1: 0.1 M ace-
tate, 0.5 M NaCl, pH 5.0; wash buffer 2: 0.1 M Tris-HCl pH 8.0) to remove non-covalently cou-
pled anti-bait antibody. Finally, the beads were washed with 200 µl RIPA lysis buffer to equil-
ibrate for the following pull-down from cell lysate. For the actual pull-down the beads were 
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incubated overnight at 4°C on a spinning wheel and washed three times on the next day with 
200 µl stringency washing buffer (20 mM Tris pH 7.6, 300 mM NaCl, 5 mM MgCl2) by centrifu-
gation (1,000 g for 2 min), supernatant was discarded. To elute proteins bound to the NHS-Sep-
harose beads, 50 µl of SDS-loading buffer was added and the beads were boiled at 95°C for 5 
min. After centrifugation (2,000 g for 5 min), the supernatant was transferred into a fresh tube 
and was set to SDS-PAGE and Western blotting (cf. II.9.1 and II.9.2).
II.9.5   Pull-down of N-glycosylated proteins
To enrich N-glycosylated proteins, Concanavalin A-Sepharose 4B (Sigma-Aldrich) was used as 
affinity matrix for pull-down experiments. Since Concanavalin A requires Mn2+ and Ca2+ ions 
for carbohydrate binding, all necessary buffers were supplemented with 5 mM MnCl2 and 5 
mM CaCl2. For one pull-down experiment 50 µl of Concanavalin A-Sepharose slurry was trans-
ferred into a 1.5 ml Eppendorf tube and centrifuged (1,000 g for 2 min) to remove the isopro-
panol conservation covering. Subsequently, the beads were washed three times with 200 µl 
ConA buffer by centrifugation (1,000 g for 2 min each) and the supernatant was discarded. Af-
terwards, the Concanavalin A-Sepharose beads were incubated with the cell lysate overnight 
on a spinning wheel at 4°C. The next day, the beads were centrifuged (1,000 g for 2 min) and 
the supernatant was removed, followed by a triple washing step with ConA buffer. To elute the 
target proteins, the beads were incubated three times with 100 µl 1 M glucose solution for 5 
min on a spinning wheel, followed by centrifugation (1,000 g for 2 min) after each elution step. 
The resulting supernatant was combined in a fresh 2 ml Eppendorf tube and set to protein pre-
cipitation (cf. II.9.7).
II.9.6   ELISA detection of secreted Aβ
1-40  
peptides
Detection of secreted Aβ
1-40
 was performed using the 96-well Multi-Array Human/Rodent 
(4G8)-Abeta 40 Ultra-Sensitive ELISA (enzyme-linked immunosrobent assay) (MSD, Gaithers-
burg, MD, USA). The assay was carried out according to the manufacturer’s instructions under 
the supervision of Vanessa Schmidt (PostDoc in the group of Thomas Willnow, MDC Berlin). 
For all experiments, SH-SY5Y cells were conditioned for 24 hrs and the conditioned medium 
was used directly for the ELISA.
II.9.7 Protein precipitation
The sample volume (not more than 300 µl) from a pull-down experiment was transferred to a 
2 ml dust-free Eppendorf tube. Next, 70 µl 2.5 M sodium acetate and 2 µl Glycoblue (Ambion) 
was added to improve precipitation. The mixture was filled up to 2 ml with 100% [v/v] etha-
nol and mixed briefly. The precipitation solution was incubated overnight at room temperature 
and centrifuged the next day with 20,000 g at 4°C for 60 min. The supernatant was removed 
carefully and the protein pellet was air dried. Precipitated protein pellets were stored at 4°C 
until use (cf. II.11.1.2).
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II.10 Assessment of oxidative stress in mitochondria
II.10.1  Isolation of mitochondria
Mitochondria were isolated from HEK293TN cells using the Mitochondria Isolation kit (Milte-
nyi Biotec) according to the manufacturer’s instructions. Mitochondria were prepared from 
104-105 HEK293TN cells. The mitochondrial protein concentration was measured spectromet-
rically using a NanoDrop ND-1000 device (Peqlab).
II.10.2 Enzymatic assay of mitochondrial aconitase activity
Measurement of oxidative stress in isolated mitochondria from HEK293TN cells was deter-
mined by mitochondrial aconitase activity (Aconitase Acitvity Assay Kit, Merck) according to 
the manufacturer’s instructions.
II.11 Liquid-chromatography mass spectrometry (LC-MS)
II.11.1  Sample preparation for mass spectrometry
II.11.1.1 In-gel digestion
To decrease sample complexity, proteins were separated based on their molecular weight by 
1-D discontinuous SDS-PAGE prior to digestion (Shevchenko et al., 2006). SDS-PAGE was per-
formed with harvested whole-cell lysates (cf. II.8.3 and II.9.1) using NuPAGE Novex 4 to 12% 
gradient gels (Invitrogen) under reducing conditions according to the manufacturer’s instruc-
tions. Proteins were fixed in fixative solution and stained afterwards with the Colloidal Blue 
staining Kit (Invitrogen). Whole gel lanes were cut into several gel slices (up to 15 slices) and 
washed three times with ABC buffer to remove Coomassie staining and detergents (SDS). Af-
terwards, reduction buffer was applied to each slice for 30 min at 56°C for reduction of dis-
ulfide bonds followed by alkylation with iodoacetamide (IAA) for 30 min at 37°C in the dark. 
After another washing step, the gel pieces were dehydrated in 100% [v/v] ethanol. The gel 
slices were rehydrated with sequence grade modified trypsin (Promega, Madison, WI, USA; 
protein:enzyme ratio of 50:1) resolved in ABC buffer and incubated overnight at 37°C. Pro-
tease activity was quenched by adding trifluoroacetic acid to adjust the pH to < 2. Peptide ex-
traction from the gel matrix was performed by incubating the gel pieces twice with extraction 
buffer for 20 min each followed by complete dehydration of the gel pieces with 100% [v/v] ac-
etonitrile. After each incubation step, the gel pieces were spun down, supernatants were re-
covered and finally combined. Lastly, samples were dried in a vacuum concentrator (Eppen-
dorf) until 10-20% original volume to remove the acetonitrile and applied to StageTips (cf. 
II.11.2) for desalting and further sample concentration.
 
II.11.1.2 In-solution digestion
Precipitated protein pellets from immunoprecipitation experiments were set to in-solution di-
gestion. 40 µl of denaturation buffer was added to precipitated pellets to solubilize the pro-
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teins. To reduce disulfide bonds 10 mM DTT was added and incubated at 56°C and 1,400 rpm 
in an orbital shaker. Next, 55 mM iodoacetamide was added and incubated at RT and 1,400 
rpm in the dark to alkylate free cysteine moieties, resulting in carbamidomethylation of all free 
cysteine residues. Proteins were then digested by Lys-C endoprotease (Wako, Osaka, Japan; to-
tal protein:LysC ratio of 50:1) for at least three hours. The in-solution digestion was finally di-
luted four times with ABC buffer to reduce the urea/thiourea concentration to 2 M before add-
ing sequence grade modified trypsin (total protein:trypsin ratio of 50:1) and incubating the 
digestion over night at RT and 300 rpm in an orbital shaker. The digestion was stopped the next 
day by adding 10 µl 10% [v/v] trifluoroacetic acid.
 
II.11.2.  Stop and Go Extraction Tip (StageTip) purification
StageTips (Rappsilber et al., 2003) were assembled by punching out small discs of C18 Empo-
re (3M) filter using a 22 G syringe and ejecting the discs into 200 μl pipet tips. The resulting 
C18 Empore columns were conditioned by methanol and equilibrated with buffer A. Peptide 
solutions from in-solution or in-gel digests were adjusted to pH <2.5 and forced through the 
C18 Empore column by centrifugation at a maximum speed of 5,000 rpm. The columns were 
washed once with buffer A*. Peptides were eluted from the StageTips by applying 60 μl of buf-
fer B to the microcolumns. Peptides were directly eluted into an HPLC autosampler plate and 
concentrated in a vacuum concentrator (Eppendorf, Hamburg, Germany) down to 2-3 μl. Af-
ter mixing the peptide solutions with an equal amount of buffer A the samples were ready for 
LC-MS/MS analysis.
 
II.11.3.  HPLC and mass spectrometry
For a single measurement, 5 μl of peptide mixture was injected by an autosampler (LC PAL; 
CTC Analytics, Zwingen, Switzerland) onto a 15 cm silica microcolumn (inner diameter: 75 μm) 
packed in-house with ReproSil-Pur C18-AQ 3-μm resin (Dr. Maisch GmbH, Ammerbuch, Ger-
many). Peptides were eluted by an Eksigent NanoLC-1D Plus liquid chromatography system 
(Eksigent, Dublin, CA, USA) on a 8-59% acetonitrile gradient (200 min) with 0.5% formic acid 
at a nanoflow rate of 200 nl/min. Eluted peptides were sprayed via an electrospray ion source 
(Thermo Scientific, Bremen, Germany) into an LTQ-Orbitrap or LTQ-Orbitrap XL hybrid mass 
spectrometer (Thermo Scientific). Data dependent mode was used for the LTQ-Orbitrap instru-
ment. For one scan cycle, one precusor ion scan was performed in the Orbitrap (m/z range = 
300-1,700; R = 60,000; target value = 106), followed by five most intense ions selected for frag-
mentation by collision induced dissociation (target value: 3,000; monoisotopic precursor se-
lection enabled; wideband activation enabled) and MS/MS scans in the LTQ (linear trap qua-
drupole) part of the machine. Ions were rejected if their charge state was unassigned or if they 
were singly charged. The dynamic exclusion duration for precursor ions selected for MS/MS 
scans was set to 60 s.
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Whole proteome experiments were mesured on Q Exactive systems (Thermo Scientific). For 
this purpose, peptide mixtures were separated by reversed phase chromatography using the 
EASY-nLC system (Thermo Scientific) on in-house manufactured 20 cm fritless silica microcol-
umns with an inner diameter of 75 µm. Columns were packed with ReproSil-Pur C18-AQ 3 µm 
resin (Dr. Maisch GmbH). Peptides were separated on a 8-60% acetonitrile gradient (108 min) 
with 0.5% formic acid at a nanoflow rate of 200 nl/min. Eluting peptides were directly ionized 
by electrospray ionization and transferred into a Q Exactive mass spectrometer (Thermo Sci-
entific). Mass spectrometry was performed in the data dependent positive mode with one full 
scan (m/z  range = 300-1,700; R = 70,000; target value: 3 x 106; maximum injection time = 120 
ms). The 10 most intense ions with a charge state greater than one were selected (R = 35,000, 
target value = 5 x 105; isolation window = 4 m/z; maximum injection time = 120 ms). Dynamic 
exclusion for selected precursor ions was set to 30 s (Kelstrup et al., 2012). 
 
II.11.4.  Processing of raw LC-mass spectrometry data
The generated raw files from the immunoprecipitation experiments, containing the acquired 
MS and MS/MS spectra, were processed using the MaxQuant platform version 1.0.13.13 (Cox 
and Mann, 2008; Cox, et al., 2009). SILAC pairs were assembled from detected isotope pat-
terns, recalibrated and quantified in the Quant module (heavy labels: Lys-8; maximum of 3 la-
beled amino acids per peptide; maximum peptide charge of 6; top 6 MS/MS peaks per 100 Da; 
polymer detection enabled). The derived peak lists were searched using the MASCOT search 
engine (version 2.2, MatrixScience, Boston, MA, USA) against an in-house concatenated tar-
get-decoy database (Nesvizhskii and Aebersold, 2005) combining forward and reversed pro-
tein sequences from the Homo sapiens IPI protein database (release 3.72) and 31 common 
contaminants. LysC specificity, cleaving peptide bonds at the C-terminal side of lysine residues, 
was required. Carbamidomethylation of cysteine was used as fixed modification; oxidation of 
methionine and acetylation of the protein N-terminus were set as variable modifications. A 
maximum of 2 missed cleavages were allowed, and the mass tolerance for fragment ions was 
set at 0.5 Da. In the Identify module, the MASCOT-generated results were further filtered. For 
protein identification, a minimum peptide length of 6 amino acids was required. At least one 
peptide was required to be a unique peptide in a protein group, and a minimum peptide count 
required for a protein group was set to one. Maximum false discovery rate was set at 1% for 
both peptide and protein identifications, estimated based on the reverse hits matched in the 
target-decoy database. Protein quantification was based on unique peptides and non-unique 
peptides assigned to the protein group with highest number of peptides (razor peptides). At 
least one peptide SILAC ratio count was required for quantification of a protein group. Protein 
tables were finally filtered to eliminate the identifications from the reverse database and com-
mon contaminants.
Raw files derived from whole proteome experiments were processed using MaxQuant version 
1.2.2.5. Here, MS/MS spectra were searched by the internal Andromeda search engine (Cox et 
al., 2011a) against the decoy Homo sapiens IPI protein database (release 3.84) containing for-
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ward and reverse sequences. Additionally the database included 248 common contaminants. 
MaxQuant analysis included an initial search with a precursor mass tolerance of 20 ppm the 
results of which were used for mass recalibration (Cox et al., 2011b). In the main Andromeda 
search precursor mass and fragment mass had an initial mass tolerance of 6 ppm and 20 ppm, 
respectively. The search included variable modifications of methionine oxidation, N-terminal 
acetylation and fixed modification of carbamidomethylated cysteine. Minimal peptide length 
was set to six amino acids and a maximum of two miscleavages was allowed. The false discov-
ery rate (FDR) was set to 0.01 for peptide and protein identifications. In the case of identified 
peptides that are all shared between two proteins, these are combined and reported as one 
protein group. Protein quantification was based on unique peptides and non-unique peptides 
assigned to the protein group with highest number of peptides (razor peptides). At least three 
peptide SILAC ratio counts were required for quantification of a protein group. Protein tables 
were finally filtered to eliminate the identifications from the reverse database and common 
contaminants.
II.12 Genome-wide association studies (GWAS)
All GWAS-related work was conducted by Matthias Heinig (MDC Berlin, Norbert Huebner 
lab).
II.12.1  Cohort data acquisition
Cohort data was acquired from two large genome wide wide association studies (GWAS) with 
753/736 cases/controls (GenADA; Li et al, 2008) and 3,941/7,848 cases/controls (GERAD; Har-
old et al., 2009). 
II.12.2  GWAS data analysis
Genomic coordinates of all genes were obtained from biomart (Ensembl release 54). SNP coor-
dinates (NCBI36 assembly) and association summary statistics of the GenADA study were ob-
tained from dbGAP (accession number phs000219v1). The same data structure for the GERAD 
study was kindly provided by the authors. For each bait protein SNP sets were defined which 
comprise all SNPs that are located within a distance of 100 kb of any gene whose protein in-
teracts with the corresponding bait protein. One-sided Wilcoxon-Mann-Whitney test was ap-
plied in order to detect differences of the means of the distribution of GWAS P-values within a 
SNP set compared to the global distribution of P-values. (Heinig et al., 2010). Combined P-val-
ues were computed using Fisher’s method.
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II.13 Bioinformatic analyses
II.13.1  Statistical data analysis
Statistical analysis was done using R statistical environment (version 2.11; Team RDC, 2009) or 
Prism 5 (GraphPad Software, Inc.).
II.13.2  Construction of protein-protein interaction networks
Interaction data was loaded to Biolayout 3D Express (version 2.0, open source software, The 
Roslin Institute, University of Edinburgh, UK) and then manipulated using standard settings 
(Theocharidis et al., 2009).
II.13.3  Cluster analysis of gene ontology (GO) terms
In order to test whether identified PPIs are enriched for certain Gene Ontology (GO) terms, an 
enrichment analysis was performed using the online DAVID bioninformatics resource (http://
david.abcc.ncifcrf.gov/) (Huang et al., 2009). Calculation of over-represented GO terms was 
done by comparing the entire list of identified PPIs per bait proteins to the background, i.e. all 
human proteins. Significant count treshold was set at 1 and the EASE score (modified Fisher’s 
exact test probability) cutoff was set to be 1. Terms with a p-value <0.01 were selected, log- 
and z-transformed, hierarchically clustered and plotted as heatmap using in-house Perl and R 
scripts.
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III Results
III.1 A quantitative proteomic screen for PPIs of neurodegenerative  
 disease proteins
A fundamental challenge in affinity purification-based protein interaction screens is the dis-
crimination of specific from background interactors, as all biochemical purification procedures 
suffer from the trade-off between sensitivity and specificity. On the one hand, mild purifica-
tion procedures achieve high sensitivity as they preserve weak protein-protein interactions 
(PPIs), however, at the same time they give rise to a larger number of unspecific binders. Con-
versely, more stringent washing conditions can reduce the number of unspecific binders but 
also result in loss of more transient PPIs (Gingras et al., 2007). In order to circumvent this is-
sue, quantitative affinity purification followed by mass spectrometry (q-AP-MS) was employed 
(Paul et al., 2011; Vermeulen et al., 2008). The q-AP-MS strategy uses the information of the 
quantitative labeling technique to compare the abundance of proteins co-purifying with the 
bait molecule relatively to proteins co-purifying within a control pull-down. In the present the-
sis, stable isotope labeling with amino acids in cell culture (SILAC) was utilized to differentially 
label two populations of HEK293TN cells. Heavy-labeled cells were transiently transfected to 
express a single N-terminal c-myc-tagged fusion protein, while light-labeled control cells were 
transfected with a corresponding empty vector control (FIG. III.1A). After overexpression of 
the vector constructs for 24 hours, an immunoprecipitation directed against the c-myc-tag was 
performed and the eluates from both pull-down conditions were combined in a 1:1 fashion. 
Finally, the proteins in the combined pull-down eluates were ethanol-precipitated and sub-
jected to LC-MS/MS analysis. Comparison of SILAC ratios obtained from the MS analysis now 
allowed discrimination of specific from unspecific binders. Specific interaction partners were 
expected to show an increased abundance in the heavy form while non-specific contaminants 
should have a 1:1 ratio. To increase the specificity, additional control experiments were carried 
out with swapped isotope labels (termed ‘crossover’ or ‘reverse’ experiments, in contrast to 
initial ‘forward’ experiments), in which protein ratios were expected to be inverted. Proteins 
were considered as specific interaction partners when they were enriched at least twofold on 
average and showed an inverted ratio in the crossover experiment (FIG. III.2).
As a proof-of-principle, the results from the ataxin-1 pull-downs are discussed in the follow-
ing. Ataxin-1 is the disease-causing protein for spinocerebellar ataxia type 1 (SCA1), an au-
tosomal dominant NDD caused by expansions of the CAG repeat tract in the corresponding 
gene sequence, leading to expanded polyglutamine (polyQ) stretches in the protein sequence. 
Healthy individuals carry up to 39 CAG repeats in the ataxin-1 gene sequence, while expanded 
tracts with 40 or more CAG repeats irrevocably cause SCA1 (Gatchel and Zoghbi, 2005). Fur-
thermore, the length of the CAG repeat expansion is inversely correlated to the age of disease 
onset (Zoghbi and Orr, 2000). Ataxin-1 is expressed in various types of neurons but most abun-
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dantly in Purkinje cells of the cerebellum. Disease-associated ataxin-1 with extended polyQ 
tract accumulates in the nucleus and induces neurodegeneration (Kang and Hong, 2009). 
First, proteins that specifically co-purify with the wild-type variant of ataxin-1 with a normal 
polyQ track length (ATXN1-Q30) relatively to the empty vector control were investigated (FIG. 
III.1B). In total, 968 proteins were identified in the ATXN1-Q30 pull-down experiments; though, 
most of these proteins had a heavy-to-light (H/L) SILAC ratio around 1 in both the forward and 
reverse experiments. Thus, these proteins are considered to represent unspecific binders. As 
an important control, the bait protein ATXN1-Q30 itself was found to have a high H/L ratio in 
the forward and an inverse ratio in the crossover experiment, indicating an efficient enrich-
ment of the bait protein during the affinity purification process. In addition, 50 proteins were 
found to specifically co-purify with ATXN1-Q30 in both forward and crossover experiments 
when compared to the empty vector control. Among these, the transcriptional repressor Capi-
FIG. III.1 | Experimental design for the q-AP-MS screen. (A) Stable istotope-labeled HEK293TN cells are transiently transfect-
ed with expression plasmids encoding a bait or control protein with a single c-myc-tag. After protein expression, the tagged 
constructs are immunoprecipitated and the eluates are combined before subsequent MS sample preparation and LC-MS/MS 
analysis. Crossover experiments are performed by swapping the transfected plasmid constructs. Specific interaction partners 
are observed by high heavy-to-light ratios in the forward and low heavy-to-light-ratios in the reverse experiments (highlighted 
by asterisks), whereas non-specific binders have 1:1 heavy-to-light ratio in both experimental conditions. (B+C) Protein-pro-
tein interaction screen for empty vector control pull-down against (B) ATXN1-Q30 (wild-type) and (C) ATXN1-Q82 (mutant), 
including reverse experiments. Specific interactors of ATXN1-Q30 and ATXN1-Q82, repectively, are marked in red. The posi-
tion of the bait protein is indicated.
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cua (CIC) was identified as interaction partner of ataxin-1. CIC is known to interact with atax-
in-1 in mouse cerebellum to cause SCA1 neuropathology (Lam et al., 2006), which indicates 
that the q-AP-MS approach can in addition identify functionally relevant in vivo interaction 
partners. Moreover, six 14-3-3 protein isoforms (beta/alpha, gamma, zeta/delta, epsilon, eta 
and theta) out of seven encoded in the genome, were identified to specifically co-purify with 
ATXN1-Q30. 14-3-3 proteins are considered to be scaffold proteins vital to many different cel-
lular functions; they are known protein interaction partners of both wild-type and mutant 
ataxin-1 and play a critical role in mediating the neurotoxicity in SCA1 (Chen et al., 2003). The 
association of 14-3-3 with ataxin-1 requires the phosphorylation of the ataxin-1 protein on ser-
FIG. III.2 | Exemplary MS/MS spectra of identified peptides from the q-AP-MS screen. SILAC pairs of the forward and the cor-
responding reverse experiment are depicted next to each other. Selected peptides contain one labeled amino acid, resulting in 
a mass difference of 8 Da (Lysine-8 label) or 10 Da (Arginine-10 label) between the light (white circle) and the corresponding 
heavy (black circle) peptide peaks. Note that the heavy-to-light ratios swap between forward and reverse experiments, indi-
cating a specific interaction (A-C). Contaminations and unspecific binders do not show a label-swap behavior (D). 
(A) Wild-type Ataxin1-Q30 interacts with YWHAG (known interaction) and TBL1XR1 (novel interaction), compared to empty 
empty-vector control. (B) Disease-associated Ataxin1-Q82 interacts with U2AF2 (known interaction) and CDC2L1 (novel in-
teraction), compared to empty vector control. (C) When both wild-type and mutant Ataxin1 variants are used as baits in an 
immunoprecipitation experiment, HDAC3 preferentially binds to Ataxin1-Q30, whereas ZNF207 preferentially binds to Atax-
in1-Q82. (D) Actin exhibits ~1:1 ratios in both forward and reverse experiments, indicating an unspecific interaction. The un-
labeled serum protein hemoglobin shows very low heavy-to-light ratios in both experimental conditions, indicating an non-
specific contamination derived from serum.
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ine residue 776 by Akt kinase. Indeed, phosphorylation of ATXN1-S776 was identified in the 
mass spectrometry data (Supplementary FIG. VII.1), indicating that the q-AP-MS approach can 
identify phosphorylation-dependent protein-protein interactions.
Most of the 50 specific interaction partners have not yet been reported to interact with atax-
in-1, however, a large fraction of the interactors is involved in either splicing (CDC2L1, ELAVL1, 
MBNL1, SF1, U2AF1) or transcriptional regulation (KDM1A, MED27, TBL1XR1, TLE4), which is 
consistent with the proposed function of ataxin-1 in the nucleus (Klement et al., 1998; Zoghbi 
and Orr, 2000). Furthermore, other identified interactors were associated with the ubiquitin-
proteasome system (PSMA4, PSMB1, SQSTM1, SKP1, SUMO2, UBC), which has been reported 
as well (Gatchel and Zoghbi, 2005; Zoghbi and Orr, 2000). A yet unanticipated finding was the 
discovery of several interactors related to mitotic checkpoint control (BUB3, CDC2, CDC2L1, 
CDK2, GSPT1), suggesting a putative role of ataxin-1 in cell cycle regulation. 
When performing the same pull-downs experiments with the polyQ-expanded mutant atax-
in-1 protein (FIG. III.1C), 49 specific interactors were identified in total. Remarkably, ~80% of 
the interactors were shared between the wild-type and the mutant ataxin-1 variants. Interest-
ingly, these results suggest that the expansion of the polyQ tract does not dramatically change 
the global protein interactome set of ataxin-1. This is consistent with the observation that 
the polyQ length per se does not influence PPIs in the absence of aggregated protein species 
(Davranche et al., 2011). It is more likely that the polyQ expansion of ATXN1 shifts the quanti-
tative rather than the qualitative balance of certain protein complexes between wild-type and 
disease-associated variants, thus contributing to SCA1 pathology (Lim et al., 2008; Zoghbi and 
Orr, 2009). 
III.1.1    Global analysis of q-AP-MS target identifications
In order to characterize protein-protein interactions of the most common disease-associated 
gene products involved in neurodegenerative diseases, six bait proteins involved in four dif-
ferent disorders were selected and q-AP-MS screens as described above were carried out. For 
each protein both wild-type and disease-associated variants were selected, resulting in 17 dif-
ferent bait candidates (TAB. III.1). Including crossover experiments, 34 pull-downs were per-
formed in total, giving rise to 468 specific protein-protein interactions between 308 unique 
proteins identifications (Supplementary TAB. VII.1). The generated interaction data was as-
sembled into a combined network and grouped for the four NDDs of interest (FIG. III.3A).
Of note, only two proteins, BAG family molecular chaperone regulator 2 (BAG2) and ubiquit-
in (UBC), were detected as interaction partners in all four diseases (FIG. III.3B). Eight further 
proteins, including five proteasomal subunits (PSMA4, PSMA5, PSMA6, PSMB1, PSMD2), two 
heat shock proteins (HSPA8 and HSPB1) and the ubiquitin ligase SKP1 were identified as inter-
action partners shared between at least three of the four diseases. These shared interactors 
are significantly enriched in gene ontology terms protein folding (p < 0.02) and regulators of 
proteolysis (p < 4.0E-05, Benjamini-Hochberg correction applied), which is consistent with the 
current hypothesis that protein misfolding is a common theme in several NDDs and cellular 
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countermeasures include the UPS and molecular chaperones (Muchowski and Wacker, 2005). 
However, the vast majority of PPIs were unique for the individual diseases. These results re-
flect not only the considerable differences between the native cellular functions of the respec-
tive disease proteins, but also suggest distinct pathogenic processes in the NDDs under inves-
tigation.
Neurodegenerative disease Gene Name Variant #
Alzheimer’s disease (AD) APP Amyloid beta A4 protein
(amyloid precursor protein)
wild-type 1
K670N/M671L 2
V717I 3
PSEN1 Presenilin-1 wild-type 4
A431E 5
Huntington’s disease (HD) Htt506 Huntingtin (N-term 506 aa) Q23 (wild-type) 6
Q145 (mutant) 7
HttEx1 Huntingtin (Exon 1) Q23 (wild-type) 8
Q79 (mutant) 9
Parkinson’s disease (PD) PARK2 Parkin wild-type 10
Q329Stop 11
SNCA Alpha-Synuclein wild-type 12
A30P 13
E46K 14
A53T 15
Spinocerebellar ataxia type 1 (SCA1) ATXN1 Ataxin-1 Q30 (wild-type) 16
Q82 (mutant) 17
III.1.2    Validation of protein-protein identifications
Altogether, the assembled NDD protein interaction network contains several PPIs which have 
been reported in the literature and possess high biological relevance. In line with the already 
mentioned ATXN1 interaction partners (cf. III.1), many other known interactions were identi-
fied, for instance the binding of huntingtin with VCP (Hirabayashi et al., 2001), association of 
PSEN1 with the oligosaccharyltransferase complex (Lee et al., 2010) or interaction of SNCA 
with CSNK2A1 (Okochi et al., 2000). To examine whether identified interactors overall exhibit 
a similar biological function and subcellular localization as their respective bait proteins, inter-
action partners of each bait protein were subjected to gene ontology analysis (FIG. III.4). Visu-
alization of enriched biological terms was done using hierarchical clustering. In terms of both 
localization and function, interaction partners showed enrichment in GO terms as expected for 
the respective bait proteins. For example, interactors of the nuclear proteins ATXN1 and SNCA 
showed enrichment for the GO term ‘nucleus’, interactors of the cytoplasmic proteins HTT and 
PARK2 were enriched in cytosolic-associated compartments and interactors of the transmem-
TAB III.1 | Bait protein variants utilized for the q-AP-MS screen. Six disease-driving proteins in neurodegeneration, covering 
the four most common neurodegenerative diseases were selected for the protein-protein interaction screen. For each of the 
six bait proteins, wild-type and disease-associated sequence variants were selected. Mutant baits are known to trigger the 
particular disease in either human patients or animal models of disease. In total, 17 different bait variants were utilized for 
the q-AP-MS screen.
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brane proteins APP and PSEN1 showed enrichment for ‘endoplasmatic reticulum’-related GO 
terms. Similarly, GO analysis of biological processes revealed that interactors share congener-
ic functional terms with their respected bait proteins. For instance, ATXN1-interactors are en-
riched in ‘mRNA metabolic processes’ or ‘regulation of gene expression’, which is consistent 
with the supposed function of ATXN1 in splicing and transcriptional regulation (de Chiara et 
al., 2009; Tsai et al., 2004). Other well-known examples are reflected by the enrichment for 
HTT interactors in vesicular trafficking (Harjes and Wanker, 2003) or the enrichment of PSEN1 
interactors in ‘proteolysis’ and ‘N-glycosylation’ (Lee et al., 2010; Selkoe and Wolfe, 2007). 
These results indicate that captured PPIs seem to reflect endogenous interactions taking place 
in the native cellular environments of the distinct bait proteins. To assess the overlap of the 
identified PPI to already published interactions systematically, the q-AP-MS interactors were 
mapped to HIPPIE, an integrated human PPI database with experiment-based quality scores 
FIG. III.3 | Global properties of the neurodegenerative disease interaction network. (A) A global disease-grouped protein-
protein interaction network comprised of 468 interactions in total. Depicted are preys (spheres), wild-type baits (donuts) and 
mutant baits (dodecahedrons). Red: polyQ diseases; green: Parkinson’s disease; blue: Alzheimer’s disease. Edges are weight-
ed according to the ratios observed in the SILAC pull-down. (B) A Venn diagram highlights unique and shared interactions be-
tween the bait proteins associated with different neurodegenerative diseases. Interactors which are shared between at least 
three diseases are indicated by name. PANTHER analysis of these ten proteins reveals significant enrichment for either protein 
folding (red) or regulators of proteolysis (blue).
FIG. III.4 | Functional characteristics of selected q-AP-MS targets. Identified interactors were grouped according to the re-
spective bait protein. Visualization of enriched biological terms for the identified interactors was done using hierarchical clus-
tering of z-transformed p-values of significantly (p < 0.01) over-represented GO terms (only Biological Process and Cellular 
Component apply). Bait proteins are additionally clustered by disease.
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(Schaefer et al., 2012). The PPI comparison resulted in a small but highly significant intersec-
tion for the ATXN1, HTT, PARK2 and SNCA interactor sets (TAB. III.2). No significant overlap was 
observed for the two transmembrane proteins APP and PSEN1, although their q-AP-MS inter-
actors are significantly enriched for membrane- and transmembrane-localized proteins, which 
is consistent with their subcellu-
lar localization (FIG. III.4). How-
ever, the utilized q-AP-MS screen 
failed to detect several known in-
teractions, as for instance binding 
of ATXN1 to RBM17 (Lim et al., 
2008) or the association of PSEN1 
with APP and other components 
of the gamma secretase complex 
(Xia et al., 1997). Missed PPI iden-
tification may be due to several 
reasons, which will be discussed 
in detail later on (cf. IV). 
In order to test the reliability of yet unreported interactions identified by q-AP-MS, alternative 
methods were employed to validate them. At first, co-immunoprecipitation (coIP) of select-
ed novel q-AP-MS hits was performed with myc-tagged bait proteins transiently transfected in 
HEK293TN cells. Indeed, in 22 out of 22 cases the Western blotting data confirmed the mass 
spectrometry results (FIG. III.5A). Since tagging and overexpression of the bait protein may al-
ter its interaction behavior, coIP-experiments were additionally performed against the endog-
enous bait proteins. For these experiments, the neuronal cell line SH-SY5Y was used to more 
closely resemble the neuronal environment of NDDs. Again, in 8 out of 8 cases the interaction 
could be validated (FIG. III.5B). Of note, only wild-type interactions could be investigated by 
coIP in SH-SY5Y cells as detection of disease-associated variant interactions would require sta-
ble or transient transfection of the mutant gene product, then again at the cost of expression-
mediated adverse effects. Collectively, the conducted validation experiments indicate that the 
q-AP-MS screening approach can detect PPIs with high specificity.
TAB III.2 | Comparison of identified q-AP-MS targets with HIPPIE. Numbers 
of interactors of each bait protein are indicated for the HIPPIE repository (Hu-
man Integrated Protein-Protein Interaction rEference; Schaefer et al., 2012) 
and identified q-AP-MS hits from the present thesis. P-values have been as-
sesseed via hypergeometric testing against the estimated number of human 
protein-coding genes (22,000).
- 61 -
III RESULTS: PPI SCREEN FOR NEURODEGENERATIVE DISEASE PROTEINS
III.1.3    Assessment of bait protein overexpression off-target effects
It is well known that overexpression of a protein in cellular systems can alter the subcellular 
localization of the protein of interest and can cause changes in the cell’s expression profile. In 
the present thesis, the q-AP-MS screening approach utilizes expression constructs with a hu-
man cytomegalovirus (CMV) promoter, which gets cross-activated via the Simian virus 40 large 
T-antigen stably transformed in HEK293TN cells (Soneoka et al., 1995). This causes a strong 
overexpression of the gene under  control of the cross-activated CMV promoter, which in turn 
might cause changes in protein levels. Disturbed protein levels might in the end lead to erro-
neous identification of protein interactors in the present screening approach.
Therefore, it was reasoned to perform additional validation experiments in order to check 
for potential side effects driven by the overexpression of the bait proteins in HEK293TN cells. 
For instance, known cellular countermeasures to overexpression of proteins include increased 
production of heat-shock proteins (HSPs) and chaprones. To get a more thorough overview on 
HSPs and chaperone binding as a function of bait protein overexpression, all specific interac-
tors of the q-AP-MS screen related to protein folding were clustered against all bait variants 
(FIG. III.5A). As evident from the heatmap analysis, not a single HSP or chaperone was found 
to bind to all bait proteins, suggesting no general cellular countermeasure towards the utilized 
tagged proteins. In fact, the distribution of HSPs and chaperones was quite diverse. While APP 
and SNCA variants exhibited only very few binders, PARK2-WT and Htt506-Q145 bound many 
different HSPs and chaperones. This is probably due to the extreme aggregation propensity of 
Htt506-145 even after 24 hours of expression and the native role of PARK2 as E3-ubiquitin li-
gase, which binds to many misfolded proteins or targets set to degradation. 
FIG. III.5 | Validation of protein-protein interactions obtained from the q-AP-MS screen. Validation of selected q-AP-MS 
identifications by co-immunoprecipitation. (A) Co-IPs of overexpressed c-myc-tagged bait proteins from HEK293TN cells. (B) 
Co-IPs of endogenous bait proteins from SH-SY5Y neuroblastoma cells.
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Yet, an even more important question to assess is whether the overexpression of the bait pro-
teins might alter the global expression profile of the cell. For instance, upregulation of a tran-
scription factor might change the abundance of certain proteins. Also, the expression of a dis-
ease-causing gene product can cause cellular disturbances leading to disturbed PPI formation 
when compared to cells expressing the wild-type variant of a bait protein. In order to detect 
FIG. III.6 | Investigation of potential overexpression off-target effects. (A) Heatmap representation of all identified interac-
tors related to protein folding or regulators of proteolysis across the different bait proteins. (B+C) Global proteome analysis of 
expression changes between wild-type and disease-associated variants after 24 hrs of bait protein overexpression. No appar-
ent changes can be observed for the two Alzheimer’s disease-associated bait proteins PSEN1 and APP. 
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quantitative changes in the proteome upon expression of the bait candidates, HEK293TN cells 
were labeled by stable-isotopes and transiently transfected with the respective expression 
constructs for 24 hours. After harvesting, the two SILAC conditions were combined 1:1 and 
then subjected to LC-MS/MS analysis. Results from the wild-type versus mutant comparison of 
the Alzheimer’s disease causing proteins APP and PSEN1 are shown (FIG. III.6B and C). After 24 
hours of overexpression of the two respective variants, the proteome showed almost no dif-
ferences between the two conditions, indicating that harvesting cells after 24 hours is a good 
point of time to minimize off-target effects driven by the overexpression setup. Thus, the over-
expression of all bait variants utilized for the q-AP-MS screen was done for 24 hours. In sum-
mary, these data indicate that off-target effects driven by the overexpression of the bait pro-
teins do not seem to cause strong cellular responses which would directly interfere with the 
identification of interactors in the employed screening approach.
III.2 Determination of disease-modifying effects in vivo
Validation of identified PPIs is crucial to highlight the specificity of the employed PPI screen-
ing method i.e. investigation of false-positive identifications. However, even true PPIs do not 
necessarily have to be involved in the actual progression of the disease, as they can simply re-
flect basic cellular functions of the bait protein without any relevance to the disorder. In order 
to characterize the potential impact of individual PPIs on the pathogenesis of NDDs, selected 
PPIs were investigated for their possible disease-modifying behavior. Since this requires in vi-
vo-derived data, only a subset of the identified q-AP-MS hits could be further examined. In the 
following, ATXN1-interactors were analyzed via an RNAi approach in D. melanogaster and Al-
zheimer-associated interactions (APP- and PSEN1-interactors) were assessed for their role in 
Alzheimer’s disease by comparing the data with genome-wide association studies (GWAS). 
 
III.2.1  RNAi in a Drosophila neurotoxicity model of ATXN1-Q82
The fruit fly Drosophila melanogaster has proven to be a valuable model system for neuro-
degenerative disease research (Bilen and Bonini, 2007; Fernandez-Funez et al., 2000; Kalten-
bach et al., 2007; Kazemi-Esfarjani and Benzer, 2000). Drosophila compound eyes are made 
up of about 750 single ommatida, each with eight photoreceptor cells. Perturbations of com-
pound eye developmental pathways or neuronal dysfunction can disturb this highly ordered 
neuronal structure leading to a so-called rough eye phenotype (REP). REP is accompanied by 
strong loss of pigmentation and disturbed surface texture. Consequential, expression of neu-
rodegeneration-related proteins under an eye-specific promoter can induce a REP. As the se-
verity of the REP is directly correlated to the loss of underlying photoreceptor neurons and the 
compound eye is moreover easily accessible by light microscopy, REP determination serves as 
a good readout to assess the impact of toxic proteins on neurodegeneration in vivo. In order 
to test whether the identified ATXN1 interactors are enriched in modifiers of ATXN1-mediated 
neurodegeneration in vivo, transgenic flies expressing the human ATXN1-Q82 under the eye-
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specific glass multiple reporter (GMR) within the UAS/GAL4 expression system were utilized 
(Brand and Perrimon, 1993; Fernandez-Funez et al., 2000). These neurodegeneration model 
flies exhibit a characteristic REP in comparison to wild-type flies or flies expressing a GMR-driv-
en control protein (FIG. III.7A-C). Subsequently, GMR_ATXN1-Q82 model flies were crossbred 
with knock-down strains available from the Vienna Drosophila RNAi Center (VDRC). The VDRC 
RNAi fly strains have been generated by random integration of shRNA-transcribing inverted re-
peats under the UAS/GAL4 control into the Drosophila genome (UAS-shRNA).
Of 61 identified human ATXN1 interaction partners in the q-AP-MS screen, 21 had orthologs 
in the fly and 20 of those were available as shRNA strains from the VDRC. To exclude off-tar-
get effects induced by the shRNA per se, all of the VDRC strains were first crossbred with wild-
type flies under control of the same eye-specific promoter (GMR-GAL4 driver line). Three of 20 
strains exhibited strong changes in the eye morphology in the F1 generation (human/fly gene 
name: HSPA5/Hsc70-3, PSMA5/Prosalpha5 and PSMB1/Pros26; Supplementary TAB. VII.3), in-
dicating that knock-down of these three genes apparently has detrimental effects on photo-
receptor integrity apart from overexpression of the toxic ATXN1-Q82 transgene. Consequent-
ly, these three strains were excluded in the subsequent modifier screen. The remaining 17 
knock-down strains were then crossbred with the GMR_ATXN1-Q82 flies. As a result, the F1 
generation expressed the human ATXN1-Q82 transgene and the respective shRNA. Out of all 
lines investigated, 6 lines did not show any overt change in ATXN1-Q82-induced REP and were 
therefore not considered as disease modifying candidates. 11 shRNA-lines did show an appar-
ent change, as either suppression or enhancement of REP was observed. Visible REP changes 
included occasionally appearing necrotic spots (purple, FIG. III.7E and F), manifesting the de-
generation of underlying photoreceptor neurons. Observed disease-modifying effects were 
classified into three categories (cf. II.4. ‘Evaluation of REP modification’), whereas only strong 
events (++, +++, --, ---) were considered as specific modifiers. In case ATXN1-Q82 expression in 
combination with gene silencing yielded no viable offspring, this effect was considered as a le-
thal enhancement (FIG. III.7G). In total, 11 out of 17 shRNA lines (65%) showed a strong REP 
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FIG. III.7 | RNAi in a Drosophila neurotoxicity model of SCA1. Wild-type (A) and lacZ expressing (B) flies are shown as con-
trols. (C) Expression of ATXN1-Q82 in the fly compound eye induces neurodegeneration (rough eye phenotype, REP). Selected 
images of ATXN1-Q82 flies crossed with RNAi strains of identified q-AP-MS targets (D-G; purple spots are necrotic lesions). 
11/17 (~65 %) tested targets show strong enhancement of the REP (e.g. state F or G; p < 1.3E-15), indicating that identified 
interaction partners are strongly enriched for REP modifiers. Additional control knockdowns of targets in Drosophila models 
of Tau did not induce an apparent change in the Tau REP. RNAi of targets in wild-type fly eyes only also did not show any ap-
parent phenotype. 
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enhancement (either ++ or +++), suggesting that the identified ATXN1 interactors are signifi-
cantly enriched (P < 1.3E-15) in modifiers of ATXN1-mediated neurodegeneration in vivo. This 
hit rate of 65% is much higher than in previously conducted forward genetic screens for mod-
ifiers of SCA1 in exactly the same fly model strain, ranging from 1-2% (Branco et al., 2008; Fer-
nandez-Funez et al., 2000). Of note, no modifier exhibiting a strong suppression of the REP 
was observed.
To test whether the observed disease-modifying effects are specific, all shRNA lines were ad-
ditionally tested in a Drosophila model expressing the human Tau protein (GMR_Tau[R406W] 
line), which is implicated in the progression of other proteopahties such as Alzheimer’s and 
Parkinson’s disease. Flies overexpressing the human Tau protein show a very similar REP (Chat-
terjee et al., 2009). None of the tested shRNA strains did show a strong REP change in the Tau 
model with the exception of the three strains that already showed an effect in the GMR control 
screen (Supplementary TAB. VII.3). This indicates that the observed REP-modifiers are specific 
for ATXN1-Q82-mediated toxic effects but not for effects driven by another neurotoxic protein 
Tau. Intriguingly, respective knock-down of the two proteins SF1/SF1 and U2AF2/U2af50 (FIG. 
III.7D and G) results in completely different ATXN1-Q82-induced REP changes, although both 
proteins bind together in a multi-protein complex involved in pre-mRNA splicing (Abovich and 
Rosbash, 1997), suggesting that members of the same macromolecular assembly can have a 
yet strikingly different impact on ATXN1-Q82-mediated pathogenesis in Drosophila.
 
III.2.1  Mapping of PPI data to Alzheimer-specific GWAS
The international HapMap project (The International HapMap Consortium, 2005) resulted in 
the identification of millions of single nucleotide polymorphisms (SNPs), constituting the most 
common DNA sequence variation within the human genome linked to disease phenotypes 
(Gandhi and Wood, 2010). Genome-wide association studies (GWAS) utilize SNP information 
from selected patients compared to healthy individuals to examine disease association across 
the entire human genome. Up to now, GWAS have defined several hundreds of genomic re-
gions containing allelic variations predisposing to a multitude of mendelian diseases (McCa-
rthy et al., 2008). 
Proteins involved in specific diseases have been reported to frequently interact with each oth-
er. Consequently, the combination of protein interaction data with GWAS-derived datasets is 
a powerful approach to decipher signaling networks related to complex disease phenotypes 
(Lage et al., 2007, Lim et al., 2006; Rossin et al., 2011). In order to elucidate the role of identi-
fied interaction partners of the AD-associated bait proteins APP and PSEN1 in the etiology of 
Alzheimer’s disease, datasets from two independent large genome wide association studies 
(GWAS) were analyzed. The GWAS data comprised the GenADA set with 753/736 cases con-
trols (Li et al., 2008) and the GERAD set with 3,941/7,848 cases/controls (Harold et al., 2009). 
First, SNPs of each interaction partner derived from all APP and PSEN1 variants were assem-
bled into SNP sets. Next, it was assessed whether these SNP sets are more likely to be associat-
ed in the GWAS than random sets of SNPs (cf. II.13.2 for more details). All SNP sets defined by 
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the APP disease-associated variants were significantly enriched in both the GenADA and the 
GERAD studies, while the APP wild-type SNP set was only enriched in the larger GERAD cohort 
(TAB. III.3). Of the PSEN1 SNP sets, only the A431E-variant SNP set was significantly enriched in 
the GenADA cohort. However, the combined analysis of both datasets showed a significant en-
richment for all APP-defined SNP sets and for interactors of PSEN1-A431E. These findings indi-
cate that SNPs in genes encoding identified interaction partners of APP are significantly more 
likely to be associated with Alzheimer’s disease and suggest that interaction partners of PS-
EN1-A431E might also be involved in the pathogenesis of AD.
TAB III.3 | GWAS SNP enrichment in two Alzheimer’s disease cohorts. Identified q-AP-MS targets of AD were mapped to 
two independent GWAS datasets for AD (GenADA and GERAD cohorts). SNPs in proximity to interaction partners of APP were 
more likely to be associated in the GWAS than random sets of SNPs. PSEN1 interactors showed enrichment in only one study, 
however the combined analysis suggests that interaction partners of PSEN1-A431E are also involved in the pathogenic pro-
cess.
GenADA cohort GERAD cohort combined
Bait Interactors SNPs p-value SNPs p-value p-value 
APP-K670N/M671L 6 121 < 1.3E-03 159 < 5.9E-03 < 1.0E-04
APP-V717I 4 101 < 7.1E-05 120 < 8.1E-05 < 1.2E-07
APP-WT 9 230 < 0.1044 282 < 8.0E-04 < 8.9E-04
PSEN1-A431E 41 1030 < 1.4E-03 1283 < 0.1344 < 1.8E-03
PSEN1-WT 63 1464 < 0.3475 1896 < 0.2073 < 0.2615
III.3 Determination of differential protein-protein interactions
So far, the presented PPI data derived from the q-AP-MS sets was accomplished by perform-
ing pull-down experiments of either wild-type or disease-associated variants against an emp-
ty vector control. This particular approach is of help to identify PPIs of each individual bait pro-
tein alone. However, it is possible that interaction partners, although binding to both wild-type 
and disease-associated variants, might prefer one over the other. Simply comparing the lists of 
identified interaction partners derived from individual pull-down experiments cannot identify 
such differential interaction partners. In addition, potential binders can escape detection in in-
dividual q-AP-MS experiments, which is in particular true for low abundant proteins or low-af-
finity binders. Thus, specific interaction partners identified only for the wild-type bait protein 
might in fact also bind to mutant bait proteins or vice versa.
To circumvent these limitations and to directly identify interactors with a differential binding 
behavior, it was sought to directly compare interaction partners of wild-type and disease-as-
sociated variant bait proteins in the very same pull-down experiment by q-AP-MS, thus allow-
ing for relative quantification of binding proteins. This approach therefore enables the explo-
ration of interactions that are affected by distinct disease-associated mutations. To this end, 
the same q-AP-MS approach as in FIG. III.1A was employed, with the exception that HEK293TN 
cells were transiently transfected with either wild-type or disease-associated variants instead 
of empty vector controls. Identified proteins were considered as differential interactors when 
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they were enriched at least by a factor of 1 on average and showed an inverted ratio in the 
corresponding crossover experiment. As an additional prerequisite, classification of differen-
tial interactors was restricted to proteins that were identified in the empty vector control pull-
down experiments to exclude false-positive identifications. In total, 107 differential interac-
tors were identified for all 17 bait variants. For example, ten proteins interacted preferentially 
with wild-type ATXN1-Q30, whereas one protein preferentially bound the disease-associated 
variant ATXN1-Q82 (FIG. III.8A). In contrast, 37 identified interactors did not show any bind-
ing preference towards either wild-type or mutant ATXN1 in the differential q-AP-MS experi-
ment. 
Several already known differential interactors were correctly identified in the differential q-AP-
MS approach. For instance, when compared to a recent proteomic analysis of differential hun-
tingtin interactors from mouse brain (Culver et al., 2012), 11 out of 68 Htt506-Q145 binders 
were correctly identified as differential interactors for mutant Huntingtin (FIG. III.8B). Contrari-
wise, 6 out of 68 Htt506-Q145 binders from the q-AP-MS screen were identified as preferential 
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FIG. III.8 | Differential PPIs obtained from q-AP-MS screen. Behavior of of differential protein-protein interactions for (A) 
Ataxin1-Q30 (wild-type) vs. Ataxin1-Q82 (mutant), (B) Huntingtin506-Q23 (wild-type) vs. Huntingtin506-Q145 (mutant), (C) 
Parkin (wild-type) vs. Parkin-Q329Stop (mutant), (D) Amyloid Precursor Protein (wild-type) vs. APP-K670N/M671L (Swedish 
mutation) vs. APP-V717I (London mutation), (E) Presenilin1 (wild-type) vs. Presenilin1-A431E (mutant), (F) Alpha-Synuclein 
(wild-type) vs. three mutants A30P, E46K and A53T, respectively. Determination of differential PPIs has been restricted to up-
front identified PPIs of the respective bait variants compared to empty vector control experiments.
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interactors of wild-type huntingtin. It has to be noted that huntingtin constructs of different 
composition were used in the present thesis and the study from Culver and coworkers, which 
might have an influence on the PPI formation. Furthermore, the association of CIC towards the 
wild-type form ATXN1 was correctly identified as preferential binder of wild-type ataxin-1 (FIG. 
III.8A), reflecting an interaction which is considered to be crucial for neurotoxic effects in the 
cerebellum of SCA1 mice (Lim et al., 2008).
In order to gain novel insights into mechanistic details of yet unreported differential interac-
tions contributing to disease pathogenesis, functional follow-up experiments were conducted 
for two selected differential interactors. First, the differential association of the oligosaccharyl-
transferase (OST) complex towards PSEN1 wild-type was investigated. Second, the preferential 
binding of LRPPRC towards the APP Swedish mutation was examined in more detail. Both fol-
low-up directions led to distinct findings, suggesting impairments in N-glycosylation and mito-
chondrial function in early-onset Alzheimer’s disease and are thus discussed in the following.
III.4 PSEN1 is a mediator of N-glycosylation changes in early-onset  
 Alzheimer’s disease
Presenilin-1 (PSEN1) is a transmembrane protein and the catalytic subunit of the γ-secretase 
complex, which is responsible for the proteolytic processing of several important integral 
membrane proteins such as Notch or APP (Selkoe and Wolfe, 2007). Wild-type PSEN1 has been 
shown to interact with the translocon subunit Sec61α and the catalytic subunit STT3B of the 
oligosaccharyltransferase (OST) complex, supporting a mechanism in which newly synthesized 
polypeptides translocated into the ER are amenable to spatially coordinated posttranslational 
processing by PSEN1 and N-glycosylation by the OST (Lee et al., 2010). Lee and co-workers pro-
vided evidence that PSEN1 is involved in N-glycan transfer, in particular for the v-ATPase V0a1. 
Furthermore, they demonstrated that both murine PSEN1 knock-out blastocysts and fibroblast 
derived from human Alzheimer’s disease patients with familial AD mutations in PSEN1 display 
a similar loss of lysosomal function. The observed autophagosome defect is mediated by inad-
equate lysosome acidification resulting from the failed N-glycosylation of V0a1 in the ER and 
subsequent PSEN1-dependent faulty trafficking of the v-ATPase (Lee et al., 2010). Consistent 
with the published interaction of PSEN1 with the OST complex, the q-AP-MS approach identi-
fied four out of seven human OST subunits as specific interactors of wild-type PSEN1, includ-
ing the catalytic subunit STT3A and both regulatory subunits RPN1 and RPN2 (Supplementa-
ry TAB. VII.1). Two additional OST subunits (STT3B and OSTC) showed a similar preference for 
binding to PSEN1-WT but did not reach enough peptide quantification events in both forward 
and reverse q-AP-MS experiments to pass the applied specificity cutoff. Interestingly, q-AP-MS 
data derived from the direct comparison of PSEN1-WT versus the AD-associated PSEN1-A431E 
mutation showed a preferential binding of the OST members towards the wild-type form of 
PSEN1 (Supplementary TAB. VII.2). These results suggest that the PSEN1-A431E mutation af-
fects the binding to the OST complex and might thus disturb the spatially coordinated process-
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ing of nascent polypeptides in the ER by both PSEN1 and the OST complex. Consequently, PS-
EN1-A431E might have additional detrimental effects on global OST-mediated N-glycosylation, 
besides the already known modulation of γ-secretase activity (Portelius et al., 2010).
 
III.4.1    PSEN1-A431E changes global N-glycosylation pattern in HEK293T cells
In light of the preferential binding of the OST complex towards wild-type PSEN1 and reported 
observations implying a role of wild-type PSEN1 in both N- and O-glycosylation of target pro-
teins (Lee et al., 2010; Leem et al., 2002; Nyabi et al., 2003), a more thorough and global anal-
ysis of PSEN1-dependent effects on OST-mediated N-glycosylation was conducted. Therefore, 
HEK293TN cells were labeled by a triple SILAC approach and transiently transfected either with 
an empty vector control, PSEN1-WT or PSEN1-A431E (FIG. III.9A). As an additional control, the 
selective N-glycosylation inhibitor tunicamycin was added in a second experiment to specifi-
cally determine OST-mediated N-glycosylation effects. After overexpression of the vector con-
structs for 24 hours, a Concanavalin A (ConA)-pull-down was performed to selectively enrich 
N-glycosylated proteins. ConA is a lectin specifically binding to α-D-glucosyl and α-D-mannosyl 
residues of glycoproteins. The OST recognizes the tetradecasaccharide Glc3Man9GlcNAc2 (three 
glucose, nine mannose and two N-acetylglucosamine residues coupled to an dolichol-pyro-
phosphate anchor) with high specificity and transfers this complete oligosaccharide to an as-
paragine residue of an acceptor polypeptide with the appropriate sequon motif N-X-S/T (Mo-
horko et al., 2011). Consequently, a ConA pull-down should selectively enrich glycoproteins 
derived by OST-mediated glycosylation. Pull-down experiments were performed for all three 
SILAC states independently and eluates were combined afterwards in a 1:1:1 fashion and sub-
jected to LC-MS/MS analysis. As PSEN1-WT constructs were transfected in the medium-heavy 
SILAC state in both experimental setups (FIG. III.9A), the medium-heavy condition served as an 
internal standard enabling comparison of all tested conditions across both experiments.
FIG. III.9B depicts the relation of fold-changes in protein abundance between tunicamycin-
treated versus -untreated cells and PSEN1-WT versus PSEN1-A431E overexpression for ap-
proximately 1,500 proteins. Proteins in quadrant III are expected to be hypoglycosylated upon 
PSEN1-A431E expression and sensitive to the tunicamycin treatment, thus are likely targets of 
OST-mediated N-glycosylation. 
To determine whether identified proteins in the ConA pull-down were enriched for Alzheim-
er-associated proteins, the ConA dataset was additionally mapped to the AlzGene database, 
which represents the largest collection of putative AD risk factors (Bertram et al., 2007). Al-
though AlzGene entries were found across the whole scatter plot distribution, they were signif-
icantly enriched (p-value < 1.0E-07) for hypoglycosylated proteins in quadrant III. Even more, 
quadrant III contains several high-ranking AlzGene entries such as APP itself, CLPTM1, SORT1 
or A2M, suggesting that changes in OST-mediated N-glycosylation upon PSEN1-A431E overex-
pression particularly affect AD-related risk factors. 
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In an attempt to validate the quantitative ConA pull-down data, selected proteins were ex-
amined by additional Western blotting (FIG. III.9C). As apparent from the blotting, the SORLA 
protein was detected with several bands in mock-treated and PSEN1-WT overexpressing cells, 
while the highest molecular weight band represents the fully glycosylated SORLA. Tunicamycin 
treatment results in disappearance of the fully glycosylated SORLA band. Overexpression of 
PSEN1-A431E leads to a similar expression profile of SORLA where the fully glycosylated form 
is absent as well.  Additional treatment of cell lysates with PNGase F, a glycosidase that specif-
ically cleaves off all asparagine-linked N-glycans, causes disappearance of the fully glycosylat-
ed SORLA isoforms in mock and PSEN1-overexpressing cells as well, indicating that the high-
est molecular weight band indeed represents the fully glycosylated isoform of SORLA. A similar 
behavior can be seen upon detection of the APP protein, however, the visible band shift be-
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FIG. III.9 | PSEN1-A431E is a mediator of N-glycosylation changes in early-onset Alzheimer’s disease. (A) Experimental 
design for the quantitative Concanavalin A pull-down. (B) Changes on global N-glycosylation pattern upon PSEN1-A431E mu-
tation. Proteins that are hypoglycosylated upon A431E expression and N-glycosylated via the OST complex show enrichment 
for Alzheimer’s disease candidate genes (marked in red, p < 1.0E-07 for quadrant III). (C) Western blot validation of LC-MS/MS 
results. PNGaseF specifically cleaves N-bound glycans. Visible band shift depends on number of N-glycosylations sites (M
W 
of 
each Glc3Man9NAc2 : 2.6 kDa). (D) Secretion of Aß1-40 decreases by ~30% upon siRNA-mediated knockdown of the OST regula-
tory subunit ribophorin 1 (RPN1) in SH-SY5Y neuroblastoma cells (n=4; ***, p <0.001; NTC: non-targeting control).
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tween the fully glycosylated and the non-glycosylated protein is much smaller. This is due to 
the numbers of N-glycosylation sites within the amino acid sequence of a given protein. While 
SORLA contains 27 predicted N-glycosylation sites, APP contains only 1-2 predicted sites, de-
pending on the cell line expressed. Each N-glycosylation residue attached to each site addition-
ally adds approximately 2.6 kDa to the molecular weight of the respective glycosylated pro-
tein. As the fully glycosylated APP isoform has a molecular weight of around 140 kDa, a 2.6-5.2 
kDa shift is more difficult to observe by Western blotting. PSEN1 did not show any apparent 
band shift behavior in the Western blotting, consistent with previous observations reporting 
no post-translational modification of PSEN1 by N-glycosylation (Walter et al., 1996). Accord-
ingly, the Western blotting data matched the quantitative ConA pull-down observations for the 
two selected proteins and proved that PSEN1 does not seem to be N-glycosylated. 
Collectively, these results suggest that the early-onset AD-causing mutation PSEN1-A431E 
changes the global N-glycosylation pattern. In particular, PSEN1-A431E mediates hypoglycosy-
lation of several other AD-related proteins, which might result in disturbed trafficking and/or 
localization of the affected glycoproteins (Leem et al., 2002) and thereby might potentiate det-
rimental effects of several AD-related effector proteins to accelerate disease progression.
 
III.4.2    Processing of APP is regulated by the oligosaccharyltransferase 
     complex 
As evident from the quantitative ConA pull-down data, several Alzheimer’s-associated gene 
products are targets of OST-mediated N-glycosylation, including the mature APP protein (cf. 
III.4.1). To determine whether the OST complex modulates the proteolytic processing of APP 
via the γ-secretase complex, the secretion of Aβ peptides was analyzed as a function of OST 
activity. For this purpose, SH-SY5Y neuroblastoma cells were mock-treated or transfected with 
siRNAs directed against RPN1 or a non-targeting control. RPN1 is the substrate-specific regu-
latory subunit of the OST complex (Wilson and High, 2007) and siRNA-mediated knock-down 
of RPN1 reduces the overall OST complex activity approximately by 70% (Ruiz-Canada et al., 
2009). After 72 hrs of siRNA transfection, fresh medium was added for another 24 hrs and 
then used in an anti-Aβ
1-40
-directed ELISA. As apparent from the bar chart (FIG. III.9D), the 
amount of secreted Aβ
1-40 
significantly decreases in RPN1 knock-down cells by almost 30% in 
contrast to mock-treated cells. Non-targeting controls did not show significant changes when 
compared to mock-treated SH-SY5Y cells. This observation is consistent with a previous report, 
in which knock-down of two different OST subunits, namely DC2 and KCP2, also reduced Aβ 
levels (Wilson et al., 2011). Therefore, the decrease in toxic Aβ
1-40
 levels upon knock-down of 
different OST subunits indicates that the OST complex specifically alters Aβ production, pre-
sumably via its direct interaction with the γ-secretase complex. 
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III.5 The role of LRPPRC in APPsw-forms of Alzheimer’s disease
Leucine-rich pentatricopeptide motif-containing protein (LRPPRC) is a RNA-binding protein 
that plays a pivotal role in mRNA metabolism in both nuclei and mitochondria. It has been re-
ported to be associated with the nuclear mRNA export machinery (Topisirovic et al., 2009) 
and to act as a transcriptional regulator for a subset of nuclear-encoded mitochondrial genes 
through its interaction with peroxisome proliferator-activated receptor coactivator 1-α (PGC-
1α) (Cooper et al., 2006). More recently, several publications have focused on the role of LR-
PPRC within the mitochondria. Here, LRPPRC cooperates with another RNA-binding protein 
called SLIRP to post-trancriptionally modulate mRNA stability of downstream targets (Sasar-
man et al., 2010; Sondheimer et al., 2010; Xu et al., 2011), presumably via promoting the poly-
adenylation of target transcripts and thus suppressing exonucleolytic mRNA decay in mito-
chondria (Chujo et al., 2012).
LRPPRC is itself a neurodegenerative disease-causing gene product as LRPPRC missense muta-
tions are cause of the rare Leigh syndrome French-Canadian type (LSFC) (Mootha et al., 2003). 
LSFC patients exhibit dramatic decreases in LRPPRC and cytochrome c oxidase levels, leading 
to a breakdown of the mitochondrial respiratory chain in cells of the brain stem that is usual-
ly fatal.
III.5.1    LRPPRC: novel links to Alzheimer’s disease?
LRPPRC was identified as specific interactor in the q-AP-MS screen for the Alzheimer’s dis-
ease-causing amyloid precursor protein (APP). In more detail, LRPPRC showed a preferential 
binding towards the double point mutation APP-K670N/M671L (FIG. III.8D and Supplementary 
TAB. VII.2), which is also called the APP Swedish mutation (APPsw, FIG. I.2). Swedish mutation-
based AD varieties are among the most aggressive forms of AD, exhibiting extremely elevated 
levels of oxidative stress compared to other types of AD based on distinct APP mutations (Bog-
danovic et al., 2001; Marques et al., 2003). To validate the differential binding of LRPPRC to 
APPsw, co-immunoprecipitation experiments were performed in HEK293TN cells overexpress-
ing three different APP variants (FIG. III.10A). Immunoprecipitation of APP revealed a similar 
protein expression level for all APP variants yet a stronger signal in the APPsw lane when co-
stained for LRPPRC. The reciprocal coIP in the same overexpression background showed sim-
ilar results: pull-down of LRPPRC exhibited equal LRPPRC expression levels but a stronger sig-
nal in the APPsw lane when co-stained with an anti-APP antibody. Together, both the q-AP-MS 
results for APP and the coIP/Western blotting data indicate that LRPPRC seems to preferential-
ly bind the APPsw variant over APP wild-type or APP London mutation (APP-V717I). Further-
more, the interaction between LRPPRC and wild-type APP was validated by co-immunoprecip-
itation with wild-type mouse brain lysate (FIG. III.10B), indicating that the interaction seems to 
be functionally relevant in vivo.
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III.5.2    Oxidative stress phenotypes of APPsw cells can be rescued by LRPPRC
Almost all NDDs exhibit severe deficiencies in mitochondrial integrity, however, the precise 
causes for underlying mitochondrial dysfunction are yet unclear in most diseases (Lin and Beal, 
2006). As LRPPRC is one of the most potent regulators of mitochondrial gene expression and 
now has been identified as differential binder of APPsw, it was reasoned that LRPPRC could 
represent a novel link to mitochondrial impairment in early-onset AD. Therefore, the impact 
of LRPPRC and APPsw on mitochondrial metabolism was studied more closely. HEK293TN cells 
were transiently transfected with different expression constructs alone, co-transfected with 
LRPPRC overexpression constructs or siRNAs directed against LRPPRC (FIG. III.10C). After 48 
hours of expression, the cells were gently lysed to preserve subcellular compartments and the 
mitochondria were subsequently isolated from these cells. Next, mitochondrial function was 
spectrometrically assessed by measuring the enzymatic activity of the mitochondrial enzyme 
aconitase. Aconitase contains an iron-sulfur cluster in its enzymatic center and is therefore ex-
tremely sensitive to oxidative stress agents as they reduce the [4Fe-4S] to an [3Fe-4s] cluster, 
hence inactivating the enzymatic activity of aconitase. Measuring the mitochondrial aconitase 
activity thus represents a good readout system for monitoring oxidative stress levels in mito-
chondria (Yan et al., 1997).
Expression of LRPPRC increased the aconitase activity in each condition, while knock-down of 
LRPPRC drastically reduced aconitase activity, suggesting that LRPPRC is essential for proper 
mitochondrial function, which is consistent with the literature (Xu et al., 2011). Expression of 
APPsw causes a significant (p < 0.005) reduction of aconitase activity when compared to APP-
WT expressing cells. Co-expression of LRPPRC together with APPsw was able to partially res-
cue the stress phenotype, suggesting that APPsw-induced stress may be related to LRPPRC. In-
terestingly, no significant difference in aconitase activity could be found between APP-WT and 
APP-V717I expressing cells, indicating that the stress phenotype is specific for APPsw but not 
for another early-onset variant of AD.
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FIG. III.10 | LRPPRC preferentially binds APPsw and partially rescues APPsw-phenotypes. (A) Western blot of APP-IP or re-
ciprocal LRPPRC-IP after overexpression of APP variants in HEK293TN cells. LRPPRC binds stronger to APPsw (K670N/M671L) 
compared to APP wild-type or APP-V717I. (B) LRPPRC can be co-immunoprecipitated with endogenous APP from wild-type 
mouse brain lysate and vice versa in reciprocal coIP experiments. (C) Overexpression of APPsw causes significantly reduced ac-
onitase activity in isolated mitochondria compared to wild-type APP, indicating higher levels of oxidative stress. Co-expression 
of LRPPRC in APPsw-expressing cells partly rescues the stress phenotype (mean ± SD; n=4; **, p < 0.005; *, p < 0.05).
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III.5.3    The APPsw-mediated phenotype is accompanied by decreased levels  
     of LPPPRC and its downstream targets
While the determination of aconitase activity revealed deficits in the mitochondrial activi-
ty of APPsw compared to wild-type APP expressing cells, tracking only one mitochondrial en-
zyme might be too simplistic for assessing the overall mitochondrial fidelity, thus a more glob-
al study was reasoned. 
At first, triple stable-isotope labeled HEK293TN cells were transfected for 48 hrs with either 
APP-WT, APPsw or APPsw co-transfected with LRPPRC in order to characterize global proteome 
changes. Expression of APPsw induced downregulation of both LRPPRC and SLIRP compared to 
cells expressing wild-type APP (FIG. III.11A, proteins marked in red). In addition, well-known 
targets of LRPPRC and SLIRP, e.g. different subunits of the cytochrome c oxidase (Complex IV) 
or NADH dehydrogenase (Complex I), exhibited reduced protein levels upon APPsw expres-
sion (FIG. III.11A, proteins marked in yellow), which is consistent with previous reports on mi-
tochondrial responses to loss of LRPPRC (Gohil et al., 2010). Co-expression of LRPPRC together 
with APPsw was able to partially rescue the expression phenotype, shifting the protein levels 
of LRPPRC, SLIRP and their downstream targets back to almost wild-type APP expression lev-
els (FIG. III.11B). 
As both LRPPRC and SLIRP are RNA-binding proteins that regulate the mRNA stability of their 
downstream targets, it was straightforward to investigate mRNA levels of the respective gene 
products as well. Quantitative RT-PCR analysis revealed a decrease of the corresponding 
mRNA levels of LRPPRC and COX1 in cells expressing APPsw compared to wild-type APP (FIG. 
III.11C).
All the aforementioned findings suggest a yet unreported interplay between LRPPRC and the 
amyloid precursor protein APP and, in particular, with the APP Swedish mutation. Paradoxi-
cally, overall LRPPRC levels seem to be downregulated upon APPsw expression, while at the 
same time the interaction between APPsw and LRPPRC is enhanced compared to cells express-
ing wild-type APP. Therefore, in an attempt to characterize the molecular details of the APP/
LRPPRC mechanisms more closely, several follow-up experiments were conducted. However, 
neither impaired trafficking of the nuclear-encoded LRPPRC into mitochondria was observed 
(Supplementary FIG. VII.3), nor enhanced degradation of LRPPRC as investigated by pulsed SI-
LAC analysis (Supplementary FIG. VII.4). However, ongoing quantitative RT-PCR experiments 
additionally link LRPPRC to APP: cells expressing APPsw in contrast to APP-WT displayed both 
a reduction of LRPPRC- and COX1-mRNA (FIG. III.11C) and dimished binding of these mRNAs in 
anti-LRPPRC RNA-immunoprecipiations experiments (FIG. III.11D).
Besides the already known binding of LRPPRC to COX1 mRNA (Gohil et al., 2009; Ruzzenente 
et al., 2011), these results suggest that LRPPRC protein could bind its own mRNA as well. On 
the other hand, the data indicate that the APPsw mutation impairs binding of LRPPRC protein 
towards COX1 and LRPPRC mRNA.
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FIG. III.11 | LRPPRC is a novel effector in APPsw-mediated Alzheimer’s disease.  (A) Global proteome changes in HEK293T 
cells as measured by SILAC-based mass spectrometry analysis. APPsw overexpression reduces LRPPRC and SLIRP levels 
(marked in red) and proteins of the mitochdonrial electron transport chain (marked in yellow). (B) LRPPRC overexpression 
partially rescues the effect of APPsw. (C) mRNA levels of LRPPRC and its downstream target COX1 are reduced in APPsw com-
pared to APP wild-type expressing cells; mean ±SD, n=5, ***, P<0.005; *, P<0.05, two-tailed Student’s t-test. (D) LRPPRC- and 
COX1-mRNA can be enriched by immunoprecipitation of LRPPRC protein, suggesting that LRPPRC binds its own mRNA in APP-
WT-expressing cells. LRPPRC- and COX1-mRNA enrichment is markedly reduced after pull-down of LRPPRC in APPsw-express-
ing cells; n=2.
- 76 -
IV Discussion
IV.1 Q-AP-MS strategy and protein-protein interactions
In the present thesis, a quantitative affinity purification followed by mass spectrometry (q-AP-
MS) approach has been utilized to screen for interactors of proteins involved in neurodegen-
erative diseases. In particular, q-AP-MS was applied to identify differential interactions that 
might be affected by distinct disease-associated mutations. The q-AP-MS approach is wide-
ly used in the proteomic community to address various biological questions and is now con-
sidered to represent to most unbiased method to study PPIs with high throughput and high 
reproducibility (Vermeulen et al., 2008). However, given their inherent design, all AP-MS ap-
proaches suffer from the tradeoff between specificity and sensitivity. In the present thesis, the 
implementation of stable isotope labeling and crossover experiments enabled to differentiate 
unspecific binders from specific interactors (FIG. III.1B and C, FIG. III.2). Moreover shown by the 
functional characteristics of the identified interactors (FIG. III.4) and further validation experi-
ments (FIG. III.5). At the same time, however, it was observed that the overlap to many known 
interactions reported in the HIPPIE database was small, though highly significant for most cas-
es (TAB. III.2). As the HIPPIE collection is comprised of data derived from different detection 
methods and various biological sources, a strong overlap to the HIPPIE database was initial-
ly not anticipated. Comparative assessment of PPI data derived from distinct high-throughput 
methods has been shown to poorly correlate, giving rise to complementary datasets with par-
ticular biases towards protein abundance and localization (von Mering et al., 2002). Although 
the HIPPIE database does represent the largest collection of NDD-associated PPIs, it is still im-
perfect: manual inspection of the identified q-AP-MS targets has highlighted several known 
PPIs reported in the literature (e.g. binding of PSEN1 to different subunits of the OST), which 
are conversely not listed in HIPPIE. Thus, the defined overlap in TAB. III.2 underestimates the 
true intersection of identified q-AP-MS targets with known PPIs from the literature. 
Surprisingly, while comparing the q-AP-MS raw data and HIPPIE-listed entries, it became ap-
parent that many literature-reported interactors were actually identified in the pull-down ex-
periments performed in the present thesis but did not exhibit the “anticipated“ ratios, thus 
they were not classified as interactors by the q-AP-MS screen. This discrepancy may be due to 
missing adaptor proteins in HEK293TN cells, which are necessary for the formation of certain 
complexes. Consequently, a putative prey protein might still be expressed in HEK293TN cells, 
but is not part of the complex interacting with the prey in a different cellular system. A second 
possibility are insufficient peptide quantification events for distinct candidate peptides. There-
fore, true interactors might be rejected by the applied specificity cutoffs. Softening of the ap-
plied rules could account for such cases, however, adversely affecting false-positive identifica-
tions at the same time. On the contrary, the HIPPIE database could also be contaminated by 
false-positive identifications reported in previous publications. For instance, as apparent from 
FIG. III.1B and 1C most of the identified proteins show roughly 1:1 ratios, thus indicating un-
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specific binding. Such proteins cannot be discriminated from specific interactors in tradition-
al, non-quantitative AP-MS experiments that are included in HIPPIE. Hence, many reported 
“true” interactors might in fact be unspecific binders. This issue can only be solved by addi-
tional validation experiments.
Still, the small overlap and the failure of the applied q-AP-MS screening approach to detect 
several known interactors from the literature indicates limitations of the method. Possible ex-
planations for false-negative identifications in the present thesis might be (i) interference of 
the tag, (ii) missing expression of prey proteins or particular scaffold proteins mediating bind-
ing of the bait to certain prey proteins in the utilized HEK293TN cell system or (iii) too stringent 
washing conditions. All the aforementioned issues are related to the tradeoff between exper-
imental simplicity and biological relevance. While HEK293TN are easy to work with regarding 
cultivation, SILAC and transient transfection, they are not neuronal cells. Performing the q-AP-
MS approach with neuroblastoma cells for instance would most certainly lead to the finding 
of partially distinct interactions that have not been found in the HEK cells, as they do not ex-
press neuron-specific proteins.
A further subject of debate is the utilization of N-terminal c-myc-tagged bait proteins within 
the q-AP-MS screen. Tagging facilitated the pull-down procedure, as the same anti-c-myc anti-
body was used for all pull-down experiments. In order to minimize tag-related side-effects re-
garding unspecific interactions or solubilization issues, the N-terminal c-myc tag (EQKLISEEDL, 
ten amino acids) was used as a rather small and frequently used tag (Jarvik and Telmer, 1998). 
Nevertheless, it cannot be ruled out that the tag might influence certain PPIs.
Beyond that, potential off-targets effects introduced by the overexpression constructs were in-
vestigated (FIG. III.6). While these experiments did not provide evidence for a strong change 
in the protein expression profile, it cannot be excluded that changes in cellular protein abun-
dance caused by the overexpression had an impact on the results. Stress-responsive proteins 
might therefore have been detected as specific interactors. However, given the co-immuno-
precipitation experiments for the endogenous bait proteins (FIG. III.5B), where all selected in-
teractions have been validated, it is expected that the provided PPI dataset is highly specific.
Finally, it is worth mentioning that a generic q-AP-MS protocol was applied to all bait proteins 
to conduct a straightforward PPI screening. Considering the distinct cellular functions of all 
bait proteins under investigation, it is conceivable that the binding affinities towards their re-
spective interactors can differ quite substantially. Hence, the generic pull-down and washing 
procedure might need optimization for each and every bait protein in order to maximize the 
PPI identification output, which would be extremely costly in terms of time and was therefore 
not carried out.
As follows from the discussion above, a proper assessment of both false-positive and false-
negative rates is almost impossible, since no available set of ‘true’ PPIs can be used for accu-
rate error rate estimation. Given all technical and biological replicates, crossover-experiments 
and subsequent validation experiments, it can be reasoned that the present data derived from 
the q-AP-MS screen is of high specificity and satisfying sensitivity. 
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With the exception of two publications (Lim et al., 2006; Limviphuvadh et al., 2007) no com-
parative analysis combining two or more NDDs has been performed so far. Thus, the pres-
ent thesis represents the first experimental attempt to generate a PPI network across several 
non-related NDDs. While Lim and coworkers developed an interaction network for 23 differ-
ent inherited ataxias, only SCA1 was under investigation in the present thesis. Consequently, 
no cross-comparative results can be drawn on from this particular dataset. Limviphuvadh and 
coworkers generated an in silico PPI network of six NDDs, three of them shared with the pres-
ent thesis. While investigating 201 bait proteins, only five proteins were commonly found in at 
least three diseases. This minor overlap between the different diseases is consistent with the 
present findings that only few proteins are actually shared between different NDDs and most 
interactions are unique to the distinct disorders (FIG. III.3B).
Potentially the most interesting results have been obtained through screening for differential 
PPIs (FIG. III.8 and Supplementary TAB. VII.2). These differential PPIs might directly reveal pro-
teins functionally involved in NDD progression. It has to be stressed again that only interac-
tors identified in the original screen were considered for differential binding behavior, in order 
to reduce increased false-positive identifications. The observed distribution of differential in-
teractions (FIG. III.8) in part reflects the unique characteristics of the respective bait variants. 
For example, the huge difference between interactions of PARK2 wild-type and Q329Stop can 
be explained by the early stop codon mutation that renders the mutated PARK2 protein com-
pletely dysfunctional. Similarly, the utilized huntingtin construct Htt506-Q145 has an extreme-
ly high aggregation propensity thus sequestering a plethora of proteins. It is therefore not sur-
prising that both HTT and PARK2 had many differential interactors. Surprisingly, in the ataxin-1 
experiment only one protein showed a preferential binding towards the mutant ataxin-1 con-
struct ATXN1-Q82. As already mentioned earlier, it is more likely that the ATXN1-polyQ expan-
sion is shifting PPI complex formation between wild-type and mutant forms in a quantitative 
rather than a qualitative way (cf. III.1).
Interestingly, all the bait proteins with point mutations (APP, PSEN1 and SNCA) showed a large 
overlap of interactions and only very few differential interactions. The majority of them exhib-
ited a preference for the wild-type variant of each respective bait protein. Single point muta-
tions might not dramatically change the interactome, unless the point mutation directly af-
fects a binding domain or a very important feature of the protein structure. This observation 
suggests that the effect of the employed disease-associated point mutations on PPI formation 
is subtle. It is expected that the differential interactions provided in the present thesis repre-
sent a rich source for fellow scientists, allowing to identify novel disease mechanisms with di-
rect implications in selected NDDs.
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IV.2 Determination of disease-modifying effects in vivo
Recently, Kaltenbach and coworkers showed that genetic modifiers of NDDs are enriched for 
interactors of the disease-causing proteins in vivo (Kaltenbach et al., 2007). Moreover, two 
ATXN1-interactors have been shown to be genetic modifiers of SCA1, critically for progression 
of the disease in the cerebellum of SCA1-mouse models (Lam et al., 2006; Lim et al., 2008). 
These data show that interaction partners of disease proteins can be informative for disease 
phenotypes. The assessment of disease-modifying effects for ataxin-1 interactors in the Dros-
ophila neurotoxicity model of SCA1 in the present thesis has now led to an extremely signifi-
cant and exalted hit rate (FIG. III.7) which is roughly 30-fold higher than in previous large-scale 
screens performed in the very same model (Branco et al., 2008; Fernandez-Funez et al., 2000). 
Combined, these results demonstrate that large-scale PPI screening combined with genetic in-
teraction studies in Drosophila represent a powerful tool to identify novel candidate modifiers 
of ATXN1-mediated neurotoxicity.
In the end, however, only 30% of all ataxin-1 interactors identified in the q-AP-MS screen 
could be assessed in the fly neurotoxicity model. As the remaining 70% did not have any or-
tholog gene in the fly or no shRNA strain was available, the vast majority of potentially inter-
esting modifiers of ATXN1-mediated neurodegeneration could not be investigated. All of the 
11 identified disease modifiers enhanced the rough eye phenotype. Hence, no REP suppres-
sors were identified in the present thesis. However, previous screens with the very same but 
also with different disease models exhibited both REP enhancers and suppressors at the same 
time (Branco et al., 2008; Fernandez-Funez et al., 2000; Muqit and Feany, 2002). In earlier pub-
lications, the ratio between identified suppressors:enhancers is roughly 1:3. Given the small 
sample size, the failed suppressor detection might simply be a random event.  Alternatively, it 
is also possible that physical interaction partners of ATXN1 have a protective role preventing 
neurodegeneration.
Surprisingly, approximately 40% of all tested Drosophila shRNA strains exhibited lethal pheno-
types in the F1 generation (Supplementary FIG. VII.2) when crossbred with the GMR_ATXN1-
Q82 flies. This high number of genes leading to lethal interactions was unexpected, as the ex-
pression of the toxic ATXN1-Q82 protein is restricted to differentiated cells of the compound 
eye, which should not interfere with the vitality of the flies under investigation. Yet, the em-
ployed GMR promoter has been reported to drive protein expression not only posterior to the 
morphogenetic furrow of the eye disc, but also in a small population of cells in the fly brain (El-
lis et al, 1993; Moses and Rubin, 1991). Consequently, demise of these non-retinal GMR-pos-
itive cells might potentiate deleterious effects of progressing degeneration in the compound 
eye. Also, necrosis of affected GMR-positive cells might spread to neighboring tissue without 
any ATXN1-Q82 expression or might release further toxic molecules, thus preventing normal 
fly morphogenesis and hatching of the fly larvae. It is important to point out that the SCA1 
neurotoxicity model in Drosophila represents a rather artificial system to screen for genetic 
modifiers. Besides the overexpression of a human transgene in an invertebrate animal model, 
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the additional knock-down of selected genes might constitute a factitious system which exhib-
its more off-target, i.e. lethal effects than expected (Ma et al, 2006; Moffat et al., 2007). How-
ever, neither the RNAi knock-downs in wild-type flies nor control screens in Tau model flies 
showed any obvious phenotype (Supplementary TAB. VII.3), suggesting that the observed le-
thal interactions are specific for ATXN1-Q82.
Arguably, the most significant assessment of NDD-modifying effects would be an experimental 
investigation of human patient material. This is very difficult to achieve due to several reasons. 
As an alternative, the PPI data was compared to genome-wide association studies (GWAS).
Overall, a significant SNP set enrichment was replicated in two independent GWAS cohorts for 
all but the PSEN1-WT SNP set. While SNP sets of interactors for all disease-associated but not 
wild-type bait variants showed a significant enrichment in the smaller GenADA cohort, this 
finding could not be replicated in the much bigger GERAD dataset (TAB. III.3). This inconsisten-
cy might be explained by the fact that GWAS cohorts are assorted with patients showing ap-
parent phenotypical symptoms of Alzheimer’s disease, however the exact disease-causing mu-
tations of each participating individual is not determined. Consequently, the GenADA but not 
the GERAD cohort might be biased by patients exhibiting similar mutations as the ones select-
ed for the q-AP-MS screening.
Noteworthy, no individual SNP reached the threshold of genome-wide significance (p-value 
< 1.0E-07) currently applied in most GWAS publications (Gandhi and Wood, 2010). Still, even 
larger p-values might become significant, when considering combinatorial effects of individ-
ual SNPs in distinct genes that could contribute to disease onset or progression (Unoki et al., 
2008). In this way, PPI data might considerably increase the usefulness of GWAS data: combi-
nation of both datasets could identify potential disease-associated genes, which are currently 
falling below commonly used genome-wide significance cutoffs.
 
IV.3 Implications of PSEN1-A431E on N-glycosylation changes in       
 Alzheimer’s disease
Recent findings have assigned a direct role of PSEN1 in the initial steps of protein N-glycosyla-
tion in the ER (Lee et al., 2010). In the present thesis, this hypothesis was corroborated by val-
idation of the interaction between PSEN1 and a large fraction of the oligosaccharyltransferase 
complex (OST) subunits, which are responsible for initial N-glycosylation. Moreover, the early-
onset AD variant PSEN1-A431E was shown to disturb the global N-glycosylation pattern in HEK-
293TN cells (FIG. III.9B), most likely due to impaired coordination of PSEN1- and OST-regulated 
post-translational processing events in the ER.
A potential pitfall of the quantitative ConA experiment performed in this study (cf. III.4.1) is 
the risk of false-positive identifications. Specifically, some proteins might show a significant ra-
tio in the experiment although their glycosylation is not affected. These false-positive identifi-
cations might be technical in nature, e.g. contaminations derived from the ConA specificity or 
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the washing conditions, or linked to other biological effects. As an example, PSEN1 was iden-
tified in the quantitative ConA pull-down experiments in quadrant III (FIG. III.9B) - indicating 
reduced expression and hypoglycosylation in the PSEN1-A431E condition. However, PSEN1 is 
reported not to be N-glycosylated (Walter et al., 1996) and did not exhibit an apparent band 
shift in the Western blot validation experiments (FIG. III.9C), thus raising the question how it 
showed up as specific target of OST-mediated glycosylation. One possible explanation might 
be a “co-purification” of PSEN1 through binding to another quadrant III-target, as for instance 
to its reported binding partner APP which is a known glycoprotein.
Surprisingly, many proteins pulled-down by ConA were not sensitive for the tunicamycin treat-
ment (FIG. III.9B, quadrant I and II). This could connote that these proteins are either not gly-
cosylated at all or glycosylated in an OST-independent manner. As ConA normally displays high 
specificity and also the applied washing conditions during the ConA pull-down were quite 
stringent, it seemed implausible that so many of the identified proteins were not glycosylat-
ed at all. It is tempting to speculate that an alternative glycosylation mechanism is respon-
sible for their identification in the ConA pull-down. As there is no comprehensive N-glyco-
sylation resource or database available, a number of proteins displayed in quadrants I and 
II were manually inspected for different post-translational glycan modifications reported in 
the literature. It was found that several of the inspected proteins (e.g. ENO1, GAPDH, IDH3A, 
LDHA, MDH1, SOD1) are experimentally validated targets of so-called glycation, a non-enzy-
matic form of carbohydrate transfer (Heath et al., 1996; Kato et al., 2000; Kil and Lee., 2004; 
Morgan et al., 2002; Pietkiewicz et al., 2009), turning them into so-called advanced glycation 
end-products (AGEs) (Singh et al., 2001). Glycation is thought to take place under normal phys-
iological conditions but is extremely elevated upon increased age or certain pathologic condi-
tions such as oxidative or carbonyl stress, both hallmarks of NDDs (Munch et al, 1997; Vicente 
Miranda and Outeiro, 2010). As many more tunicamycin-insensitive proteins were identified 
in quadrant I (specific for PSEN1-A431E) than in quadrant II (specific for PSEN1-WT), it seems 
that overexpression of the mutant PSEN1-A431E could induce glycation events. In fact, sever-
al different PSEN1 mutations increase both cellular levels of oxidative stress and reactive car-
bonyl compounds (Guo et al., 1997; LaFontaine et al., 2002), leading to accumulation of AGEs 
in more than 75% of pyramidal neurons in human AD patients with PSEN1 mutations (Munch 
et al., 2002). The present findings could indicate a similar role for PSEN1-A431 in provoking in-
creased glycation events in Alzheimer’s disease.
In a very recent publication, Coen and coworkers were unable to reproduce the findings pro-
posed by Lee et al. (Coen et al., 2012), showing that N-glycosylation is not a necessary prereq-
uisite for proper targeting of the v-ATPase V0a1 in PSEN-/- cells. In contrast, the data from the 
present thesis did identify the related v-ATPase subunit V1a (ATP6AP1, FIG. III.9B, quadrant III) 
as strongly regulated upon PSEN1-A431E expression, going along with the original data by Lee 
and coworkers. Still, the proposed role of PSEN1 in early N-glycosylation steps must be critical-
ly scrutinized in further validation experiments to provide additional support for this hypoth-
esis.
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IV.4 Identification of LRPPRC as novel effector for oxidative stress in  
 APPsw-mediated forms of Alzheimer’s disease
Early-onset Alzheimer’s disease is caused by mutations in either APP or PSEN1/2. Simulta-
neously, increased oxidative stress levels might play an additional role in the progression of 
AD (cf. I.1.2). APP Swedish mutation (APPsw)-mediated forms are among the most aggressive 
types of AD, as they exhibit extremely elevated levels of oxidative stress (III.5.1), accompanied 
by a very rapid disease progression. However, the distinct underlying mechanisms for this are 
yet unknown. 
The present work revealed preferential binding of LRPPRC to APPsw compared to APP wild-
type or the APP-V717I mutation. So far, the conducted experiments show reduced levels of 
both LRPPRC protein and mRNA in APPsw-expressing cells (FIG. III.11A and C). In addition, co-
expression of LRPPRC with APPsw partially rescued APPsw-mediated oxidative stress in mi-
tochondria (FIG. III.10C), suggesting a direct role of LRPPRC in APPsw-mediated forms of AD. 
Since neither trafficking impairments nor enhanced degradation of LRPPRC protein could ac-
count for the observed mitochondrial deficits (Supplementary FIG. VII.3 and VII.4), the re-
duced LRPPRC levels thus cannot be explained by translational or post-translational effects on 
LRPPRC driven by APPsw. However, given the reported role of LRPPRC in post-transcriptional 
regulation and the data obtained from the RNA-immnuoprecipitations (FIG. III.11D), a novel 
feedback mechanism of LRPPRC is proposed on the basis of the data available (FIG. IV.1), which 
includes post-transcriptional regulatory effects as well. According to this model, LRPPRC sta-
bilizes its own transcript in wild-type APP-expressing cells, hence maintaining mitochondrial 
function through positive regulation of respiratory chain-encoded gene products. In contrast, 
sequestration of LRPPRC by APPsw causes reduced stabilization of its own and target mRNAs 
leading to diminished levels of these targets and LRPPRC itself. Since RNA-binding proteins 
such as LRPPRC play crucial roles in gene expression, their spatio-temporal abundance is itself 
tightly regulated, often times by autoregulatory mechanisms (Kishore et al., 2010). It is like-
ly that the observed decline of the LRPPRC protein levels might in the end be a combinatory 
effect of both impaired transcript stability and reduced translation efficiency, due to the pro-
posed LRPPRC-mediated mRNA regulation in human mitochondria (Chujo et al., 2012).
This hypothesis is based on the assumption that LRPPRC could bind its own mRNA, as suggest-
ed by the performed RIP experiments. Yet, pull-down of LRPPRC could be complicated by LRP-
PRC protein that is actually just being translated and thus associated with its own mRNA. In a 
way to provide final evidence for binding of LRPPRC to its own transcript, PAR-CLIP (Photoac-
tivatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation) analysis would be 
desirable (Hafner, Landthaler et al., 2010) and is envisaged within the near future. Hence, not 
only the mRNA-protein interaction but also the direct binding sites could be mapped accord-
ingly. 
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The aforementioned follow-up experiments suggest a novel role of LRPPRC in APPsw-mediat-
ed early onset forms of Alzheimer’s disease. Still, the normal cellular function of LRPPRC bind-
ing to wild-type APP remains unaddressed so far. The actual subcellular location of the interac-
tion is of particular interest. Both proteins exhibit a large intersection of subcellular locations: 
while APP is mainly located at the cell surface and the secretory compartment (De Stroop-
er and Annaert, 2000), proteolytic fragments have been detected in the cytoplasm (Gao and 
Pimplikar; 2001) and the nuclei of neurons as well (Baek et al., 2002; von Rotz et al., 2004). 
Moreover, APP can also be targeted to mitochondria (Anandatheerthavarada et al., 2003). On 
the other side, LRPPRC is mainly mitochondrial (Mili and Pinol-Roma, 2003), but has a signifi-
cant role in the nucleus (Cooper et al., 2006; Topisirovic et al., 2009) and is present in the cyto-
plasm during translation. Successive immunofluorescence co-localization studies on APP and 
LRPPRC have not generated satisfying results (data not shown), thus no conclusive statement 
can be made so far and further studies have to investigate the exact site of the interaction in 
more detail. 
Nevertheless, based on several published findings with regard to the transcriptional activity of 
APP, which is exerted through its proteolytic fragment AICD (cf. III.1.2.), it is tempting to specu-
late that the interaction between APP and LRPPRC takes place in the nucleus. As described ear-
lier, both proteins can act as transcriptional regulators. Interestingly, expression of the APPsw 
not only correlates with the preferential binding of LRPPRC to APP but also with enhanced 
processing of APP to both Aβ and AICD (Kim et al., 2003; Belyaev et al., 2010). APPsw-driven 
and enhanced generation of AICD would sequester LRPPRC in the nucleus, which subsequent-
ly leads to the observed effects on mitochondrial gene expression (cf. IV.1). This assumption 
would be consistent with published findings, which link AICD to mitochondrial function (Hamid 
et al., 2007; Ward et al., 2010). Although very tempting, this hypothesis is not entirely consis-
tent with the current q-AP-MS and follow-up data: as the initial PPI screen was performed with 
N-terminal c-myc-tagged APP variants, the observed interaction must happen with either the 
full-length protein or the ß-secretase-cleaved sAPPß fragment, which still carries the N-termi-
nal myc-tag. The AICD fragment is cleaved off from the C-terminus of the full-length APP pro-
tein, thus it does not carry the N-terminal tag anymore when translocated into the nucleus in 
the present experimental setup. 
Given the present data, three possible explanations await further investigation: (i) the inter-
action independently takes place in the nucleus and an additional compartment; (ii) the inter-
action takes place in only one specific compartment not yet determined; (iii) the interaction is 
an artifact that occurs post-lysis. While (i) requires a much more complex mode of action, (ii) 
is at present considered more unlikely as full-length APP has not been detected so far in the 
mitochondrial matrix (main LRPPRC environment) and LRPPRC has not been detected at the 
plasma membrane or the secretory compartment (main full-length APP environment). Hence, 
high-resolution confocal microscopy experiments should enable a more thorough co-localiza-
tion study of LRPPRC and full-length APP protein. The results of these experiments would al-
low drawing conclusions about the main site of the interaction in more detail.
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FIG. IV.1 | Hypothetical feedback mechanism of LRPPRC in cells expressing either wild-type or Swedish mutation APP. (Left 
panel) LRPPRC binds wild-type APP to act in a yet unknown fashion. LRPPRC protein levels remain physiological, thus allow-
ing proper binding of LRPPRC towards its own (blue) and target mRNAs (yellow; COX1 as exemplified target). LRPPRC-bound 
mRNAs are post-transcriptionally stabilized (Chujo et al., 2012), mitochondria function normally. (Right panel) LRPPRC binds 
stronger towards APPsw, thus less free LRPPRC protein molecules are amenable for mRNA regulation. Downstream mRNA tar-
gets are destabilized and mitochondrial function is hence affected.
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Protein-protein interaction networks offer a way to generate predictions of pathogenic path-
ways in human diseases involving complex molecular processes (Jordan et al., 2012). This sys-
tems perspective was harnessed in the present thesis to generate the first comparative analysis 
of four neurodegenerative disorders at the molecular level and to establish the first systematic 
quantitative PPI screen for normal and disease-associated variants of neurodegenerative dis-
ease proteins. The obtained PPI data corroborated the hypothesis that the four diseases under 
investigation indeed share some functional characteristics. In fact, all of them being responses 
to well-known protein misfolding events in these disorders. However, most interactions were 
unique for each disease, possibly explaining their very different phenotypical manifestations 
and clinical symptoms. Moreover, a significant link to disease phenotypes in vivo was estab-
lished for AD and SCA1 interactors, thus the present PPI dataset provides a promising entity of 
protein binders which seem to play a critical role in the pathogenesis of NDDs.
The present findings on LRPPRC and its role in APP-expressing cells may of help to better un-
derstand the underlying mechanisms responsible for the extensive mitochondrial deficits ob-
served in AD patients carrying the APP Swedish mutation. LRPPRC potentially represents a nov-
el effector protein for these specific early-onset AD cases. In this context, it will be of particular 
interest to further investigate the role of LRPPRC in AD. Based on the present findings, ongoing 
work is centered on the validation of the LPPPRC interaction with APP in human brain samples 
derived from AD patients with the Swedish mutation. Also, investigation of metabolic changes 
in APPsw-conditions and flux analysis of selected metabolites is currently performed. 
Consequently, all work in that direction has important practical implications. Given the sim-
ilarity of contact surfaces of temporary protein complexes with the active sites of enzymes, 
PPIs represent challenging but attractive targets for small molecules or drugs (Archakov et al., 
2003; Sugya et al., 2007). Since there is currently no prospect of total cure for any of the afore-
mentioned neurodegenerative diseases, much effort is now spend towards developing small 
molecule inhibitors of several proteins involved in NDDs (Blazer and Neubig, 2009). The re-
spective knowledge on the most relevant PPIs is an imperative prerequisite in order to devel-
op feasible treatment options to eventually cure these devastating disorders. The assembled 
PPI network for NDDs gained in the present work and, more importantly, the differential PPIs 
may thus be explored for further conceivable drug targets.
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VII.2 Posters and Talks
• Keystone Symposium ‘Proteomics & Interactomes’ 2012, Stockholm, Sweden. “Quan-
titative interaction proteomics identifies LRPPRC as novel target for APPsw-mediated 
forms of Alzheimer’s disease (Poster presentation)
• 4th EU Summer School in Proteomics 2010, Bressanone/Brixen, Italy. “Quantitative in-
teractome profiling of proteins contributing to neurodegenerative diseases“ (Poster pre-
sentation)
• 12th MDC/FMP PhD Retreat 2010, Rheinsberg, Germany. “Quantitative interactome pro-
filing of proteins contributing to neurodegenerative diseases“ (Oral presentation) 
• 2nd Annual Meeting NGFN-Plus and NGFN-Transfer in the Programme of Medical Ge-
nome Research 2009, Berlin, Germany. “Constructing a functional network for a polyQ-
disease model using quantitative proteomics and probabilistic modeling” (Poster presen-
tation)
• Proteomic Forum 2009, Berlin, Germany. “Quantiative proteomics combined with gene 
interaction analysis reveals Huntington’s disease mechanisms “ (Poster presentation)
• 11th MDC/FMP PhD Retreat 2009, Kremmen, Germany. “Quantiative proteomics com-
bined with gene interaction analysis reveals Huntington’s disease mechanisms “ (Poster 
presentation)
• 1st Annual Meeting NGFN-Plus and NGFN-Transfer in the Programme of Medical Ge-
nome Research 2008, Munich, Germany. “Identification and quantification of protein-
protein interactions in neurodegenerative diseases“ (Poster presentation)
• 10th MDC/FMP PhD Retreat 2008, Templin, Germany. “A protein-protein interaction 
screening approach by quantitative proteomics” (Poster presentation)
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VII.3 Supplementary data
VII.3.1 Supplementary figures
Supplementary Figure VII.1 | Detection of phosphorylation-dependent interactions. Phosphorylation of Ataxin-1 at Ser-
ine776 facilitates binding of Ataxin-1 to the 14-3-3 protein. Shown is the MS/MS spectrum of the corresponding peptide 
RWS(p)APESR of Ataxin1 with annotated b- and y-ions. The mass shift of respective b- and y-ions comprising a phosphate 
moeity is indicated by asteriks.
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Supplementary Figure VII.4 | pSILAC analysis reveals no degradation of LRPPRC upon APPsw expression. (A) Light labeled 
HEK293TN cells were transfected with either empty vector control, APP-WT or APPsw. After 24 hrs of expression, light cells 
were pulsed for 24 hrs with medium-heavy medium. 48 hrs post-transfection, medium-heavy cells were harvested and heavy 
cells were spiked in 1:3 to each condition as internal reference control. (B) Heavy peptide peaks were used as reference to 
compare the degradation of light-derived peaks from APP-WT- versus APPsw-transfected cells over time by LC-MS/MS analy-
sis, thus allowing ratio-of-ratio generation. (C) Global protein expression changes for roughly 1,600 proteins do not show any 
apparent degradation effect for LRPPRC or SLIRP. Individual protein ratios are normalized to median changes of all proteins 
quantified.
Supplementary FIG. VII.3 | APPsw does not impair LRPPRC trafficking. HEK293TN cells were transiently transfected with in-
dicated expression constructs for 48 hrs. Subsequent Western blot analysis of isolated mitochondrial fractions and mitochon-
dria-depleted cellular lysates is depicted. Consistent with reported publications, mitochondrial localization can be observed 
for LRPPRC and COX1, whereas APP is not located to the mitochondria. Protein levels of LRPPRC do not show an apparent 
change in mitochondrial localization or retention in the cytosol upon expression of the APP Swedish mutation K670N/M671L, 
thus indicating that LRPPRC trafficking is not disturbed in APPsw-expressing cells compared to wild-type APP cells.
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VII.3.2. Supplementary tables
Supplementary Table VII.1 | Identified prey proteins from q-AP-MS screen
Listed are gene names of identified interactors from the q-AP-MS screen for each bait variant, 
respectively (for specificity assessment cf. III.1). Log2FC reflects the absolute logarithmized H/L 
ratio fold changes from the combined forward and reverse experiment, compared to the em-
pty vector control pull-down. If an H/L ratio could not be assigned by the MaxQuant analysis 
software due to extreme H/L ratios, however, ion intensities have been detected for both the 
corresponding light and heavy peptide peaks, an infinite ratio was assigned (= INF).
Disease Bait variant Prey Log
2
FC Disease Bait variant Prey Log
2
FC
PD PARK2-WT PCBP1 2.021 SCA1 ATXN1-Q30 CDC2 2.001
PD PARK2-WT RPL11 2.032 SCA1 ATXN1-Q30 HSPA5 2.111
PD PARK2-WT RPLP2 2.033 SCA1 ATXN1-Q30 PPP2R1A 2.456
PD PARK2-WT TUBB2C 2.037 SCA1 ATXN1-Q30 MYOM2 2.470
PD PARK2-WT AIFM1 2.083 SCA1 ATXN1-Q30 HSPA1A 2.478
PD PARK2-WT RUVBL2 2.102 SCA1 ATXN1-Q30 MED27 2.586
PD PARK2-WT PGK1 2.138 SCA1 ATXN1-Q30 OBSCN 2.622
PD PARK2-WT CFL1 2.162 SCA1 ATXN1-Q30 HSPA1B 2.624
PD PARK2-WT TUBB 2.164 SCA1 ATXN1-Q30 UBC 2.648
PD PARK2-WT YWHAZ 2.178 SCA1 ATXN1-Q30 ELAVL1 2.762
PD PARK2-WT RPS25 2.190 SCA1 ATXN1-Q30 NID1 3.076
PD PARK2-WT TUBA1C 2.196 SCA1 ATXN1-Q30 DNAJB6 3.169
PD PARK2-WT TUFM 2.200 SCA1 ATXN1-Q30 KDM1 3.212
PD PARK2-WT RPLP0 2.250 SCA1 ATXN1-Q30 U2AF1 3.252
PD PARK2-WT HNRNPH1 2.333 SCA1 ATXN1-Q30 PCMT1 3.283
PD PARK2-WT P4HB 2.341 SCA1 ATXN1-Q30 PSMB1 3.318
PD PARK2-WT CCT6A 2.423 SCA1 ATXN1-Q30 GSPT1 3.423
PD PARK2-WT CCT2 2.444 SCA1 ATXN1-Q30 HSPA8 3.423
PD PARK2-WT XRCC5 2.465 SCA1 ATXN1-Q30 HDAC3 3.502
PD PARK2-WT TXN 2.509 SCA1 ATXN1-Q30 PSMA4 3.599
PD PARK2-WT BAG2 2.511 SCA1 ATXN1-Q30 SF1 3.720
PD PARK2-WT MATR3 2.524 SCA1 ATXN1-Q30 SKP1 3.739
PD PARK2-WT PGAM1 2.571 SCA1 ATXN1-Q30 CDK2 3.815
PD PARK2-WT EEF1A1 2.575 SCA1 ATXN1-Q30 BUB3 4.198
PD PARK2-WT VCP 2.595 SCA1 ATXN1-Q30 SUMO2 4.279
PD PARK2-WT HNRNPF 2.609 SCA1 ATXN1-Q30 TLE4 4.311
PD PARK2-WT PKM2 2.611 SCA1 ATXN1-Q30 EIF4E2 4.499
PD PARK2-WT MYL12B 2.631 SCA1 ATXN1-Q30 RNH1 4.500
PD PARK2-WT ACTBL2 2.637 SCA1 ATXN1-Q30 WDR68 4.603
PD PARK2-WT CCT3 2.646 SCA1 ATXN1-Q30 MLF1 4.936
PD PARK2-WT PDIA6 2.662 SCA1 ATXN1-Q30 SQSTM1 5.364
PD PARK2-WT CCT1 2.671 SCA1 ATXN1-Q30 PRDX4 5.683
PD PARK2-WT ACTG1 2.696 SCA1 ATXN1-Q30 MLF2 6.123
PD PARK2-WT CCT4 2.699 SCA1 ATXN1-Q30 CDC2L1 6.163
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PD PARK2-WT ACTC1 2.750 SCA1 ATXN1-Q30 BAG2 6.283
PD PARK2-WT MDH2 2.771 SCA1 ATXN1-Q30 MBNL1 6.383
PD PARK2-WT HSPD1 2.778 SCA1 ATXN1-Q30 YWHAB 6.613
PD PARK2-WT RPS13 2.839 SCA1 ATXN1-Q30 YWHAZ 6.893
PD PARK2-WT EIF5A 2.859 SCA1 ATXN1-Q30 YWHAE 6.934
PD PARK2-WT NCL 2.898 SCA1 ATXN1-Q30 YWHAG 6.975
PD PARK2-WT PDIA3 2.901 SCA1 ATXN1-Q30 HSPB1 7.382
PD PARK2-WT HNRNPA2B1 2.926 SCA1 ATXN1-Q30 U2AF2 7.442
PD PARK2-WT CCT5 2.936 SCA1 ATXN1-Q30 YWHAH 7.752
PD PARK2-WT PPIA 2.969 SCA1 ATXN1-Q30 TBL1XR1 7.845
PD PARK2-WT HNRNPA1 3.084 SCA1 ATXN1-Q30 YWHAQ 8.069
PD PARK2-WT ENO1 3.088 SCA1 ATXN1-Q30 CIC INF
PD PARK2-WT ANXA11 3.114 SCA1 ATXN1-Q30 CDC16 INF
PD PARK2-WT FKBP4 3.118 SCA1 ATXN1-Q30 TBC1D9B INF
PD PARK2-WT NME1-NME2 3.128 SCA1 ATXN1-Q30 UBQLN1 INF
PD PARK2-WT GAPDH 3.129 SCA1 ATXN1-Q30 UBQLN2 INF
PD PARK2-WT CCT8 3.141 SCA1 ATXN1-Q82 C15orf24 2.001
PD PARK2-WT EZR 3.155 SCA1 ATXN1-Q82 PYCRL 2.069
PD PARK2-WT PRDX2 3.157 SCA1 ATXN1-Q82 MED27 2.194
PD PARK2-WT NACA 3.185 SCA1 ATXN1-Q82 PTPN1 2.266
PD PARK2-WT PRDX1 3.186 SCA1 ATXN1-Q82 HSPA5 2.310
PD PARK2-WT CSE1L 3.203 SCA1 ATXN1-Q82 SPCS3 2.374
PD PARK2-WT GSTP1 3.206 SCA1 ATXN1-Q82 OBSCN 2.466
PD PARK2-WT HSP90AB1 3.240 SCA1 ATXN1-Q82 CHORDC1 2.487
PD PARK2-WT TPI1 3.286 SCA1 ATXN1-Q82 DNAJB6 2.505
PD PARK2-WT HSP90AA1 3.333 SCA1 ATXN1-Q82 NID1 2.507
PD PARK2-WT CCT7 3.398 SCA1 ATXN1-Q82 MYOM2 2.520
PD PARK2-WT NPM1 3.434 SCA1 ATXN1-Q82 UBC 2.611
PD PARK2-WT TKT 3.494 SCA1 ATXN1-Q82 HSPA1A 2.660
PD PARK2-WT UBC 3.496 SCA1 ATXN1-Q82 PSMB1 2.677
PD PARK2-WT HSP90B1 3.552 SCA1 ATXN1-Q82 SNCA 2.717
PD PARK2-WT EEF2 3.555 SCA1 ATXN1-Q82 WDR68 2.793
PD PARK2-WT PSMD2 3.597 SCA1 ATXN1-Q82 HSPA1B 2.797
PD PARK2-WT FASN 3.762 SCA1 ATXN1-Q82 SF1 3.168
PD PARK2-WT LDHB 3.795 SCA1 ATXN1-Q82 GSPT1 3.224
PD PARK2-WT AHCY 3.894 SCA1 ATXN1-Q82 U2AF1 3.408
PD PARK2-WT PFN1 3.918 SCA1 ATXN1-Q82 SKP1 3.423
PD PARK2-WT PSMA5 4.002 SCA1 ATXN1-Q82 HSPA8 3.477
PD PARK2-WT PSMA6 4.223 SCA1 ATXN1-Q82 ZNF207 3.540
PD PARK2-WT HNRNPAB 4.271 SCA1 ATXN1-Q82 PCMT1 3.555
PD PARK2-WT LDHA 4.384 SCA1 ATXN1-Q82 SUMO2 4.054
PD PARK2-WT ALDOA 4.873 SCA1 ATXN1-Q82 TLE4 4.880
PD PARK2-WT PA2G4 4.900 SCA1 ATXN1-Q82 BUB3 4.895
PD PARK2-WT MTHFD1 5.393 SCA1 ATXN1-Q82 ARG1 5.131
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PD PARK2-WT MAT2A 5.516 SCA1 ATXN1-Q82 RNH1 5.668
PD PARK2-WT HSPA4 6.600 SCA1 ATXN1-Q82 BAG2 5.709
PD PARK2-Q329Stop BAG2 2.767 SCA1 ATXN1-Q82 TPM3 5.934
PD SNCA-WT CSNK2A1 1.282 SCA1 ATXN1-Q82 SYNE2 5.979
PD SNCA-WT NCL 4.511 SCA1 ATXN1-Q82 HDAC3 6.211
PD SNCA-WT NOL7 3.161 SCA1 ATXN1-Q82 YWHAB 6.251
PD SNCA-WT ILF2 3.380 SCA1 ATXN1-Q82 MLF2 6.303
PD SNCA-WT ILF3 3.464 SCA1 ATXN1-Q82 HSPB1 6.373
PD SNCA-WT NOL11 2.818 SCA1 ATXN1-Q82 CDC2L1 6.424
PD SNCA-WT PARK7 6.945 SCA1 ATXN1-Q82 YWHAG 6.664
PD SNCA-WT HSP90B1 5.596 SCA1 ATXN1-Q82 U2AF2 6.765
PD SNCA-WT HSPA4 5.048 SCA1 ATXN1-Q82 YWHAE 6.846
PD SNCA-WT TTLL12 3.960 SCA1 ATXN1-Q82 TBL1XR1 7.110
PD SNCA-WT PSMA2 3.790 SCA1 ATXN1-Q82 YWHAZ 7.220
PD SNCA-WT HSPD1 1.686 SCA1 ATXN1-Q82 YWHAH 7.634
PD SNCA-WT UBA1 3.348 SCA1 ATXN1-Q82 YWHAQ 7.986
PD SNCA-WT LRPPRC 3.683 SCA1 ATXN1-Q82 CIC INF
PD SNCA-WT YWHAZ 2.757 SCA1 ATXN1-Q82 CDC16 INF
PD SNCA-WT PSMC3 2.575 SCA1 ATXN1-Q82 TBC1D9B INF
PD SNCA-WT YWHAB 2.121 SCA1 ATXN1-Q82 UBQLN1 INF
PD SNCA-WT YWHAE 4.147 SCA1 ATXN1-Q82 UBXN1 INF
PD SNCA-A30P NCL 4.152 HD HTT506-Q23 CSNK2A1 2.080
PD SNCA-A30P NOL11 1.859 HD HTT506-Q23 HSPA1A 2.213
PD SNCA-A30P ILF2 2.154 HD HTT506-Q23 RUVBL1 2.423
PD SNCA-A30P ILF3 2.182 HD HTT506-Q23 IPO9 2.444
PD SNCA-E46K NOL8 2.050 HD HTT506-Q23 DHX30 2.762
PD SNCA-E46K CSNK2A1 2.148 HD HTT506-Q23 IPO7 3.316
PD SNCA-E46K DNAJC9 2.096 HD HTT506-Q23 VIM 3.657
PD SNCA-E46K NOL11 1.661 HD HTT506-Q23 ACTG1 4.072
PD SNCA-E46K GTPBP4 2.056 HD HTT506-Q23 IPO4 4.099
PD SNCA-E46K NOLC1 2.927 HD HTT506-Q23 ACTA1 4.194
PD SNCA-E46K HSPH1 2.669 HD HTT506-Q23 UBC 4.519
PD SNCA-A53T THRAP3 4.326 HD HTT506-Q23 KPNB1 5.938
PD SNCA-A53T NOL11 1.088 HD HTT506-Q23 HSPB1 7.899
PD SNCA-A53T NCL 1.484 HD HTT506-Q145 RANGAP1 2.006
PD SNCA-A53T ILF3 1.206 HD HTT506-Q145 DNAJB6 2.012
PD SNCA-A53T NOL7 1.269 HD HTT506-Q145 FASN 2.084
PD SNCA-A53T ILF2 1.292 HD HTT506-Q145 UBC 2.089
PD SNCA-A53T NOL8 1.319 HD HTT506-Q145 CAD 2.090
PD SNCA-A53T CSNK2A1 1.444 HD HTT506-Q145 BAT3 2.116
AD PSEN1-WT PCBP2 2.062 HD HTT506-Q145 RUVBL1 2.147
AD PSEN1-WT SCD 2.068 HD HTT506-Q145 FLOT1 2.243
AD PSEN1-WT ARF4 2.070 HD HTT506-Q145 DDB1 2.337
AD PSEN1-WT SSR3 2.076 HD HTT506-Q145 MATR3 2.513
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AD PSEN1-WT ARL1 2.123 HD HTT506-Q145 HBXIP 2.595
AD PSEN1-WT SAR1A 2.134 HD HTT506-Q145 HSPA1A 2.706
AD PSEN1-WT CNOT7 2.136 HD HTT506-Q145 WDR61 2.719
AD PSEN1-WT SLC1A5 2.145 HD HTT506-Q145 AP2B1 2.758
AD PSEN1-WT RDH11 2.193 HD HTT506-Q145 SUMO2 2.904
AD PSEN1-WT PSMD14 2.201 HD HTT506-Q145 ACLY 2.906
AD PSEN1-WT PGRMC1 2.250 HD HTT506-Q145 PPP1R10 3.026
AD PSEN1-WT PTPLAD1 2.310 HD HTT506-Q145 POLR2H 3.027
AD PSEN1-WT RANGAP1 2.332 HD HTT506-Q145 PPIH 3.031
AD PSEN1-WT TMCO1 2.342 HD HTT506-Q145 POLR1C 3.072
AD PSEN1-WT PSMA6 2.364 HD HTT506-Q145 PSMD6 3.096
AD PSEN1-WT ZW10 2.381 HD HTT506-Q145 KPNB1 3.161
AD PSEN1-WT TMED10 2.403 HD HTT506-Q145 PSMA4 3.207
AD PSEN1-WT DNAJA2 2.405 HD HTT506-Q145 PSMB1 3.227
AD PSEN1-WT EIF4G1 2.472 HD HTT506-Q145 PSMB2 3.261
AD PSEN1-WT FADS1 2.571 HD HTT506-Q145 EPPK1 3.290
AD PSEN1-WT PSMA2 2.613 HD HTT506-Q145 ALDOA 3.328
AD PSEN1-WT SSR4 2.686 HD HTT506-Q145 VPS28 3.353
AD PSEN1-WT SSR1 2.757 HD HTT506-Q145 KDM1 3.406
AD PSEN1-WT ATP2A2 2.773 HD HTT506-Q145 EIF3B 3.432
AD PSEN1-WT HSD17B12 2.804 HD HTT506-Q145 GEMIN7 3.562
AD PSEN1-WT PSMD2 2.825 HD HTT506-Q145 HNRNPM 3.566
AD PSEN1-WT TBL3 2.827 HD HTT506-Q145 COMMD1 3.574
AD PSEN1-WT ERLIN2 2.890 HD HTT506-Q145 LSM5 3.577
AD PSEN1-WT RPL38 2.961 HD HTT506-Q145 HGS 3.653
AD PSEN1-WT STT3A 2.967 HD HTT506-Q145 IMMT 3.694
AD PSEN1-WT PSMC2 2.985 HD HTT506-Q145 PSMA6 3.761
AD PSEN1-WT TMEM33 3.002 HD HTT506-Q145 PSMD13 3.835
AD PSEN1-WT TNPO3 3.018 HD HTT506-Q145 HSPA8 3.839
AD PSEN1-WT DNAJB11 3.029 HD HTT506-Q145 ACTR3 3.839
AD PSEN1-WT DDOST 3.074 HD HTT506-Q145 PLEC1 3.918
AD PSEN1-WT TMEM43 3.160 HD HTT506-Q145 COMMD3 3.931
AD PSEN1-WT PSMA5 3.174 HD HTT506-Q145 PSMA7 4.108
AD PSEN1-WT PSMA7 3.185 HD HTT506-Q145 PPP1CA 4.162
AD PSEN1-WT RPN2 3.203 HD HTT506-Q145 OGT 4.174
AD PSEN1-WT PSMA4 3.211 HD HTT506-Q145 SKP1 4.177
AD PSEN1-WT HSPA5 3.235 HD HTT506-Q145 PPGB 4.221
AD PSEN1-WT PSMB5 3.305 HD HTT506-Q145 PSMD2 4.255
AD PSEN1-WT CDKN2A 3.319 HD HTT506-Q145 EEF1B2 4.391
AD PSEN1-WT FAF2 3.319 HD HTT506-Q145 PSMD14 4.591
AD PSEN1-WT BCAP31 3.364 HD HTT506-Q145 UFD1L 4.631
AD PSEN1-WT PSMB1 3.380 HD HTT506-Q145 DYNLL1 4.640
AD PSEN1-WT HSPA8 3.466 HD HTT506-Q145 SEC13 4.660
AD PSEN1-WT PSMB2 3.469 HD HTT506-Q145 RANBP1 4.672
- 114 -
VII SUPPLEMENT
AD PSEN1-WT TTC35 3.488 HD HTT506-Q145 DNAJA2 4.687
AD PSEN1-WT RPN1 3.534 HD HTT506-Q145 COPS3 4.709
AD PSEN1-WT COX4NB 3.603 HD HTT506-Q145 NEFL 4.750
AD PSEN1-WT FADS2 3.619 HD HTT506-Q145 GLB1 4.775
AD PSEN1-WT DHCR24 3.673 HD HTT506-Q145 PSMD7 5.068
AD PSEN1-WT FAM62A 3.782 HD HTT506-Q145 WDR82 5.069
AD PSEN1-WT KIAA0090 3.815 HD HTT506-Q145 PPP6C 5.170
AD PSEN1-WT BAT3 3.840 HD HTT506-Q145 DNAJA1 5.176
AD PSEN1-WT DNAJB12 3.945 HD HTT506-Q145 CALM1 5.209
AD PSEN1-WT SKP1 4.183 HD HTT506-Q145 ACTA1 5.280
AD PSEN1-WT UBC 4.329 HD HTT506-Q145 CARM1 5.294
AD PSEN1-WT DNAJA1 4.401 HD HTT506-Q145 NRBP1 5.349
AD PSEN1-WT SOAT1 4.587 HD HTT506-Q145 PSMD1 5.385
AD PSEN1-WT MLF1 4.592 HD HTT506-Q145 ACTBL2 5.438
AD PSEN1-WT CYP51A1 5.155 HD HTT506-Q145 STRAP 5.453
AD PSEN1-WT DNAJC7 5.357 HD HTT506-Q145 ACTG1 5.482
AD PSEN1-WT MAGEB2 5.419 HD HTT506-Q145 EIF3G 5.530
AD PSEN1-WT HSPB1 5.506 HD HTT506-Q145 PRRC1 5.640
AD PSEN1-WT SRPRB 5.780 HD HTT506-Q145 PSMA5 5.652
AD PSEN1-WT BAG2 7.495 HD HTT506-Q145 EIF4E2 5.720
AD PSEN1-A431E FAF2 2.091 HD HTT506-Q145 RAE1 5.743
AD PSEN1-A431E RHBDL7 2.109 HD HTT506-Q145 EEF1G 5.767
AD PSEN1-A431E TMEM43 2.112 HD HTT506-Q145 VCP 5.793
AD PSEN1-A431E PSMA5 2.124 HD HTT506-Q145 CNOT10 6.035
AD PSEN1-A431E DDX20 2.127 HD HTT506-Q145 EEF1D 6.038
AD PSEN1-A431E GLB1 2.135 HD HTT506-Q145 CETN2 6.210
AD PSEN1-A431E CHMP1A 2.150 HD HTT506-Q145 NEFM 6.398
AD PSEN1-A431E PSMC3 2.167 HD HTT506-Q145 G3BP1 6.644
AD PSEN1-A431E STT3A 2.176 HD HTT506-Q145 WDR68 6.666
AD PSEN1-A431E MLEC 2.176 HD HTT506-Q145 ATXN2L 6.683
AD PSEN1-A431E PSMA6 2.225 HD HTT506-Q145 CNOT7 6.785
AD PSEN1-A431E HSPA8 2.296 HD HTT506-Q145 EIF3I 6.786
AD PSEN1-A431E TMEM33 2.381 HD HTT506-Q145 PABPC4 7.036
AD PSEN1-A431E PSMB1 2.442 HD HTT506-Q145 LSM12 7.252
AD PSEN1-A431E PSMB2 2.442 HD HTT506-Q145 PABPC1 7.272
AD PSEN1-A431E PSMA4 2.536 HD HTT506-Q145 VIM 7.482
AD PSEN1-A431E KIAA0090 2.586 HD HTT506-Q145 UBL4A 7.492
AD PSEN1-A431E SOAT1 2.671 HD HTT506-Q145 HSPB1 8.387
AD PSEN1-A431E TTC35 2.673 HD HTT506-Q145 BAG2 8.500
AD PSEN1-A431E DEGS1 2.728 HD HTT506-Q145 CNOT3 8.587
AD PSEN1-A431E UBC 2.799 HD HTT506-Q145 CNOT2 INF
AD PSEN1-A431E PSMA2 2.812 HD HTT506-Q145 CNOT8 INF
AD PSEN1-A431E FADS2 2.885 HD HTT506-Q145 COMMD4 INF
AD PSEN1-A431E DHCR24 2.927 HD HTT506-Q145 HAUS2 INF
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AD PSEN1-A431E PSMA7 2.934 HD HTT506-Q145 HAUS3 INF
AD PSEN1-A431E COX4NB 3.048 HD HTT506-Q145 HAUS4 INF
AD PSEN1-A431E HSPA5 3.050 HD HTT506-Q145 HAUS5 INF
AD PSEN1-A431E DNAJA1 3.103 HD HTT506-Q145 HSPB11 INF
AD PSEN1-A431E SAR1A 3.194 HD HTT506-Q145 KDM5B INF
AD PSEN1-A431E SKP1 3.194 HD HTT506-Q145 WDR45 INF
AD PSEN1-A431E DNAJC7 3.462 HD HTT-Ex1-Q79 RPL13 2.372
AD PSEN1-A431E MAGEB2 3.709 HD HTT-Ex1-Q79 ST13 2.778
AD PSEN1-A431E BAT3 3.929 HD HTT-Ex1-Q79 UBC 2.956
AD PSEN1-A431E SRPRB 4.292 HD HTT-Ex1-Q79 HSPB1 2.993
AD PSEN1-A431E CYP51A1 4.554 HD HTT-Ex1-Q79 BAG2 3.112
AD PSEN1-A431E SCD 4.579 HD HTT-Ex1-Q79 HSPA8 3.229
AD PSEN1-A431E HSPB1 4.665 HD HTT-Ex1-Q79 DNAJA1 3.910
AD PSEN1-A431E RDH11 4.939 HD HTT-Ex1-Q79 RBM25 4.804
AD PSEN1-A431E BAG2 6.406
AD APP-WT VGF 2.601
AD APP-WT PARP1 4.911
AD APP-WT LRPPRC 3.854
AD APP-WT CBX1 2.897
AD APP-WT CBX5 2.542
AD APP-WT CBX3 4.415
AD APP-WT PDIA6 4.052
AD APP-WT PDIA4 3.337
AD APP-WT PDIA3 4.037
AD APP-K670N/M671L PDIA3 2.825
AD APP-K670N/M671L VGF 2.090
AD APP-K670N/M671L LRPPRC 1.509
AD APP-K670N/M671L CBX1 2.509
AD APP-K670N/M671L CBX5 1.546
AD APP-K670N/M671L CBX3 2.981
AD APP-V717I LRPPRC 1.346
AD APP-V717I CBX1 3.839
AD APP-V717I CBX5 4.179
AD APP-V717I CBX3 4.890
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Supplementary Table VII.2 | Identified differential PPIs from q-AP-MS screen
Listed are gene names of identified differential interactors from the q-AP-MS screen for each 
preferential bait variant, respectively (for specificity assessment cf. III.1). Log2FC reflects the 
absolute logarithmized H/L ratio fold changes from the combined forward and reverse expe-
riment of the direct wild-type versus disease-associated variant pull-down experiments. (e.g. 
CSNK2A1 binds preferentially to Htt506-Q23 compared to Htt506-Q145, observed absolute 
log2FC from both forward and reverse experiments was 2.002). In case several mutants were 
screened (applies for APP and SNCA screens), the preferential variants are indicated.
Bait variant Prey Log
2
FC Bait variant Prey Log
2
FC
pref. HTT506-Q23 CSNK2A1 2.002 pref. ATXN1-Q30 KDM1 1.019
pref. HTT506-Q23 KPNB1 3.424 pref. ATXN1-Q30 PRDX4 1.038
pref. HTT506-Q23 UBC 3.446 pref. ATXN1-Q30 TBL1X 1.262
pref. HTT506-Q23 IPO9 4.486 pref. ATXN1-Q30 SQSTM1 1.279
pref. HTT506-Q23 DHX30 4.977 pref. ATXN1-Q30 HDAC3 1.320
pref. HTT506-Q23 IPO7 5.138 pref. ATXN1-Q30 EIF4E2 1.434
pref. HTT506-Q23 IPO4 5.149 pref. ATXN1-Q30 CDK2 1.740
pref. HTT506-Q145 RANGAP1 1.139 pref. ATXN1-Q30 CHORDC1 1.774
pref. HTT506-Q145 DDB1 1.367 pref. ATXN1-Q30 HEY2 2.193
pref. HTT506-Q145 ACLY 1.385 pref. ATXN1-Q30 CIC 2.844
pref. HTT506-Q145 ILF2 1.517 pref. ATXN1-Q82 ZNF207 1.074
pref. HTT506-Q145 FLOT1 1.539 pref. PSEN1-WT DDOST 0.990
pref. HTT506-Q145 EPPK1 1.567 pref. PSEN1-WT BCAP31 1.035
pref. HTT506-Q145 AP2B1 1.593 pref. PSEN1-WT SLC1A5 1.080
pref. HTT506-Q145 MATR3 1.611 pref. PSEN1-WT RPN1 1.145
pref. HTT506-Q145 HSPA8 1.637 pref. PSEN1-WT SCD 1.301
pref. HTT506-Q145 PSMD6 1.668 pref. PSEN1-WT DHCR24 1.370
pref. HTT506-Q145 COMMD3 1.767 pref. PSEN1-WT SRPRB 1.376
pref. HTT506-Q145 PPIH 1.784 pref. PSEN1-WT TMED10 1.476
pref. HTT506-Q145 POLR1C 1.793 pref. PSEN1-WT RDH11 1.554
pref. HTT506-Q145 COPS7B 1.959 pref. PSEN1-WT CYP51A1 1.570
pref. HTT506-Q145 SUMO2 2.058 pref. PARK2-WT GSTP1 1.232
pref. HTT506-Q145 IMMT 2.084 pref. PARK2-WT HNRNPAB 1.244
pref. HTT506-Q145 PLEC1 2.156 pref. PARK2-WT HSP90AB1 1.324
pref. HTT506-Q145 VCP 2.230 pref. PARK2-WT CSE1L 1.364
pref. HTT506-Q145 GEMIN7 2.279 pref. PARK2-WT YWHAZ 1.470
pref. HTT506-Q145 LSM5 2.296 pref. PARK2-WT CFL1 1.556
pref. HTT506-Q145 PSMD1 2.343 pref. PARK2-WT MDH2 1.619
pref. HTT506-Q145 NRBP1 2.352 pref. PARK2-WT ALDOA 1.648
pref. HTT506-Q145 WDR61 2.365 pref. PARK2-WT PKM2 1.957
pref. HTT506-Q145 EIF3B 2.379 pref. PARK2-WT EIF5A 2.054
pref. HTT506-Q145 OGT 2.383 pref. PARK2-WT ACTG1 2.227
pref. HTT506-Q145 HGS 2.407 pref. PARK2-WT PRDX2 2.464
pref. HTT506-Q145 PSMD7 2.461 pref. PARK2-WT PPIA 2.474
pref. HTT506-Q145 PSMD14 2.546 pref. PARK2-WT PGK1 2.661
pref. HTT506-Q145 PPGB 2.556 pref. PARK2-WT PFN1 2.663
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pref. HTT506-Q145 UFD1L 2.643 pref. PARK2-WT LDHB 2.696
pref. HTT506-Q145 KDM1 2.645 pref. PARK2-WT LDHA 2.836
pref. HTT506-Q145 PPP1CA 2.696 pref. PARK2-WT HSPD1 3.119
pref. HTT506-Q145 HNRNPM 2.710 pref. PARK2-WT NCL 3.388
pref. HTT506-Q145 COMMD1 2.808 pref. PARK2-WT NPM1 3.416
pref. HTT506-Q145 EEF1B2 2.817 pref. PARK2-WT HNRNPA2B1 3.504
pref. HTT506-Q145 CALM1 3.092 pref. APP-WT over APP-K670N/M671L CBX3 3.023
pref. HTT506-Q145 PPP6C 3.224 pref. APP-WT over APP-K670N/M671L CBX5 3.880
pref. HTT506-Q145 NEFL 3.256 pref. APP-WT over APP-K670N/M671L PARP1 3.893
pref. HTT506-Q145 EIF4E2 3.408 pref. APP-K670N/M671L over APP-WT LRPPRC 1.442*
pref. HTT506-Q145 RAD23B 3.436 pref. SNCA-A30P over SNCA-A53T YWHAE 1.037
pref. HTT506-Q145 STRAP 3.445 pref. SNCA-A30P over SNCA-A53T HSPD1 1.584
pref. HTT506-Q145 ATXN2L 3.450 pref. SNCA-A53T over SNCA-A30P ILF2 1.294
pref. HTT506-Q145 COPS3 3.514 pref. SNCA-A53T over SNCA-A30P ILF3 1.417
pref. HTT506-Q145 WDR68 3.529 pref. SNCA-E46K over SNCA-A53T HSPD1 1.320
pref. HTT506-Q145 UBL4A 3.634 pref. SNCA-WT over SNCA-A30P LRPPRC 3.683
pref. HTT506-Q145 DYNLL1 3.699 pref. SNCA-WT over SNCA-A53T YWHAE 1.687
pref. HTT506-Q145 DNAJA2 3.767 pref. SNCA-WT over SNCA-A53T UBA1 2.915
pref. HTT506-Q145 NEFM 3.859 pref. SNCA-WT over SNCA-A53T LRPPRC 2.937
pref. HTT506-Q145 VIM 3.919 pref. SNCA-WT over SNCA-A53T HSPD1 4.692
pref. HTT506-Q145 CNOT10 3.929 pref. SNCA-WT over SNCA-E46K ILF2 1.969
pref. HTT506-Q145 EIF3G 3.966 pref. SNCA-WT over SNCA-E46K ILF3 2.112
pref. HTT506-Q145 DNAJA1 3.977 pref. SNCA-WT over SNCA-E46K LRPPRC 3.867
pref. HTT506-Q145 WDR82 4.213 pref. SNCA-WT over SNCA-E46K NCL 5.138
pref. HTT506-Q145 CETN2 4.286
pref. HTT506-Q145 EEF1D 4.341
pref. HTT506-Q145 EEF1G 4.358
pref. HTT506-Q145 BAG2 4.360 * log2FC from the forward experiment only, no LRPPRC peptides
pref. HTT506-Q145 EIF3I 4.462    could be quantified in the corresponding reverse experiment
pref. HTT506-Q145 RAE1 4.492
pref. HTT506-Q145 TCEB2 4.533
pref. HTT506-Q145 PRRC1 4.572
pref. HTT506-Q145 CNOT7 5.003
pref. HTT506-Q145 G3BP1 5.357
pref. HTT506-Q145 LSM12 5.459
pref. HTT506-Q145 CARM1 5.629
pref. HTT506-Q145 PABPC1 5.759
pref. HTT506-Q145 PABPC4 6.267
pref. HTT506-Q145 SEC13 6.290
pref. HTT-Ex1-Q79 HSPA8 1.509
pref. HTT-Ex1-Q79 HSPB1 2.649
pref. HTT-Ex1-Q79 DNAJA1 3.963
pref. HTT-Ex1-Q79 BAG2 4.512
pref. HTT-Ex1-Q79 ST13 4.624
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Supplementary Table VII.3 | Utilized shRNA fly strains
Modifications by the induction of RNAi in polyQ and tau models were categorized as follows: 
wild type-like phenotype (---); obvious REP suppression (--); subtle REP suppression (-); no 
change of REP (0); subtle enhancement of REP (+); obvious enhancement of REP (++) and le-
thal (+++); n.a. = not assessable
* = due to MaxQuant software version issues, initially 7 additional candidates have been ana-
lyzed for disease-modifying effects in the fly, although they are not included in the final PPI 
network. For consistency reasons, they are listed here and depicted in Supplementary FIG. 
VII.2 as well.
# VDRC 
acces-
sion 
number
Human 
Gene 
ID
Human 
Gene 
Symbol
Fly 
Gene 
ID
Fly 
Gene 
Symbol
Fly 
Annotation 
Symbol
REP 
effect
Tau 
effect
control
RNAi
effect
1 30280 47 ACLY 36760 ATPCL CG8322 ++ 0 0 *
2 35296 9532 BAG2 39679 - CG7945 ++ 0 0
3 21037 9184 BUB3 43490 Bub3 CG7581 ++ 0 0
4 41838 983 CDC2 34411 cdc2 CG5363 + - +
5 45127 984 CDC2L1 40292 Pitslre CG4268 +++ 0 +
6 22300 26973 CHORDC1 42874 CHORD CG6198 ++ 0 0
7 27858 10399 GNB2L1 34070 Rack1 CG7111 ++ 0 0 *
8 35513.5 8841 HDAC3 44446 Hdac3 CG2128 + 0 0
9 30561 23493 HEY2 35764 Hey CG11194 ++ 0 0
10 14882 3309 HSPA5 32133 Hsc70-3 CG4147 +++ +++ +++
11 45596 3312 HSPA8 39542 Hsc70-1 CG8937 ++ + 0
12 45121.5 3608 ILF2 41529 - CG5641 + 0 0 *
13 25218 23028 KDM1 40217 Hdm CG17149 +++ 0 0
14 13697 9442 MED27 40696 MED27 CG1245 +/- 0 0
15 45280 11051 NUDT21 39083 - CG3689 +++ 0 0 *
16 43254 10549 PRDX4 39083 Jafrac2 CG1274 +++ 0 0
17 16104 5686 PSMA5 53577 Prosalpha5 CG10938 +++ +++ +++ *
18 34801 5689 PSMB1 39855 Pros26 CG4097 +++ +++ +++
19 22214 65263 PYCRL 42106 Ptp61F CG5840 n.a. 0 0
20 13426 7536 SF1 43912 SF1 CG5836 0 0 0
21 20943 10946 SF3A3 40678 noi CG2925 0 + 0 *
22 28975 6500 SKP1 36298 skpB CG8881 + 0 0
23 51149 9789 SPCS2 32095 Spase25 CG1751 + 0 0 *
24 1414 60559 SPCS3 42885 Spase22-23 CG5677 +++ 0 0
25 40862 6907 TBL1X 33212 ebi CG4063 - 0 0
26 24177 11338 U2AF2 32602 U2af50 CG9998 +++ 0 0
27 15884 7531 YWHAE 42186 14-3-3ε CG31196 n.a. n.a. n.a.
28 48724 7534 YWHAZ 36059 14-3-3ζ CG17870 ++ 0 0
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